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1 PROLOGUE 
We heard the remote sound of sirens from the ambulance. The characteristic alarm to get the 
attention in the surroundings. But we were in the emergency department and we were already 
notified. The ambulance had called to tell us about the young woman who was found 
unconscious. From the report we knew that there was ongoing cardiopulmonary resuscitation. 
I caught a glimpse of the medical records and found no known disease of relevance. 
She was brought into the emergency room and we took over from the ambulance personnel. 
We continued longstanding heart compression; we attempted to defibrillate her low-
amplitude rhythm, possibly ventricular fibrillation; and we continued pharmacological 
approaches. In the meantime, we did an echocardiography that showed markedly increased 
hypertrophy of the septal wall. The team continued cardiopulmonary resuscitation for an 
extended period even though there were no signs of hemodynamic restoration. In fact, there 
was no spontaneous circulation at all and the body was getting cold. She was dead. Definitely 
dead.  
I undertook the task of informing the closest relatives. Professionalism is helpful, but some 
cases affect you more than others. Later, the autopsy confirmed the diagnosis of hypertrophic 
cardiomyopathy. Since then my mind has been engulfed by a question: how can sudden 
cardiac death be prevented by implantable cardioverter defibrillators in hypertrophic 
cardiomyopathy? 
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2 ABSTRACT 
Background. Hypertrophic cardiomyopathy (HCM) is a heterogeneous disease with various 
clinical manifestations, including sudden cardiac death, which can be prevented by an 
implantable cardioverter defibrillator (ICD). Aims. The general aim of this thesis was to 
elucidate different aspects of ICD treatment in patients with HCM. This includes the use of 
ICDs among HCM patients with focus on risk stratification for ventricular arrhythmias, 
mortality, and cause of death; assessment of health-related quality of life; qualitative aspects 
of living with an ICD; and characterization using positron emission tomography (PET) to 
explore risk markers for sudden death. Methods. The Swedish Pacemaker and ICD Registry 
was retrieved to identify eligible patients. Data from the National Patient Registers, the Cause 
of Death Register, Statistics Sweden, and medical records were used. Health-related quality 
of life was assessed using SF-36. Interviews were analyzed by hermeneutics and latent 
content analysis. PET and echocardiography were performed. Results and Conclusions. In 
Paper Ⅰ, the nationwide cohort of unselected HCM patients with ICDs was based on 
established risk factors for sudden cardiac death at the time. ICDs effectively terminated 
potentially life-threatening ventricular arrhythmias in HCM. The cumulative incidences of 
first appropriate ICD therapy at 1 year, 3 years, and 5 years were 8%, 15%, and 21%, 
respectively. Left ventricular ejection fraction less than 50% and atrial fibrillation were strong 
predictors of appropriate ICD therapy. In Paper Ⅱ, among HCM patients with ICDs, the main 
cause of death is deterioration of systolic function leading to end-stage heart failure. The risk 
of sudden cardiac death was almost eliminated. Still, there was an increased risk of death 
(standardized mortality ratio 3.4) compared to the Swedish general population matched for 
age, sex, and calendaric time. In Paper Ⅲ, generic health-related quality of life, both mental 
and physical components, was lower in HCM patients with ICDs than in Swedish age- and 
sex-matched population norms. Systolic heart failure and atrial fibrillation are determinants of 
low health-related quality of life, especially physical functioning. In Paper Ⅳ, based on 
qualitative interpretation, HCM patients with ICDs perceive poor health due to limiting 
dyspnea but accept the change in lifestyle. They feel grateful for their device, which gives 
them hope during the life course despite necessary restrictions and adaptation, even after 
experiencing inappropriate shocks. The knowledge about the disease and device therapy 
varies substantially and the support from the health care providers is generally constrained to 
technical issues rather than an attempt at a holistic approach. In Paper Ⅴ, HCM patients with 
ICDs represent advanced disease manifestation determined as decreased myocardial blood 
flow at stress, altered oxidative metabolism, and sympathetic denervation using the tracers 
15O-water, 11C-acetate, and 11C-HED during PET exams. The endocardium/epicardium 
myocardial blood flow gradient at adenosine stress is lower in HCM patients with 
nonsustained ventricular tachycardia, which provides a potential marker for risk stratification 
of sudden cardiac death. 
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5 INTRODUCTION 
5.1 HISTORY OF HYPERTROPHIC CARDIOMYOPATHY AND SUDDEN DEATH 
A case report by Vulpian, published in 1868, on hypertrophic cardiomyopathy (HCM) 
described findings of septal hypertrophy from an autopsy at Hôpital de la Salpêtrière in 
Paris.1 The following year, Liouville and Hallopeau described further morphological findings 
of HCM.2,3 Before that, during the 17th century, Bonet wrote in the Sepulchretum 
Anatomicum, a collection of post mortem reports, “A coachman died suddenly in his carriage 
whose heart was larger than that of any bullock, another sudden death of a heart far 
exceeding its natural bulk.” This report was later mentioned by Morgagni (1682-1771) who 
refined the description of sudden cardiac death (SCD) and its association to heart pathology.4 
During the Renaissance, the physician of Pope Clement XI, Lancrisi evaluated sudden 
unexpected deaths in Rome in 1705 in De subitaneis mortibus, reporting on death associated 
with left ventricular (LV) myocardial hypertrophy.5,6 Thus, at that time the gross anatomical 
findings and the association of sudden death were established, and could be causally linked to 
the observations of Hippocrates, “Persons who have had frequent and severe attacks of 
swooning, without any manifest cause, die suddenly.”7,8 Indeed, unexplained syncope, 
previously called swooning, was already recognized as a risk factor for SCD. Lancrisis’ 
contribution also included the documentation of the hereditary component of cardiac disease 
when a family with disease transmission in four generations was described.6,9 
Following years of pathology descriptions, the development of heart catheterization and 
angiography in the 1930s increased our understanding of physiological hemodynamics. In 
1957, Brock realized that the LV outflow tract (LVOT) gradient was due to subvalvular 
stenosis in a patient with a normal aortic valve seen at the operation.10 Bercu further 
described the familiar disease of unexplained LV hypertrophy as pseudo-aortic stenosis that 
occurred in the absence of valve obstruction or hypertension, which still provides the basis of 
the definition of HCM.11 In 1958, Teare published a case series of asymmetrical hypertrophy 
in eight young adults, of whom seven died suddenly; he described symptoms, family history, 
and myocardial disarray.12 The same year, in 1958, Cleland resected part of the hypertrophy, 
considered to be the first myectomy, which relieved the patient from symptoms.13 This 
inspired Morrow, who during his career performed 299 cases of myectomy in order to relieve 
outflow obstruction, to develop a procedure that sometimes bears his name. In 1959, he and 
Braunwald published a report on three patients with functional aortic stenosis described as 
malformation characterized by resistance of the LV outflow.14 In 1964, they described a case 
series of ten myectomy patients who were assessed postoperatively by left heart 
catheterization evaluation. The myectomy procedure remains the optimal treatment option for 
many symptomatic patients, because complications are few and it has excellent long-term 
results.15–17 Ironically, Morrow himself was diagnosed with idiopathic hypertrophic subaortic 
stenosis, the term at the time, by Braunwald in 1961 solely by stethoscope auscultation 
finding of systolic ejection murmur of the precordium. Despite severe symptoms of 
exertional shortness of breath, syncope, atrial fibrillation (AF), and stroke, Morrow refused 
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further evaluation and treatment. He died suddenly at the age of 60 years and the autopsy 
confirmed the diagnosis of HCM with increased mass (645 gram), septal hypertrophy, 
thickened anterior mitral leaflet, dilated left atrium, myocyte disarray, scarring, and 
microvascular abnormalities. Morrow provided evidence of the genetic transmission of the 
condition as two of his three children were affected; his daughter underwent transplant and 
his son had the procedure his father had invented.18  
The development from M-mode echocardiography two-dimensional imaging to cardiac 
magnetic resonance (CMR) enhanced our morphological and functional understanding of the 
disease and has gained vast interest as a tool in risk stratification.19–22 The advanced 
functional imaging technique of positron emission tomography (PET) is evolving as to 
understand pathophysiological aspects of the disease using specific tracers and has the 
potential to refine risk assessment.23,24 
The molecular linkage of the familiar form of HCM was elucidated in 1989 by the 
identification of a locus on chromosome 14q1 that accounts for the expression of sarcomeric 
dysfunction.25 Since then a rapid evolution of knowledge of the various genetic bases of 
HCM has established genetic evaluation as an essential part of routine management. Over the 
past decade, the knowledge of the underlying genetic basis has been proven to be useful in 
cascade screening by identifying relatives without the phenotype and also relatives who do 
not need further follow-up. Genetic information can help confirm diagnosis, offer more 
insight into prognosis, and likely improve individualized management.26–28 SCD in HCM 
remained the ultimate, disastrous outcome despite advances in diagnosis and pharmacological 
and interventional treatments. Together with Mower, Mirowsky realized his vision to 
terminate ventricular fibrillation (VF) with an implantable cardioverter defibrillator (ICD). In 
1978 they published their successful experiment using an implantable defibrillation system in 
dogs from their self-funded laboratory.29 Despite major obstacles from authorities in the 
medical community, they continued their efforts. Finally, they got approval to conduct a 
study in humans with the inclusion criterion that the patient had to have survived two (!) 
episodes of cardiac arrest. In 1980, their first case series was published.30 In fact, two of these 
three patients had HCM.31 The defibrillator lead was placed epicardially via thoracotomy 
until 1992 when the transvenous lead was launched. This spurred the initial trials of ICDs in 
secondary prevention after cardiac arrest or ventricular tachycardia (VT) and later as primary 
prevention in patients with heart failure due to ischemic or non-ischemic dilated 
cardiomyopathy.32–34 Risk stratification in HCM was different and had to rely on empirical 
data from smaller observational studies. In 2000, the landmark trial of ICD in HCM was 
published, which showed high efficacy and appropriate therapy at an annual rate of 11% in 
secondary prevention and 5% in primary prevention.15 The experiences from numerous 
observational trials over the last two decades have shaped current guidelines.15,16,35 Basically 
there are two strategies, either risk factor assessment or a prediction model, or possibly a 
combination. Nevertheless, the consideration of individual patient perspectives along with 
health care resources is a challenge. There remain controversies in strategies for risk 
prediction and there is a need for refinement of risk stratification.  
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This field of science has moved far from the early observations of HCM several decades ago 
into a field of evidenced-based approaches grounded on more solid, systematic data. This has 
been made possible through the integration of innovation, development, and implementation 
of various fields. Promising advancements in medicine and technology in general will likely 
benefit HCM patients. Indeed, a bright future for HCM patients depends on collaboration, 
first to conduct meaningful research in the form of ground-breaking trials, but second with 
systematic organizational efforts to implement evidence-based medicine and bring these 
findings to clinical practice. Nevertheless, the inherent heterogeneity of HCM expression will 
always require careful judgement by clinicians and must also consider patient preference. 
5.2 DEFINITION AND DIAGNOSTIC PRINCIPLES 
A cardiomyopathy is defined by the morphological pathology of the ventricular chamber(s) 
of the heart that is not due to significant epicardial coronary disease and/or abnormal loading 
conditions, although concomitant disease sometimes occurs.15 Therefore, it is important to 
judge whether a hypertrophied myocardium can be explained by hypertension, aortic 
stenosis, or any other condition with abnormal loading of the left ventricle.15,36 A ventricular 
wall thickness of at least 15 mm in adults is typically required for the diagnosis of HCM. In 
cases with 13-14 mm in at least one myocardial segment, careful evaluation, including family 
history, is needed; if a first-degree relative (sibling, parent, and children) is affected HCM is 
likely.15,16 In borderline cases, extracardiac signs, electrocardiogram (ECG) pathology, 
laboratory exams, and findings of CMR imaging in addition to echocardiography may be 
useful to differentiate between underlying etiologies. It is crucial to be aware of co-existing 
valvular disease, essential or secondary hypertension, physiological response to intense 
exercise over extended periods, and isolated mild hypertrophy of the basal part of the septum 
commonly seen in the elderly.15,37,38 
The European Society of Cardiology (ESC) guidelines’ concise statement of definition is as 
follows: “HCM is defined by the presence of increased LV wall thickness that is not solely 
explained by abnormal loading conditions.”15 This statement ratifies a classification system 
based on morphological and functional criteria, regardless of possible extracardiac disease. 
Thus, other genetic as well as non-genetic causes are included in the ESC definition of HCM: 
inborn metabolic errors, neuromuscular diseases, mitochondrial disease, malformation 
syndromes, drug-induced forms, and amyloidosis. Moreover, this broad approach comprises 
all ages, including the pediatric population.  
Here, the American College of Cardiology Foundation (ACCF)/American Heart Association 
(AHA) guidelines from 2011 hold another position.16 They recognize HCM as a clinical 
entity “…characterized by unexplained LV hypertrophy associated with nondilated 
ventricular chambers in the absence of another cardiac or systematic disease that itself would 
be capable of producing the magnitude of hypertrophy…”. There are numerous conditions, 
especially diagnosed during childhood and early adult years, which mimic hypertrophy 
attributable to sarcomeric protein mutations. The American guidelines emphasize that these 
conditions, so-called phenocopies, should not be included in the term HCM. 
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Using the American definition and terminology for HCM, there are other groups of diseases 
and conditions that present with hypertrophy. These can be categorized based on cellular 
mechanisms, i.e. neuromuscular, mitochondrial, and metabolic disorders (glycogen storage, 
carnitine, lysosomal storage). Among the metabolic disorders, glycogen storage diseases such 
as Danon disease, Pompe disease, and Anderson-Fabry disease are occasionally encountered 
in adult cardiology.39 Patients with malformation syndromes are typically diagnosed in 
pediatric cardiology; LEOPARD (lentiges, ECG abnormalities, ocular hypertelorism, 
pulmonary stenosis, abnormal genitalia, retardation of growth, and sensorineural deafness), 
Noonan syndrome (facial features, short height, congenital heart disease, bleeding problems, 
and skeletal malformations), and others.15 There are complex pathophysiological pathways 
that are involved in the biological underpinnings of hypertrophy.40–42 LV hypertrophy can be 
acquired in different conditions. Patients with diabetes mellitus or renal failure often have 
myocardial hypertrophy.43–45 There are endocrine disorders, i.e. hyperparathyroidism, 
acromegaly, primary aldosteronism, pheochromocytoma, and paraganglioma that can cause 
hypertrophy.15,46–49 Hypertrophy also occurs in morbidly obese persons.50 Myocarditis and 
other forms of inflammatory/infiltrative disease can cause reversible thickening of the 
myocardial walls.51–53 Synthetic anabolic steroids but also long-term pharmacological 
treatment with chloroquine, corticosteroids, and tacrolimus may cause hypertrophy.15,54,55 
Cardiac hypertrophy is often seen in amyloidosis which can be divided into different forms 
with specific therapies in some cases.56–58 Imaging tools, laboratory markers, and sometimes 
biopsy are useful to differentiate amyloidosis from HCM.59–62 LV non-compaction 
cardiomyopathy can mimic HCM and is difficult to distinguish.63 Furthermore, it is important 
to discern athlete's heart from cardiomyopathies.64 
5.3 EPIDEMIOLOGY 
The prevalence of HCM is often reported as 1:500 (0.2%), based on several studies with 
diverse methodologies, widespread geographical areas and health care systems, and different 
populations.65,66,66–71 Recently the prevalence of HCM in Iceland was reported as 1:1,600.72 
In the frequently cited United States (US) cohort (aged ranged from 23 to 35 years), 7 out of 
4,111 (0.17%) unrelated individuals had signs of hypertrophy on echocardiography but only 1 
reported cardiac symptoms.65 Both underestimation and overestimation is likely to be 
common in clinical routine and misclassification seems to be common.73 HCM is recognized 
all over the world but prevalence varies, likely due to differences in diagnostic resources.74 
The diagnosis of HCM may be delayed or unrecognized in some patients because they are 
asymptomatic, have vague or mild symptoms, or are not properly evaluated in family 
screenings. Interestingly, a remarkably high prevalence (about 1:200) was reported when 
both phenotypes and genotypes were included based on cohorts from expert centers.75  
In Sweden, the prevalence of HCM is largely unknown. In general, the Swedish National 
Patient Register data are considered highly reliable and are used for research purposes in 
addition to evaluation of health care quality but no nationwide validation, specifically with 
regard to HCM, has been done.76 
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5.4 NOMENCLATURE 
Historically, the descriptions and insights in the field of HCM, often in parallel 
developments, have led to a diverse nomenclature. In fact, at least 58 different names have 
been used in the past for the disease known today as HCM.77 Asymmetrical septal 
hypertrophy is not a prerequisite, but the term hypertrophic obstructive cardiomyopathy, 
abbreviated as HOCM, is still frequently used. Nevertheless, obstruction is dynamic due to 
physiological conditions and may be provoked during physiological or pharmacological 
challenge. In order to avoid confusion, the term HCM should be used.15,16 However, one 
challenge is that hypertrophy is not always present at the time of diagnosis because some 
patients develop dilatation of the left ventricle and the hypertrophy disappears. The evolution 
of genetic characterization has led to categorization of patients with the genotype but no 
phenotype. This group of genopositive-phenonegative mutation carriers is likely to increase 
due to more widely used cascade screening. 
5.5 CLINICAL EVALUATION 
5.5.1 Diagnostic work-up  
The diagnostic work-up of a definite HCM including underlying etiologies requires an 
integrated assessment using anamnesis, physical examination, laboratory testing, ECG, and 
imaging. Besides routine cardiological assessment with extracardiac and molecular 
approaches, a cardiomyopathy-oriented mindset likely improves diagnostic accuracy.78 The 
heterogeneity of morphological expression should be recognized; most typically it manifests 
as septal hypertrophy but other forms, such as apical, lateral, concentric, and even right 
ventricular hypertrophy, is seen.15 
A specific diagnosis is the prerequisite for targeted evidenced-based management of the 
individual but also for the relatives. Sometimes HCM is diagnosed in a post-mortem analysis 
of the heart, including molecular diagnosis, which may explain the underlying cause of death. 
In order to avoid pitfalls, a standardized autopsy protocol in combination with blood samples 
to ensure possible postmortem molecular testing has been advocated.79 A definite diagnosis 
of HCM may be of potential benefit for the biological relatives of victim. 
5.5.2 Symptoms 
In patients with suspected or established HCM, careful assessment of symptoms is crucial. 
Dyspnea, especially at exertion, is the predominant symptom of HCM.80,81 Often the patient 
has decreased physical stamina and tiredness, causing the diagnostic presentation to be vague. 
This is caused by the relaxation dysfunction of the left ventricle during diastole and/or LVOT 
obstruction. This outflow obstruction is dynamic with regard to filling pressure, heart 
frequency, and body position and may be influenced by pharmaceutical agents that affect 
both the heart, vessels, and autonomous system.15,81 Progressive HCM may occasionally 
imply deterioration of the systolic function of the left ventricle with reduced ejection fraction 
(EF). If the left ventricle dilates and hypertrophic regions remodel into dilatation, this 
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indicates a worse prognosis.82–84 Sometimes the New York Heart Association (NYHA) 
functional classification is used for estimation of functional capacity in patients with cardiac 
disease, even though it has not been specifically validated for HCM (Table 1).85–87 
Table 1. NYHA functional classification. 
CLASS  FUNCTIONAL CAPACITY 
I Ordinary physical activity does not cause undue fatigue, palpitation, dyspnea, or 
angina. 
II Comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea, 
or angina. 
III Comfortable at rest. Less than ordinary physical activity causes fatigue, palpitation, 
dyspnea, or angina. 
IV Inability to carry on any physical activity without discomfort and even symptoms at 
rest. 
Modified from: The Criteria Committee of the New York Heart Association.87 
Chest pain, or probably better reflecting patients' wording, chest discomfort or chest pressure, 
is often described in conjunction with physical activities. Often, the coronary angiogram is 
normal and without significant lumen-narrowing epicardial coronary disease. Cardiac 
microvascular dysfunction and fibrosis are part of the cardiac disease deterioration; 
myocardial biopsies often reveal disarray, and modern PET imaging techniques can confirm 
both structural and functional abnormalities, which may explain reported symptoms.15,23 
Palpitations of various duration or symptomatic extra beats are often encountered. In some 
cases, the first symptom of HCM may be a dramatic syncopal episode. The 
pathophysiological pathways could be either hemodynamic compromise or cardiac 
arrhythmias or a combination thereof. Pre-syncope, near-syncope or dizziness is a less 
specific symptom compared to manifest syncope, but the evolution of these symptoms may 
lead to subsequent diagnosis. Bradycardia can cause syncope, but in HCM, ventricular 
arrhythmia should be suspected. Atrial arrhythmias, mostly AF, but sometimes atrial flutter or 
ectopic atrial tachycardia, are common among HCM patients. It seems that AF in HCM is 
linked to a high risk for ischemic stroke, likely by embolization.88,89 
Ventricular tachyarrhythmias that lead to SCD are a well-known, dreaded complication of 
HCM. Unfortunately, death may be the first manifestation. In such cases, the autopsy often 
confirms HCM even though the microscopy and postmortem genetic evaluation will be 
beneficial. The definite diagnosis of HCM in such cases is important, as relatives need to be 
evaluated. 
5.5.3 Physical examination 
Broad physical examination in patients with HCM and phenocopies may provide clues for 
further diagnostics.78 An attempt should be made to provoke a cardiac murmur by the 
Valsalva maneuver and, if it occurs, its intensity will vary with the patient’s hemodynamic 
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state. The physician needs to pay attention to other organs and evaluate the patient’s function, 
i.e. deafness, visual impairment, walking difficulties, motoric and sensory loss, paraesthesia, 
lentigines, angiokeratoma, and hypo- or hyperhidrosis. Notably, carpal tunnel syndrome may 
be a sign of amyloidosis.90  
5.5.4 Laboratory testing 
Sometimes basic laboratory markers may give clues for further diagnostics. Liver 
transaminases may be elevated in mitochondrial disorders, Danon disease, and metabolic 
disturbances of fatty acids. Lactate may be elevated in mitochondrial disorders, which should 
be part of differential diagnostics in selected cases.15 Glucose may also be elevated in 
mitochondrial disorders, but lowered in disorders of fatty acid and carnitine disorders. 
Creatinine and proteinuria may be elevated in patients in with Anderson-Fabry disease or 
amyloidosis. In patients with suspected Anderson-Fabry disease, the alpha galactosidase level 
is typically very low in male patients but normal in females. Immunoglobulin-free light chain 
and urine electrophoresis are useful in the diagnostic work-up in suspected amyloidosis.15 
In general, laboratory biomarkers may contribute to the diagnostic and prognostic assessment. 
Anemia encumbers the cardiovascular system. Elevated levels of NT-pro-brain natriuretic 
peptide and troponin T reflect cardiac strain and imply worse outcome.91–94 When the 
diagnosis of HCM is definite, the main role of laboratory testing is to reveal complicating 
factors such as comorbidities. 
5.5.5 The electrocardiogram 
For HCM patients, the 12-lead ECG often shows abnormalities.95,96 In a tertiary center 
cohort, only 6% of patients with an echocardiography established HCM diagnosis had a 
normal ECG.97 There are no pathognomonic ECG for HCM but some of the patterns are 
highly suggestive of specific differential diagnoses or morphological phenotypes. P-wave 
prolongation is a marker of left atrial dilatation and adverse prognosis and is often seen in 
conjunction with repolarization abnormalities and signs of hypertrophy.98 Short PQ interval 
and a delta wave (pre-excitation) is linked to LAMP2 or PRKAG2 mutations or Anderson-
Fabry disease.99 Q-waves (duration 40 ms or depth >3 mm or ≥5% of the R-wave) correlates 
with transmural fibrosis and late gadolinium enhancement (LGE).100,101 In two studies of 
HCM, 90% and 96% of patients had an abnormal ECG, but only 2% showed isolated QRS 
criteria for hypertrophy using the Sokolow-Lyon or Cornell score.102,103 On the other hand, 
low amplitudes ≤5 mm in every limb lead is suspicious of amyloidosis. Bundle branch block 
is often due to septum reduction procedures, such as myectomy or alcohol septal ablation 
(ASA).104 Fragmentation (additional R-wave) is a marker of fibrosis. An ST-T segment 
abnormality is frequently seen in HCM; deep T-wave inversion in lateral leads is typical of 
apical hypertrophy. QT-prolongation (QTc exceeding 480 ms) is seen in 13% of HCM 
patients and 0.5% in control group and has been suggested as a marker for SCD.105,106 J-
waves (J-point elevation >0.1 mV in ≥2 contiguous inferior and/or lateral leads) are seen in 
approximately a tenth of HCM patients and seem to predict cardiac events.107  
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The T-peak-to-T-end interval has been suggested as marker for ventricular arrhythmia.108 The 
ECG also has an important role in screening, and there are clues to differentiate athlete’s 
heart from HCM.109 T-wave abnormalities are suggestive of apical forms of cardiac 
hypertrophy.110 In a study of athletes with T-wave inversion (half of the study population was 
black, the other half white) and a normal echocardiogram, after comprehensive investigations 
21% were diagnosed with a cardiac disease and 91% of these diagnoses were HCM; an 
inversion in lateral leads was frequently observed.111 Based on Swedish HCM patients, a risk-
score based on ECG amplitudes has been suggested.112 Thus, the ECG can provide a clue to 
differentiate between athlete’s heart and HCM. The sum of the Q-wave and the S-wave in 
lead III are higher in HCM compared to athletes (0.71 SD 0.69 mV vs 0.21 SD 0.17 mV; 
p<0.001), which may provide additional sensitivity to international criteria for athletic ECG 
interpretation.113 
The presence of fragmented QRS in ≥3 territories (inferior, lateral, septal, and/or anterior) 
was independently associated with outcome (SCD or appropriate ICD therapy) in HCM 
patients, which provides incremental value to conventional risk factors.114 
Holter monitoring, ambulatory ECG for 24-48 hours, is frequently used in follow-up of HCM 
patients. It provides information about supraventricular tachycardia, VT, extrasystoles, and 
bradycardia. The presence of nonsustained VT (NSVT) on Holter monitoring is used for risk 
stratification of SCD. It varies between cohorts. The prevalence of NSVT was 31% in one 
non-tertiary center and 20% in a tertiary center cohort.115,116  
The insertable cardiac monitor provides continuous ECG monitoring. Current ESC guidelines 
consider insertable cardiac monitors a tool for evaluation of HCM patients with recurrent 
unexplained syncope, who are otherwise deemed as low risk of SCD.15,117 We prospectively 
evaluated the burden of arrhythmia among HCM patients with a mean 5-year risk of 2.4%, 
which yielded 31% AF, 21% NSVT, and 38% sinoatrial block/arrest.118,119  
5.5.6 Exercise test 
Exercise testing, in Sweden almost exclusively the ergometer bicycle test, has been 
frequently used in cardiac evaluation of diverse patient groups, including HCM, and is 
considered safe.120 It may also add information helpful for the differential diagnosis of 
athlete’s heart and metabolic disorders using simultaneous measurement of respiratory 
gases.15 The test provides quantitative measurement of physical performance in addition to 
personal history, which are sometimes ambiguous. This may also be useful in the evaluation 
of septum reductive procedures.15 Several studies have shown peak VO2 as a predictor of 
heart failure progression and mortality.121–123 
Preexisting ECG abnormalities may lead to interpretation challenges with false-positive 
results. However, chest discomfort is common in HCM but often due to microvascular 
dysfunction, increased oxygen demand of the hypertrophied myocardium, compressive 
systolic forces on the arterioles, and impaired diastolic function.124 Indeed, when epicardial 
disease is present, it implies higher mortality.125 In intermediate-to-high risk, invasive 
 14 
angiography may be the preferred option, while computerized tomography (CT) offers a 
noninvasive alternative in the setting of low-risk patients.120 Single-photon emission 
computed tomography lacks specificity in HCM, and false-positive tests have been seen in 
half of the patients.126,127  
Stress echocardiography, preferably using physiological exercise, has a role in the evaluation 
of provocable LVOT gradients. The dynamic nature of gradients can often be reproduced and 
may explain exercise-related symptoms from personal history, which are amenable to septum 
reductive treatment. Alternatively, the Valsalva maneuver is used simultaneously with 
echocardiography assessment, but it has low sensitivity and high specificity regarding LVOT 
gradients.128 
A hypotensive or attenuated blood pressure response at exercise testing as an independent 
risk factor for SCD has shown conflicting results in larger studies.121,129 
5.5.7 Misclassification 
The diagnosis of HCM can sometimes be challenging. In western Sweden, 611 cases (mean 
age 58.9 years) of cardiomyopathies were validated and categorized into three groups: 
dilated, hypertrophic, and others (restrictive, arrhythmogenic right ventricular 
cardiomyopathy, LV non-compaction, takotsubo, peripartum).130 The diagnostic accuracy of 
HCM was 88%. We did a regional validation of HCM-related codes 142.1 and 142.2 
(International Classification of Diseases) which are used for the Swedish National Patient 
Register. Approximately one third (31.8%) of the patients had another diagnosis and were 
thus misclassified as HCM. This implies that registry data on HCM should be interpreted 
with caution, depending on the purpose.73 
5.6 CARDIAC IMAGING 
Cardiac imaging techniques provides the basis for phenotypic assessment of HCM. Besides 
echocardiography, CMR has an important role while CT and scintigraphy are occasionally 
useful. PET has unique properties but are currently limited to research purposes. Imaging is 
used for diagnostics and follow-up, including risk stratification. 
5.6.1 Echocardiography 
Echocardiography is a cornerstone in the diagnosis of HCM and valuable for routine follow-
up. It is widely available. Nevertheless, it requires careful evaluation, preferably using a 
standardized protocol. Most often the hypertrophy involves the septal part of the heart, but it 
may affect any segment, even the right ventricle. Adequate transmission and visualization are 
crucial, including correct beam alignment without oblique views. An oblique view may lead 
to overestimation of the wall thickness. For this reason, M-mode measurements in the 
parasternal long axis can be a pitfall. Visualization and accurate measurements are sometimes 
difficult, especially in the apical or antero-lateral part of the left ventricle. The linearity of the 
wall can be enhanced by ultrasound contrast agents. CMR provides high resolution and often 
resolves these issues. Wall thickness measurement is essential for the diagnosis but also as 
  15 
part of risk stratification, which makes accurate assessment so important.131 Recently, body 
surface area adjustment was shown to impact diagnostic cutoff, especially in women.132 
Mitral valve abnormalities are often seen in HCM. The mitral leaflets may obstruct the 
LVOT during systole. This phenomenon, systolic anterior motion, is seen at rest in 
approximately one-third, whereas another third of patients only exhibit this during increased 
loading conditions and contractility.133,134 Some anatomical features of the affected valve 
apparatus are common: papillary muscle hypertrophy, displacement, and elongation. These 
abnormalities of the mitral valve, together with the septal hypertrophy, serve as substrate for 
the LVOT obstruction. 
The definition of LVOT obstruction is ≥30 mmHg independent of rest or physiological stress, 
the Valsalva maneuver, or upright body posture. A higher value, above 50 mmHg, can cause 
hemodynamic and possibly symptomatic changes.15  
The left atrium is prone to enlargement in HCM because of increased filling pressures and 
mitral insufficiency. The size can be quantified using diameter along the parasternal axis and 
body surface area indexed volume.135,136 The former is used for calculation of SCD risk 
assessment.137 
Echocardiographic assessment of diastolic dysfunction includes several aspects; systolic 
pulmonary arterial pressure, left atrial size, filling patterns, and strain.138 Systolic function, 
expressed as EF, is often above the normal values; indeed, it can be supranormal, i.e. very 
high values. The radial contractility is often normal or increased, while longitudinal 
contractility is decreased in the hypertrophied parts.139 When HCM patients deteriorate into 
end-stage heart failure, the EF is reduced. Echocardiography also provides valuable 
morphological and functional information to differentiate among the various etiologies of 
hypertrophy. Transesophageal echocardiography is recommended in perioperative 
assessment during myectomy.15 Echocardiography should be performed for screening 
purposes in persons at genetic risk every 1-2 years between the ages of 10-20 years and then 
every 2-5 years during adulthood.15,140 
5.6.2 Cardiac magnetic resonance 
CMR is nowadays often part of the baseline evaluation. In the situation of inadequate 
visualization of the whole heart by echocardiography, CMR provides diagnostic information 
as well as maximal wall thickness used for risk stratification. LGE seems to reflect 
myocardial fibrosis, has been shown to be useful in risk stratification, and is a 
prognosticator.141,142 Although the amount of LGE correlates with prognosis, LGE findings 
are not part of the current ESC guidelines for risk stratification of SCD. LGE analyses can aid 
in the differentiation among amyloidosis, Anderson-Fabry disease, and sometimes athlete’s 
heart, even though LGE can be absent in patients with mild disease.143 CMR has an important 
role in tissue characterization and differentiation of phenocopies. 
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CMR offers advantages over echocardiography due to its superior spatial resolution and 
accurate volume assessment. Body habitus, chest wall configuration, and pulmonary tissue 
disease can sometimes limit echocardiographic assessment. Of note, CMR quality requires 
gating regarding rhythm and respiratory breath hold for some sequences. Furthermore, its 
availability, portability, and costs limit its use compared to echocardiography. 
Hindieh et al compared maximal wall thickness between echocardiography and CMR in 195 
HCM patients (median age 52.8 years) with both investigations performed within a median of 
41 days.144 The echocardiographic measurements were along the parasternal long and short 
axes and CMR along the short axis. The mean value, using a Bland-Altman plot, was similar 
(difference 0.5 mm). However, in 49.7% of the patients, the discrepancy between methods 
was ≥10%. Underestimation in echocardiography was due to focal LV hypertrophy and poor 
acoustic windows, while overestimation was due to the inclusion of the right ventricular 
myocardium, LV trabeculations, papillary muscle, and apical-septal bundle, as well as 
imaging plane obliquity. 
Accurate assessment of maximal LV wall thickness in HCM is important in several aspects. 
It is needed to determine a definite diagnosis, prognosis, and risk stratification. Both imaging 
techniques are instrumental in HCM evaluation. Echocardiography is portable, easily 
accessible, and allows superior hemodynamic assessment, including measurement of 
dynamic obstruction, quantification of mitral regurgitation severity. CMR provides improved 
spatial resolution, even when limited by acoustic windows. In addition to wall thickness, 
CMR also allows for additional risk stratification by LGE. However, they are not equal when 
it comes to LV wall thickness assessment. 
Assessment of LV wall thickness may vary depending on the technique used. In a 
comparative study, 618 HCM patients were evaluated using CMR and echocardiography on 
the same day.145 Overall, the median difference between these two measurement techniques 
was 3 mm. However, for massive hypertrophy with LV wall thickness ≥30 mm, results 
diverged such that 53% were identified as massive using CMR compared to 17% with 
echocardiography. Only 30% of this subpopulation (n=63) had a diagnosis of massive 
hypertrophy in both CMR and echocardiography. 
5.6.3 Computerized tomography and scintigraphy 
CT is an option in patients if echocardiography is inconclusive and CMR is contraindicated. 
CT may be useful for high-resolution measurement of wall thickness, chamber volumes, and 
LV mass.  
In differentiation of transthyretin amyloidosis bone scintigraphy 99mTC-DPD is useful.146 
Transthyretin-derived fibrils have an affinity for bone tracers and thus help differentiate 
HCM caused by sarcomeric protein gene mutations from other forms of HCM. Otherwise, 
scintigraphy is not useful in microvascular disease with more general disease distribution 
because scintigraphy shows relative perfusion rather than a quantitative assessment. 
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5.6.4 Positron emission tomography 
PET is a noninvasive imaging modality using radionuclide tracers to quantify 
pathophysiological phenomena in the heart.147 Myocardial ischemia without epicardial 
coronary artery disease is a common feature of HCM and implies worse prognosis.147 In 
general, cardiology patients referred for coronary angiography with normal angiograms 
(HCM were excluded) and subjected to sympathetic stimulation using cold pressor testing 
showed that impaired myocardial blood flow (MBF) predicted cardiovascular events.148 
Endocardial dysfunction as a predictor of cardiovascular events aligns with several other 
invasive investigations.149–151 Notably, myocardial perfusion imaging using PET is a sensitive 
marker for microvascular dysfunction. As far back as 1991, Camici et al reported impaired 
MBF using NH3 in both hypertrophied and non-hypertrophied segments in HCM.
152 The 
predominant mechanism of microvascular dysfunction is proliferation of smooth muscle 
collagen in the vessel, which gives rise to luminal narrowing.153,154 A myocardial disarray, 
fibrosis, and small vessel disease have been described.155 MBF at rest is often preserved or 
slightly decreased, and during stress MBF is often decreased.156–162 Cecchi et al showed the 
correlation between MBF impairment and adverse outcome, but there have not been any 
large-scale outcome studies.157 
Oxidative metabolism can be evaluated using 11C-acetate PET and one study showed 
myocardial oxygen consumption (MVO2) was not significantly different between HCM 
gene carriers (no phenotype) and controls, whereas myocardial external efficiency (MEE) 
was significantly lower in carriers.158 This suggests that myocardial energetics is an early 
component of the pathophysiological pathways in HCM. 
PET also provides insights into other pathophysiological phenomena such as oxidative 
metabolism and denervation. While it is still used as research tool in HCM, a clinical role has 
not yet emerged.23,24,163 
5.7 ATRIAL FIBRILLATION AND HEART FAILURE 
5.7.1 Atrial fibrillation 
AF is commonly encountered in HCM due to the pathophysiological enlargement of the left 
atrium caused by increased pressure, diastolic dysfunction, decreased cavity size, outflow 
obstruction, and mitral insufficiency.88,89 In fact, if the left atrial diameter is ≥45 mm, 48-hour 
ambulatory ECG every 6-12 months is recommended.15 
Stroke is recognized as a leading cause of death, disability, and morbidity, including an 
association with dementia.164 AF is a complex condition in interplay with other risk factors 
and is known to cause stroke and systemic embolization, which can be prevented by 
anticoagulant therapy.165 A non-vitamin K antagonist oral anticoagulant is the preferred 
choice for anticoagulation therapy because of superior efficacy, lower risk of bleeding, and 
fewer interactions.166 Both the ACCF/AHA and the ESC guidelines support the prescription 
of anticoagulation regardless of the patient’s CHA2DS2-VASc score.167 More recently, this 
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approach has been confirmed.168 Jung et al showed that HCM patients with AF but without 
any CHA2DS2-VASc risk factors had the same risk for stroke as those with a score of 3, 
which is considered a strong indication for anticoagulation.169 In a Korean registry, patients 
with HCM and AF had better outcomes (both efficacy and safety) on non-vitamin K 
antagonist oral anticoagulants than warfarin (HR 0.47).170 In the Korean registry, the 
incidence rate of AF-associated stroke was 2.94 per 100 person-years but 1.49 in patients <45 
years and 1.48 if the CHA2DS2-VASc score was 0 or 1.
170 
The onset of AF with rapid ventricular response can be highly symptomatic in HCM and 
should generally be managed by beta-blockers and direct cardioversion.171 Calcium-channel 
blockers and amiodarone are sometimes used, but digoxin should be avoided if obstructive 
disease exists.15  
In retrospective studies, catheter-based pulmonary vein isolation was associated with 
favorable outcome in HCM patients with AF.171 
5.7.2 Heart failure 
Patients with HCM may deteriorate into systolic heart failure. When this stage, sometimes 
called end-stage disease, is reached, the obstruction diminishes and wall thinning occurs 
when dilatation takes place.84,172,173 In a tertiary center, end-stage HCM patients comprise 2-
3% of cohorts.174 On an individual level, sarcomeric mutations cannot predict development 
although genopositive patients, as a group, have higher risk.175  
The approach to end-stage HCM is usually the same general pharmacological treatment used 
for heart failure patients with reduced EF, even though no large-scale studies have been 
conducted specifically in the end-stage HCM population.33,176 Cardiac resynchronization 
therapy (CRT) can be used to delay the worsening of heart failure, but transplantation or 
possibly an LV assist device (LVAD) is considered the definitive treatment in selected 
patients. In a cohort of transplanted HCM patients the mean age was 42 years, and 8 years 
elapsed from symptom onset to transplant.173 The survival after transplant has been reported 
as 85% at 1 year and 75% at 5 years, which is at least as good as in other underlying cardiac 
diseases.177,178 LVAD seems to offer similar results, but experience with HCM patients is 
limited.179 In Scandinavia, 2.1% of cardiac transplant procedures were attributable to 
HCM.180 
5.8 GENETIC TESTING 
In approximately half of the HCM cases, genetic panels can reveal a disease-causing 
mutation.181–183 There are numerous mutations, but the vast majority affect myosin protein 
genes MYH7 and MYBPC3. Occasionally, other genetically determined structures of the 
actin-myosin coupling filaments (for example troponins or tropomyosin), are found to be the 
culprit. With some exceptions, the inheritance pattern is autosomal dominant.184 In younger 
patients with the classical phenotype, there is a higher probability of finding a disease-causing 
mutation.  
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Genetic counselling should be an integral part of the evaluation. A detailed family history 
should be obtained and assessed, requiring information from multiple sources. The 
counselling should be performed by trained personnel in a multidisciplinary team. It is 
important to understand that genetic testing cannot rule out HCM. Moreover, a genetic 
variant of unknown significance may complicate interpretation.15  
Typically, the proband is the person in the family who has initially come to medical attention 
and who takes the first step to inform the relatives. The clinician can facilitate this by 
providing a letter that can be distributed among the relatives. In families where a disease-
causing mutation is identified, it can be used to select patients for further evaluation whereas 
genotype negative individuals can be discharged from further follow-up.185 In the case of 
genotype negative results or if a variant of unknown significance is present in a person with 
HCM, first-degree adult relatives should still be evaluated by echocardiography and ECG. 
The penetrance is related to age and repeated assessment is therefore warranted; every 6-12 
months is advised in the beginning then less often (every 2-5 years), unless symptoms 
develop. In children, a pediatric cardiologist should evaluate the findings and inform the 
patient and family about the potential consequences and timing of genetic testing. 
There is a lack of long-term observational data in persons with the genotype but not the 
phenotype. The risk of SCD in individuals who are phenotype-negative seem to be very low, 
except for certain troponin mutations. Again, it is important to follow persons who have not 
yet developed any morphological expression of the disease and provide advice on an 
individual basis.15 
A French registry of 1,432 HCM patients from 26 centers (11 expert and 15 non-expert) 
reported 20% were genopositive and 19% genonegative, while the remaining patients were 
not tested.186 In a Finnish HCM cohort, 38% were genopositive.187 The proportion of 
genopositive patients varies between centers and up to 60% have a genotype that explains the 
disease.15,188,189  
Data from the Sarcomeric Human Cardiomyopathy Registry (SHaRe) showed that compared 
to genonegative HCM patients, genopositive patients had a doubled risk for adverse 
outcomes, which was highest for ventricular arrhythmias.27 Patients with multiple pathogenic 
mutations have earlier penetrance and more severe disease.190,191 
5.9 SUDDEN CARDIAC DEATH 
SCD is usually defined as the “unexpected witnessed sudden death with or without VF or 
death within 1 h of new symptoms or nocturnal deaths with no antecedent history of 
worsening symptoms”192 There has been much attention on the dramatic events of otherwise 
healthy athletes who died suddenly from arrhythmia due to underlying HCM.  
In 2016, Maron et al published data from the US National Registry of 842 competitive 
athletes who died of SCD between 1980 and 2011.193 The most common finding was HCM 
(36%), which was present more often in males than females (39% vs 11%; p<0.001).  
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HCM was more common in African Americans and other minorities (42%) compared to 
Caucasians (31%; p<0.001). 
From a study in Australia and New Zealand, Bagnall et al reported 490 cases (72% males) of 
SCD in patients who underwent autopsy and genetic testing.194 The annual incidence was 1.3 
per 100,000 years with 3.2 per 100,000 in the age group 31 to 35 years. Coronary artery 
disease (24% of cases) was the most common cause, while all inherited cardiomyopathies 
together accounted for 16%. 
Landry et al reported 74 cardiac arrests during sports activities (16 during competitive sports, 
58 during non-competitive sports) in Canada, of whom 44% survived to discharge from the 
hospital.195 The incidence was 0.76 per 100,000 athlete-years in the age range 12 to 45 years. 
For competitive sports, 2 deaths (12.5%) were attributed to HCM compared to 6.9% in non-
competitive sports. In athletes <35 years of age, structural cardiac disease and primary 
arrhythmias were the most common causes of cardiac arrest, but at older ages, coronary 
artery disease was most common of cardiac arrest. 
Finocchiaro et al reported United Kingdom (UK) data on 357 SCD cases in athletes (mean 
age 29 years, 92% males).196 Sudden arrhythmic death was the most common cause of death, 
and HCM accounted for 6% of all deaths. There was a strong association of arrhythmogenic 
right ventricular cardiomyopathy and LV fibrosis with exercise-induced SCD. Notably, 40% 
of athletes died at rest. A smaller Italian cohort of 54 fatal cases (mean age 27 years; 76% 
men) revealed HCM in 9.2%.197 
Lynge et al reported 7% SCD (68% males) among all deaths in persons aged ≤35 years in a 
nationwide Danish study.198 The incidence rate was doubled in men compared to women (3.6 
vs 1.8 per 100,000 person-years; p<0.01).199 Between the years 2000 and 2009 there was a 
decline in SCD from 3.1 per 100,000 person-years to 2.5 per 100,000 person-years. This 
decline was more pronounced in females. The distribution of the underlying causes remains 
basically unchanged. Among autopsied individuals (68%), the proportion of the combined 
group with definite or possible HCM was 9%. In this combined group, 58% could be 
classified as definite HCM. More than half (55%) reported symptoms before death, and 76% 
of these patients were evaluated by medical professionals. 
Wisten reported Swedish forensic autopsies, drug abuse excluded, in persons 15 to 35 years 
between 1992 and 1999 (73 males) and the incidence of SCD was 0.9 per 100,000.200 There 
was a decline in incidence among females. While no structural heart disease was seen in 21% 
of the population, dilated cardiomyopathy and HCM were observed in 12.2% and 10.5%, 
respectively.  
Premortal symptoms suggesting possible cardiac disease included chest pain, dizziness, 
syncope, palpitations, and dyspnea. Notably, in half (50.0%) of all cases, premortal 
symptoms were reported. In HCM patients, three-quarters (75%) reported symptoms before 
death. 
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5.10 RISK STRATIFICATION IN HYPERTROPHIC CARDIOMYOPATHY 
SCD remains a disastrous consequence of HCM. The proven efficacy of ICD therapy, 
documented in diverse HCM cohorts along with the technological advancement, availability, 
reduced costs, and remote monitoring, have provided a lifesaving tool for patients at risk. 
However, risk stratification continues to be a major challenge in management of HCM 
patients. Due to the heterogeneity of the disease, simple risk assessment is not possible. 
Instead, over the years, guidelines have developed that advise clinicians, but controversies 
about the weight of each risk factor and potential modifiers are subject to much debate. There 
are no randomized ICD trials of HCM patients and observational studies do not consistently 
report outcome and methodologies and risk assessment profiles differ among studies. These 
issues are further complicated by treatment options, including septum reduction therapies.  
In 2003, the ACCF/AHA/ESC guidelines were published, which provided a consensus at the 
time.35 In 2011, the ACCF/AHA published updated guidelines.16 The ESC published its 
current guidelines in 2014, which endorsed the HCM Risk-SCD calculator.15 This approach 
has been both welcomed and criticized. In 2019, a more current, updated, standpoint of 
ACCF/AHA guidelines was published.142 In Table 2, the latest three of these documents are 
summarized. 
In the 2011 ACCF guidelines16 four risk modifiers are used: 
 
● LVOT gradient ≥30 mmHg at rest, 
● LGE on CMR, 
● LV apical aneurysm, 
● Genetic mutations considered as “malignant.” 
 
In the ESC guidelines,15 the classes of recommendation are used: 
● Class I: recommended/indicated, 
● Class IIa: should be considered, 
● Class IIb: may be considered, 
● Class III: not recommended. 
 
The corresponding wording in the ACCF/AHA guidelines are: I: should; IIa: reasonable; IIb: 
may be considered; and III: no benefit/harm. The level of evidence A is based on solid 
evidence from randomized trials, B a single randomized trial or observational trials, C from 
smaller studies and expert opinion.15,16 In fact, none of the recommendations in the ESC or 
the ACCF/AHA guidelines for HCM is level A. 
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Table 2. Summary of guidelines and expert opinion regarding risk factors for SCD.15,16,142 
Predictor Model Key message 
Age ACCF/AHA NSVT is more important in age <30 years. 
Enhanced ACCF/AHA Age >60 years implies low risk of SCD. ICD decision on “case-by-case 
basis only when risk markers are perceived to carry particular weight in the 
individual patient.” 
ESC Lower age implies increased risk. NSVT, severe LV hypertrophy, and 
syncope imply higher risk in younger patients. Model used at age >16 
years. 
NSVT ACCF/AHA, IIa C May be a risk factor in the presence of other risk factor/modifier. Some 
value as a risk factor in long-term ECG when detected on 24-h monitoring. 
Enhanced ACCF/AHA Risk factor when ≥3 repetitive brief episodes and/or >1 episodes with ≥10 
beats at ≥130 BPM, usually over 24 to 48 hours of ambulatory ECG. 
More important when associated with another risk marker, particularly 
LGE. 
ESC Risk factor if ≥120 BPM during <30 s, independent of frequency, rate, and 
duration. 
Maximal wall 
thickness 
ACCF/AHA, IIa C Risk factor if ≥30 mm cutoff (binary). 
Enhanced ACCF/AHA Echocardiographic or CMR measurement ≥30 mm, and borderline 28-29 
mm in individual patients. 
ESC Echocardiographic measurement. Continuous variable, non-linear, 
quadratic term used. Caution is urged for interpretation if ≥35 mm.  
Family history 
of SCD 
ACCF/AHA, I B Family history of SCD or appropriate ICD therapy. 
Enhanced ACCF/AHA Family history of SCD likely due to HCM in ≥1 first-degree or other close 
relatives ≤50 years. 
ESC History of SCD in ≥1 first-degree relatives under 40 years of age or SCD in 
a first-degree relative with confirmed HCM at any age (antemortem or 
postmortem diagnosis). 
Syncope ACCF/AHA, I B Unexplained recent syncope. 
Enhanced ACCF/AHA Unexplained syncope, generally ≤5 years. 
ESC Unexplained syncope. Episodes within 6 months are more predictive. 
Left atrial size ACCF/AHA Not part of guidelines. 
Enhanced ACCF/AHA Not part of guidelines. 
ESC Echocardiography, parasternal axis: left atrial diameter. 
LVOT 
obstruction 
ACCF/AHA, IIb B Marked LVOT obstruction if borderline risk, based on other risk factors. 
Enhanced ACCF/AHA LV outflow obstruction with gradient of 50 mmHg or greater at rest is a 
modifier in the presence of another risk factor. 
ESC Maximal LVOT gradient at rest and with the Valsalva maneuver. 
Abnormal 
blood pressure 
response 
ACCF/AHA, IIa C Possibly when associated with another risk factor or modifier. 
IIb C without another risk factor/modifier. 
Enhanced ACCF/AHA Possibly when associated with another risk factor. 
ESC Not a HCM Risk-SCD variable. Recognized to be associated with SCD in 
patients ≤40 years. 
LGE ACCF/AHA, IIb B Risk modifier if borderline risk, based on other risk factors. 
Enhanced ACCF/AHA Fibrosis ≥15% of LV assessed by CMR, using LGE or estimated by visual 
inspection to be extensive and diffuse. 
ESC Not part of guidelines. 
EF<50% ACCF/AHA, IIb C NYHA II/III, optimal medical therapy, EF≤50%. 
Enhanced ACCF/AHA End-stage phase, EF<50% by echocardiography or CMR, usually in 
severely symptomatic patients. 
ESC Not part of guidelines. 
AF ACCF/AHA Not part of guidelines. 
Enhanced ACCF/AHA Not part of guidelines. 
ESC Not part of guidelines. 
Aneurysm ACCF/AHA Modifier that may warrant consideration. 
Enhanced ACCF/AHA Echocardiography or CMR apical aneurysm, independent of size, with 
discrete, thin-walled, dyskinetic segments with contiguous apical scarring. 
ESC Not a HCM Risk-SCD risk factor. 
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The ESC guidelines do not recommend (III B) an ICD in patients with a 5-year risk <4% and 
no proven risk factors. However, there is a statement “…flexible to account for scenarios not 
encompassed…” which opens up the possibility of individual judgment in special cases. The 
HCM Risk-SCD calculator is not validated for those who have undergone or plan to have a 
myectomy or ASA procedures. Genopositive patients without phenotype should not be 
considered for ICDs. In the 2011 ACCF/AHA guidelines, double or compound mutations 
were regarded as a modifier (IIb C), but ESC guidelines do not support this approach. In the 
2003 guidelines, “intense (competitive) physical exertion” was listed as a possible risk factor 
“in individual patients,” but the 2011 guidelines stated that an ICD was not to be considered 
as a reason to allow participation in sports competitions and the HCM Risk-SCD calculator 
was not appropriate for the subpopulation of competitive athletes. Moreover, 
electrophysiological studies should not be part of risk stratification. 
The strongest predictor of SCD is a history of cardiac arrest due to ventricular arrhythmias. 
Such patients have a 40% risk of another episode of SCD in five years so no further risk 
stratification is required.201–203 The low survival rate for cardiac arrest (~10%) makes it 
appropriate to consider ICDs for primary SCD prevention.204 The conflicts between 
guidelines in light of the findings presented in this paper will be extensively elaborated in the 
Discussion.  
5.11 ICD TREATMENT 
Although the decision to implant an ICD in HCM patients, especially for primary prevention, 
requires careful clinical judgement, the implantation itself is often technically feasible.205 
High defibrillation thresholds (DFTs) have been reported, but nowadays perioperative DFT 
testing is seldom performed in Sweden. Single-coil leads are often used and result in adequate 
safety margins and make extraction easier.206 Single-chamber systems can be used unless 
there is an indication for atrial pacing. The atrial lead will allow for atrial pacing in sinus 
node dysfunction, AV-synchronous pacing in high degree AV-block and CRT when sinus 
rhythm is present. Moreover, an atrial lead can detect atrial arrhythmias and allows for 
possibly better discrimination between atrial and ventricular arrhythmias. The principles 
guiding ICD programming should be applied.  
In a detailed analysis of ventricular arrhythmias in HCM patients with ICDs, monomorphic 
VT was the most prevalent (86%), followed by VF/ventricular flutter (9%) and polymorphic 
VT (5%). Ventricular arrhythmias were triggered by premature ventricular complexes in 72% 
of the cases. The risk was highest during midday and lowest at night.207 The ICD delivers 
treatment by either antitachycardia pacing (ATP) or cardioversion. An example of successful 
ATP treatment is depicted in Figure 1. 
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Figure 1. Monomorphic VT terminated by ATP (burst) from an ICD. 
AS, atrial sensing; VS, ventricular sensing 
5.11.1 ICD complications 
Perioperative complications with an ICD as well as short and long-term complications, may 
require intervention. Inappropriate shocks may occur when the ICD cannot effectively 
discriminate between supraventricular tachycardias and VT/VF or because of T-wave 
oversensing, lead dysfunction due to insulation defect or lead fracture, and oversensing of 
external sources.  
In a review published in 2012, complications were reported that occurred in HCM patients 
with ICDs.208 In the meta-analysis, the summary estimate of annualized inappropriate ICD 
shocks was 4.8% (95% confidence interval (CI) 2.9-6.7%). Based on 9 studies, 15% of the 
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patients experienced complications categorized as lead dysfunction (7%), infection (3%), lead 
dislodgement (3%), and others (2%), with an annual estimate of 3.4% per year. In a later 
review published in 2017, the annualized inappropriate ICD shock was 4.9%, lead 
dysfunction 1.4%, lead dislodgement 1.3%, and infection 1.1%, which confirmed previous 
analyses.209  
HCM patients with ICDs are generally younger with long life expectancy. Because of the 
high rate of AF in HCM, thoughtful programming and pharmacological strategies to slow 
AV-conduction are crucial.210 In our Swedish national cohort, the annualized event rate was 
3.0% and the cumulative first inappropriate ICD shock at 1, 3, and 5 years was 7.0%, 10.8%, 
and 14.3%, respectively.211 Notably, 28.2% of the patients experienced recurrent episodes of 
inappropriate shock. In a multivariable analysis, AF was significantly associated with 
inappropriate shock (HR 3.5; p<0.001) while sex, age, secondary indication, and device type 
was similar. The most common trigger for inappropriate shock was atrial arrhythmia (56.5%), 
defined as AF, atrial flutter or ectopic atrial tachycardia. Less common were sinus 
tachycardia (14.5%), lead dysfunction (14.5%), T-wave oversensing (13.0%), and 
myopotential oversensing (1.4%). Complications that resulted in surgical revision occurred in 
28.2% of the patients during a mean follow-up of 5.4 years. In 31.5% of those patients, at 
least one more intervention took place, with the maximum number of repeated interventions 
in one patient being 6. The incidence rate for surgical revision was 8.6 per 100 patient years. 
The cumulative incidence was 9.1%, 15.4%, 24.3% at 1, 3, and 5 years, respectively. Most 
reinterventions were classified as lead-related (70.0%), the vast majority involving the ICD 
leads. Reinterventions were required because of device recalls, a loose setscrew, device 
removal, or pocket modification to ease discomfort (9.3%). When a new device system had to 
be implanted (7.3%), the main reason stated was infection. Interestingly, reintervention was 
associated with female sex (HR 1.6; p=0.04). Thus, device-related complications requiring 
surgical interventions and inappropriate shocks are not negligible in HCM patients with 
ICDs. 
Register-based complication rates may underestimate complications and typically do not 
report inappropriate shocks. In a Danish nationwide validation of cardiac implantable 
electronic devices (pacemaker, ICD, CRT), 9.5% of the patients had a complication in the 
first 6 months (among new implant 9.9%, generator exchange 5.9%, upgrade/revision 14.8%, 
respectively).212 Females had significantly higher risk (adjusted relative risk (RR) 1.3) for 
complications. Dual-chamber ICD was associated with a doubled risk compared with single-
chamber devices. 
5.11.2 The subcutaneous ICD 
In 2009, the subcutaneous ICD (S-ICD) was approved in the European Union and in 2012 in 
the United States.213 The S-ICD constitutes an important evolution in device-based rescue 
therapy, because the entire system is positioned outside the thoracic cavity and does not need 
vascular access for lead placement.214 Transvenous leads have procedure-related 
complications related to vascular access, such as accidental arterial punction, pneumothorax, 
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and nerve plexus injury. Moreover, the lead itself can damage the tricuspid valve, provoke 
arrhythmias, and perforate the right ventricle. In addition, the lead may occlude the vein and 
thrombosis may occur. Leads are prone to insulation breakage and fracture. The system is 
also at risk for infection – a potentially severe complication.215,216 This is not trivial, as 
approximately 20% of ICD leads fail within 10 years.217–219 From this perspective, S-ICDs 
are advantageous in HCM patients, who often have long life expectancy. However, an S-ICD 
does not provide bradycardia pacing or ATP, but there are promising developmental efforts to 
combine so-called “leadless pacing” using an S-ICD with another device to offer CRT.220 
There has been a concern that QRS and T-wave oversensing may be more common in HCM. 
In 27 HCM patients eligible for S-ICD, 4 failed the ECG screening due to bundle branch 
block.221 In the pooled data of 99 HCM patients with an S-ICD, successful DFT testing was 
achieved in 98.9% and complication rates of 7.3% (no lead complications) at 12-month 
follow-up were similar to non-HCM patients with an S-ICD.222 The National Cardiovascular 
Database ICD Registry reported on the use of DFT testing and inadequate safety margins 
with an S-ICD, since these devices require more energy to defibrillate than conventional 
systems.223 Inadequate defibrillation energy, defined as an output <65 J, occurred in 6.9% of 
patients with an initial implant of an S-ICD. This study evaluated S-ICD patients, not all of 
whom had HCM. Risk markers for high DFT were the need for ventricular pacing, 
hypertension, greater body surface area, elevated body mass index, and lower EF.223 
Inappropriate shocks remain a problem for both S-ICD and conventional systems with a 
similar incidence for both types of devices.224 
5.12 PACEMAKER TREATMENT 
According to the general guidelines, HCM patients are indicated for a bradycardia pacemaker 
if they have sick sinus syndrome, high-degree AV-block, or tachy-brady syndrome.117 In 
addition, right-ventricular pacing from the apical region can improve symptoms. AV-
sequential pacing seem to exert a negative inotropic effect and reduces hypercontractility, 
causes dyssynchronous septal-lateral activation, and delays septal thickening, which can 
reduce LVOT gradient.225 In elderly patients and those with bradycardia pacing indication, 
pacing may still be an option.226 In the early 1990s, observational studies showed promising 
results.227–229 However, this could not be confirmed in subsequent randomized studies.230–232 
Perhaps optimized pacing site selection and device programming can improve outcomes. 
Subsequent observational studies with long-term follow-up should be taken into account for 
guidance for patients, especially those with ICDs.226,233,234 In patients with sinus rhythm, this 
could be a reason to implant an atrial lead, i.e. select a dual-chamber system. 
In a recently published paper from the largest center in Sweden, the mean age of HCM 
patients with bradycardia pacemakers was 71 SD 10 years, while ICD recipients were 
younger (53 years).235 Among pacemaker patients, there was an equal distribution between 
the sexes, but among ICD recipients, the vast majority was men (70%). Of all cardiac 
implantable electronic devices, ICDs constituted 59%. 
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5.13 CARDIAC RESYNCHRONIZATION THERAPY 
In a subset (5 to 7%) of HCM patients, systolic dysfunction may develop. An EF<50% is 
considered the onset of end-stage heart failure and some patients rapidly progress toward 
much lower values.172  
CRT has been suggested for HCM patients who develop end-stage cardiomyopathy with 
dilatation of the LV. A small cohort (n=9) of HCM patients did not show prolonged survival 
with CRT.177 In another study of HCM patients with left bundle branch block (n=20; mean 
age 57 years), patients were followed for 13 months, and improvement of one NYHA class 
was seen in 40% and EF improved (41% to 50%; p=0.009).236 Reverse remodeling of the left 
atrium was seen, and the left atrial diameter decreased from 65 mm to 57 mm (p=0.005).236  
In a US study of end-stage heart failure (defined as EF<50% and NYHA III or IV), 130 
patients were included with an EF of 35 SD 14% and a QRS duration of 156 SD 17 ms; 
20/130 patients underwent CRT device implant. At 1-year follow-up 14/20 improved at least 
one NYHA class and echocardiographic parameters showed a decrease in LV end-diastolic 
diameter from 54 to 51 mm (p=0.02).237 Five of these responders deteriorated later and two of 
them received heart transplant.237 
In a cohort of 61 HCM patients with end-stage heart failure, 13 underwent CRT implant 
(mean age 49 years).238 Left bundle branch block was seen in all except one and mean QRS 
was 173 ms and mean EF was 42%. At one year, there was improvement of one NYHA class 
in 54% of the patients but during a mean follow-up of 5.2 years, 46% died.238 The initial 
improvement was not sustained, and it has been speculated that presence of fibrosis may 
make CRT less efficient.239,240 
In summary, CRT may be beneficial in some HCM patient with end-stage heart failure, but 
results may not be durable, many patients will deteriorate, and LVAD/heart transplant may be 
the better treatment option for selected cases. 
5.14 PHARMACOLOGICAL TREATMENT  
The use of pharmacological agents aims to reduce symptoms. Typically, it is targeted to 
reduce obstruction, because there is no pharmacological treatment that delays or reverses 
disease progression. Beta-blockade and non-dihydropyridine calcium-channel blockade seem 
to improve symptomatic burdens, especially exercise tolerance.241 The negative inotropy and 
chronotropy reduce obstruction and improve diastolic filling of the LV. A combination of 
calcium-channel blocker and beta-blocker may cause bradycardia. Less frequently prescribed 
is disopyramide, the use of which is limited due to its anticholinergic side effects and 
proarrhythmia.184,242 Unfortunately, ranolazine does not improve functional capacity in 
HCM.243 Angiotensin blocking agents are currently being investigated in sarcomeric HCM. 
In patients with obstruction, digoxin, diuretics, and vasodilators, including phosphodieserase 
inhibitors, can worsen symptoms.244 
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5.15 SEPTUM REDUCTIVE TREATMENT 
There are two invasive strategies, ASA or myectomy, for reducing septal thickness in order to 
relieve symptomatic obstruction in HCM. Historically, there have been some controversies 
about the preferred option, with an American preference for myectomy, but nowadays both 
methods are considered as safe and effective with some advantages and disadvantages that 
can be discussed in the individual case.245–247 
In a systematic review from 2015, a total of 16 myectomy cohorts and 11 ASA cohorts were 
evaluated.247 The median age of myectomy (n=2,791) and ASA (n=2,013) patients was 47 
and 56 years, respectively. The mean follow-up in myectomy patients was 7.4 years and in 
ASA patients 6.2 years. Long-term mortality was similar, myectomy 1.4% per year and ASA 
1.5% per year (p=0.47). The annualized rate of SCD, or appropriate ICD shock was also 
similar (myectomy 0.5% per year, ASA 0.4% per year). In ASA patients, a reintervention 
was more often required (7.7%) compared to myectomy (1.6%). Permanent pacemaker 
implantation was needed in 4.4% of myectomy patients and 10.0% of ASA patients. Because 
of improvement in periprocedural care, an analysis of procedures after 2000 showed similar 
periprocedural mortality; myectomy 1.1%, ASA 1.3%. The risk of stroke was similar at <1% 
after both ASA and myectomy (p=0.15). Thus, both myectomy and ASA are safe and 
effective, but there are differences in background characteristics, need for reintervention, and 
complications. 
Septal reduction was recently evaluated in a US cohort from a single center with 10 years 
experience of ASA (n=99) and myectomy (n=378) patients; ASA patients were older (66 vs 
53 years; p<0.001) and had a higher burden of comorbidities.248 The periprocedural mortality 
was 0% in ASA and 0.8% in myectomy and permanent pacemaker implant was necessary in 
6.1% of ASA patients and 5.0% of myectomy patients. Over a mean follow-up of 4.0 years, 
mortality was 2.0% for ASA and 2.9% for myectomy, which was not different from the US 
general population. The efficacy, expressed as NYHA I/II was 96% of myectomy patients 
and 90% for ASA. ASA is the preferred choice in the elderly and in patients with substantial 
comorbidity, while myectomy may be preferred in younger patients. Based on several ASA 
cohorts, the risk of SCD is very low.249–252 It should be emphasized that a low volume of 
procedures implies a higher risk of worse outcome and therefore referral to center of 
excellence should encouraged.253 In a European study of myectomy (n=347, median age 47 
years), with a mean follow-up time of 5.2 years, the mean resting gradient decreased from 72 
mmHg to 13 mmHg, 72% of patients improved one NYHA class, there were 5 perioperative 
deaths, and the 5-year survival was 97% (including perioperative mortality) in those with 
septal myectomy alone.254 In total, 6.9% underwent permanent pacemaker implant due to 
preprocedural AV-block. Patients who underwent concomitant mitral valve procedures had 
worse outcomes.254 
A more recent systematic review of myectomy confirmed low 30-day mortality (1.4%) and 
long-term mortality 0.7% per year in procedures after the year 2000.255 
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In a review by Fitzgerald et al, left bundle branch block was common after septal myectomy 
(50-100%), while right bundle branch block more often affected patients who underwent 
ASA (37-70%). A significant AV-block requiring a permanent pacemaker occurred in 2-3% 
of myectomy patients but 10-15% in ASA patients. The authors concluded that both 
procedures should be performed in experienced centers.104 
5.16 LIFESTYLE MODIFICATION 
HCM is indeed a heterogeneous disease with varying expression and burden of symptoms. 
Therefore, individualized counselling is important. Patient education is crucial in order to 
avoid misunderstanding and promote shared decision-making. HCM patients should refrain 
from competitive sports participation according to guidelines, which at the same time 
encourage a healthy lifestyle. Evidence-based approaches to exercise in HCM are lacking. 
Nevertheless, sports activities seem to be safe in athletes with ICDs and the individual’s 
preferences may be taken into account.109,256–258 Historical observations about SCD in HCM 
athletes have been updated to a more currently accepted incidence range of 0.03-0.10%, with 
most fatal events occurring outside sports activities.259,260 Sweeting et al evaluated physical 
activity in HCM patients with and without ICDs using accelerometer data for one week.261 
From the International Physical Activity Questionnaire, mean physical activity was 239 SD 
300 min/week with 51% who fulfilled physical activity guidelines and was similar between 
groups. Interestingly, nearly half of the participants claimed that the ICD made them more 
confident to exercise. 
There are few data specifically on HCM, but moderate-intensity physical activity seems to 
improve exercise capacity.262,263 Because obesity confers an adverse prognosis, a healthy 
lifestyle should be encouraged.264 Advice on athletic activities should primarily be based on 
phenotype and rather than genotype only.265 
Patients with obstructive disease may worsen from large meals, dehydration, sauna, and 
triggers for sympathetic autonomic nervous system activation.  
The disease may influence a patient’s occupational activities, life insurance, pregnancy, 
education, and driving, so a holistic approach is warranted for individual counselling. 
Fortunately, unhealthful diet, sedentary lifestyle, obesity, sleep-breathing disorder, anxiety, 
and depression are all amenable to treatment and should be targeted in HCM overall 
management.266 
5.17 PROGNOSIS AND SEX DIFFERENCES 
Contemporary treatments for HCM are reassuring for a majority of patients with regard to the 
risk of SCD.267 The heterogeneous nature of the disease also translates into prognosis. In a 
recent meta-analysis, the pooled 1, 5, and 10-year survivals are 98%, 82%, and 75%, 
respectively.268 Thus, the timely diagnostic evaluation and treatment is warranted in order to 
recommend interventions to improve survival rates of HCM patients. 
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A higher proportion of men (55-65%) has been reported in numerous HCM cohorts.269 
Female hearts are generally smaller, even when adjusted for body surface area, which may 
affect application of diagnostic criteria based on wall thickness. Females are often older at 
initial evaluation and express more symptomatic burden and possibly worse survival. The 
reason for this difference is not fully understood and it has been speculated based on animal 
models that estrogen exerts cardioprotective effects.270,271 In a large tertiary US cohort of 
HCM patients (n=2,123), all-cause mortality was higher in women (9% vs 5%, p=0.001) after 
a mean follow-up of 3.9 years; however, specficially HCM-related mortality rates were 
similar and after age adjustment, there was no significant difference between the sexes in all-
cause mortality.272 Notably, the age at first appropriate ICD therapy was similar, albeit 
women presented with HCM 6 years later. At presentation, more women than men had 
symptomatic HCM categorized as NYHA II-IV (73% of women vs 53% of men), more often 
developed drug-refractory heart failure, and were diagnosed a mean of 6 years later. In 
another large US cohort similar findings was seen with worse survival of women in uni- and 
multivariable analysis (HR 1.17; p<0.001) and using propensity score matching.273 In a Dutch 
cohort of 1,007 HCM patients (62% males), females had a higher age at presentation (56 vs 
49 years; p<0.001), more LVOT obstruction (37% vs 27%; p<0.001), and more women than 
men had a low EF (17% vs 11%; p=0.01), but all-cause mortality and cardiovascular 
mortality were not significantly different at 6.8 years of follow-up.274 Recently in a study of 
4,893 HCM patients from several European tertiary centers (64% males, 49.2 years at first 
evaluation), the standardized mortality rate (SMR) was 2.0 (95% CI 1.5-2.6), with higher 
SMR for women than men (2.7 vs 1.7; p<0.001).275 
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6 RATIONALE OF THE THESIS 
HCM is a heterogeneous disease with diverse clinical manifestations. Unfortunately, SCD is 
a well-known outcome of HCM and risk stratification is both challenging and controversial. 
ICD is an established treatment in the prevention of SCD but the determination of appropriate 
candidates for device-based treatment among unselected HCM patients is largely unknown. 
In this regard, the Swedish Pacemaker and ICD Registry provides a valuable resource to 
identify HCM patients who received an ICD. This nationwide cohort of unselected patients 
and subsequent validation of medical records from all relevant health care providers 
constitutes a unique tool for studying the efficacy and association of risk factors without 
tertiary center bias. The mortality and causes of death of HCM patients with ICD have been 
largely unknown in unselected patients. Swedish registries and population statistics also 
provide data for age, sex, and calendaric match compared to the general population. The 
benefits of ICDs need to be elucidated as part of overall survival rates in long-term studies. 
Health-related quality of life (HRQL) is an essential part of patient-related outcome 
measurements and should be assessed in specific groups, including HCM patients with ICDs, 
rather than generalized from other patient groups. HCM patients are younger, have different 
disease manifestations, and have a longer life expectancy than general cardiomyopathy 
patients. Besides quantitative assessment of HRQL, a holistic view of patients with HCM 
using a qualitative approach may provide a basis for a deeper understanding from a patient 
perspective.  
Finally, starting with confirmatory analyses of HCM patients with ICDs, an explorative 
approach using PET technology was performed in order to potentially refine current 
understanding and risk stratification. Hence, the rationale for this thesis is to elucidate 
different aspects of ICD treatment in HCM. 
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7 AIMS 
7.1 GENERAL AIM 
The general aim of this thesis was to elucidate different aspects of ICD treatment in patients 
with HCM. This includes: characterization of current ICD use among HCM patients with a 
focus on risk stratification for ventricular arrhythmias requiring ICD therapy, mortality, and 
cause of death; assessment of HRQL; qualitative aspects of living with an ICD; and 
characterization using PET and exploration of risk markers for sudden death. 
7.2 SPECIFIC AIMS 
The specific aims of each paper were: 
Ⅰ. To describe the characteristics of HCM patients with ICDs in Sweden based on the 
nationwide cohort and study associations of risk markers and appropriate ICD therapy during 
long-term follow-up. 
Ⅱ. To assess causes of death, including contributing causes, of HCM patients with ICDs in a 
nationwide cohort, establish predictors of death, and compare mortality to the matched 
Swedish general population. 
Ⅲ. To examine generic HRQL among ICD patients with HCM, including comparisons of 
sub-groups, and compare it to age- and sex-matched general Swedish norms. 
Ⅳ. To qualitatively explore the individual, patient-reported, experience of living with HCM 
and an ICD. 
Ⅴ. To describe HCM patients with ICDs using PET parameters that reflect MBF at rest/stress, 
oxidative metabolism, and innervation, and explore associations of HCM with the presence of 
NSVT at device interrogation.  
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8 MATERIALS AND METHODS 
This section covers study design, setting, participants, variables, data sources/measurements, 
bias, study size, statistical methods, including the handling of quantitative variables using the 
structure of strengthening the reporting of observational studies in epidemiology (STROBE) 
statement.276 For the qualitative study, standards for reporting qualitative research (SRQR) 
applies, which specifically addresses the qualitative approach and research paradigm, 
researcher characteristics and reflexivity, context, sampling strategy, data collection and 
processing, data analyses, and trustworthiness.277  
8.1 STUDY DESIGN 
Papers Ⅰ and Ⅱ were quantitative longitudinal observational studies using a retrospective 
approach. 
Paper Ⅲ was a quantitative cross-sectional observational study using a questionnaire. 
Paper Ⅳ was a qualitative study using a hermeneutic approach and latent content analyses. 
Paper Ⅴ was a quantitative observational study using both a prospective and retrospective 
approach. 
8.2 SETTING 
All participants in the studies and comparison groups, i.e. population norms and demographic 
data, were citizens of Sweden. Their ethnic origins were unknown. Paper Ⅰ, Ⅱ, and Ⅲ were 
based on the nationwide Swedish Pacemaker and ICD Registry. In Paper Ⅳ, the interviews 
were conducted with patients living in Region Gävleborg and Region Västerbotten. Paper Ⅳ, 
part of the PET-project, recruited patients from four regions: Gävleborg, Dalarna, 
Västerbotten, and Värmland. A map of Sweden (Figure 2) shows the regions and cities 
relevant for Paper Ⅳ and Ⅴ. 
8.3 PARTICIPANTS 
8.3.1 Paper Ⅰ, Ⅱ, and Ⅲ: recruitment and data collection 
All patients with an ICD due to HCM were identified by the Swedish Pacemaker and ICD 
Registry in November 2012. It included every patient with this combination who ever had an 
ICD, including CRT, with the underlying etiology classified as HCM. Patients who were 
younger than 18 years at the time for data extraction were removed from the dataset. All 
patients who were alive were contacted for consent to retrieve data from their medical records 
for data collection, including validation of the underlying diagnosis. They were contacted by 
regular mail, including telephone reminders if there was no response by mail. We used the 
Swedish Tax Authority Census Bureu online, which is frequently updated, for information 
whether the patient was alive before contact was attempted. Patients were asked to list all 
relevant outpatient visits and inpatient care at hospitals. The same information was retrieved 
from the National Inpatient and Outpatient Register, but patients were also asked to cover for 
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possible delay in registration. The same data collection, including retrieval of medical 
records, was obtained for deceased patients based on ethical approval. In total, 12 major sites 
and regional archives were visited for data collection to review medical records, including 
paper charts, microfilms, and scanned data. The clinics with only a few relevant records were 
asked to send copies by mail. Patients with an unequivocal diagnosis of HCM were included 
and phenocopies were excluded. It was sometimes challenging to validate HCM diagnoses, 
and all patients who were excluded or for whom there was diagnostic uncertainty were 
discussed in detail by the two cardiologists, Magnusson and Mörner. 
The survey was sent by regular mail including a postage-paid envelope for return to the 
investigators. After three mail reminders, a phone call was made to remind patients who had 
not returned the survey. When the survey was returned, the patient was contacted if there 
were missing data in order to obtain complete answers for each item. 
Figure 2. Map of Sweden with marked regions relevant for Paper Ⅳ and Ⅴ. Map modified 
from Statistics Sweden, with permission.278 
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8.3.2 Paper Ⅳ: recruitment and data collection 
This study was based on interviews of identified HCM patients from the Swedish Pacemaker 
and ICD Registry who were living in the Region Gävleborg or Region Västerbotten at the 
time. All patients were adults, >18 years of age, and had an implant of a transvenous ICD at 
least two years ago to reflect a more chronic state. To explore several aspects of HCM 
patients with ICDs, a maximum sampling of variables was the objective. This sampling 
strategy including variables such as age, sex, time since diagnosis, both primary and 
secondary indications for ICDs, history of appropriate ICD therapy, but also inappropriate 
shock complications. The candidates were contacted by phone and scheduled for an 
appointment with the interviewer. The patient could choose if the interview would take place 
at the research facility, clinic, or as a home visit.  
8.3.3 Paper Ⅴ: recruitment and data collection  
Potentially eligible candidates for participation were identified by an updated search in the 
Swedish Pacemaker and ICD Registry based on their postal address described in the section 
above. Medical records were scrutinized in order to validate the diagnosis of HCM, but 
phenocopies were excluded. Patients with a history of decompensated systolic heart failure or 
CRT were likewise excluded, as they were considered to represent end-stage heart failure at 
the time of inclusion. Patients who had epicardial coronary artery disease with lumen 
narrowing of 50% or more at coronary angiography or CT angiography for any clinical 
evaluation outside the study protocol were excluded. Because PET examinations were part of 
the study, patients who were pregnant or had a history of claustrophobia were deemed 
ineligible and thus excluded. As adenosine was part of the exam using 15O-water to achieve 
physiological stress, a known allergic response or signs of intolerability to adenosine, 
hypotension (systolic pressure 100 mmHg), increased intracranial pressure, hypovolemia, and 
concomitant dipyramidole treatment were considered as contraindications.  
8.4 VARIABLES 
The definitions of the clinical variables are listed below. They agree with widely used 
definitions in the scientific literature but also reflect areas where there are no commonly 
agreed standards. 
8.4.1 Primary and secondary prevention 
Prevention of SCD by ICDs is divided into two categories. Secondary prevention refers to 
implantation in survivors of cardiac arrest or sustained VT with hemodynamic compromise. 
Primary prevention, on the other hand, refers to patients without verified sustained VT/VF 
and is based on evaluation of risk factors. This distinction adheres to the commonly used 
strategy throughout risk stratification regarding SCD.32–34 
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8.4.2 Risk factors 
The risk factors in the Papers are described below. 
● Family history of SCD 
Our studies used a family history of SCD, or the surrogate appropriate ICD therapy, in a first-
degree relative, i.e. parent, child, or sibling, before the age of 55 years and assumed to be due 
to HCM. This was not prespecified before data collection but turned out to reflect the practice 
of clinicians who use it as risk factor in the decision-making whether to implant an ICD. The 
statement in the ESC definition is “...one or more first-degree relatives have died suddenly 
aged <40 years with or without a diagnosis of HCM, or when SCD has occurred in a first-
degree relative at any age with an established diagnosis of HCM.”15 The ACCF/AHA 
guidelines has a definition without any age cut-off: “sudden death presumably caused by 
HCM in one or more first-degree relatives.”16 Although not a formal guidelines endorsed by 
an organization, a recent update modified the statement: “Family history of SCD judged to be 
definitively or likely caused by HCM in one or more first-degree or other close relatives 50 
years or younger.”142 See Table 3. 
 
● Unexplained syncope 
In Papers Ⅰ-Ⅲ, syncope (but not pre-syncope or near-syncope) deemed unexplained by the 
physician who decided about ICD implantation was considered a risk factor. 
 
● NSVT 
A run of ventricular beats, ≥3 in a row at a rate of 150 BPM (400 ms) with a duration of <30 s 
was considered NSVT in risk stratification in Paper Ⅰ-III.  
 
● Maximal myocardial wall thickness 
The maximal wall thickness of any segment of the entire LV either on echocardiogram or 
CMR. If there was a discrepancy between imaging methods, typically the higest value was 
used unless it was deemed invalid from the reasoning in the medical records. 
 
● Abnormal blood pressure response at exercise 
Although several definitions of this variable exist, we adhered to the inability to increase 
blood pressure by ≥20 mmHg or a hypotensive response on exercise test. In Sweden, 
ergometer bicycle tests are almost always used for this assessment. 
 
● Atrial fibrillation 
According to the generally accepted definition of AF, only episodes of ≥30 s was 
considered.167 We included all kinds of reliable monitoring devices for AF in addition to the 
standard 12-lead ECG, i.e., previous pacemaker EGM, insertable cardiac monitor (formerly 
known as an implantable loop recorder), ambulatory ECG like 24-48 h ECG, or R-test. 
Thumb-ECG was not used in any case to assess AF. 
  
● Systolic heart failure 
Patients often had several echocardiography evaluations. If the EF was <50%, it was deemed 
a risk marker. This cut-off also harmonizes with current guidelines. CMR was used for EF 
assessment only if echocardiographic imaging quality was poor. 
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● Outcome 
Appropriate ICD therapy was defined as the combined endpoint of cardioversion, i.e. 
“shock,” and ATP, i.e. burst or ramp. Multiple treatments of different episodes VT/VF within 
24 hours were counted as one event. In Paper Ⅴ, the rate of 160 BPM was used because of 
uniform assessment of NSVT among ICDs at interrogation. The composite outcome was 
sustained ventricular arrhythmias consisting of VT with a duration of at least 30 s, cardiac 
arrest, or appropriate ICD therapy. 
 
● PET-specific variables 
In Paper Ⅴ, several PET variables were used. These PET variables are specified in section 
8.5.3.3 along with theoretical background; echocardiographic variables are described in 
section 8.5.4. 
Table 3. Summary of definitions in the largest ICD studies (n >100) of HCM patients. 
First author Year Size 
(n) 
PP 
(n) 
Family history of SCD NSVT 
Begley279 2003 132 85 ≥2 sudden death in first- 
degree relatives <55 
years. 
NSVT on Holter. 
Maron203 2007 506 383 SCD judged to be 
definitively or likely 
caused by HCM in ≥1 
first-degree or other 
close relatives ≤50 
years. 
≥3 repetitive brief 
episodes each consisting 
of ≥3 or more beats and/or 
1 or more prolonged 
episodes (≥10) at ≥130 
BPM, usually over 24 to 
48 hours of ambulatory 
ECG. 
Cuoco250 2008 123 100 SCD in a first-degree 
relative. 
Not used as risk factor. 
Syska280 2010 104 78 HCM‐related SCD ≥1 
first‐degree relatives, 
aged <40 years. 
≥3 beats at heart rate of 
≥100 BPM on 24‐hour 
Holter. 
O’Mahony281 2012 334 307 SCD attributed to HCM 
in ≥1 first-degree 
relatives. 
NSVT on Holter 
monitoring. 
Vriesendorp282 2013 134 93 ≥1 HCM-related SCD in 
close relatives. 
NSVT on Holter 
monitoring. 
Magnusson283 
 
2016 321 237 SCD (or appropriate 
ICD therapy) of ≥1 first-
degree relative assumed 
to be due to HCM. 
≥3 beats at heart rate of 
≥150 BPM on any type of 
ECG. 
Thavikulwat284 2016 135 125 SCD in a first‐degree 
relative. 
≥3 beats ≥100 BPM with a 
duration ≤30 s. 
Wang285 2017 160 155 According to ACCF 
2011 guidelines. 
≥3 consecutive beats at a 
rate of >120 BPM, 24- or 
48-hour ambulatory ECG. 
 
PP, primary prevention 
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8.5 DATA SOURCES 
This thesis is based on studies in which patients with HCM were primarily identified using 
the Swedish Pacemaker and ICD Registry in conjunction with the National Inpatient and 
Outpatient Register. To validate registry data, all relevant medical records were scrutinized. 
In Paper Ⅱ, demographic data from Statistics Sweden were used.286 In Paper Ⅲ, a national 
Swedish population norm was used for comparisons. 
Sweden has a history of registration of personal data, which dates back to 1686 when it 
became compulsory for the Swedish church to administer parish registers.287 This facilitated 
civic planning, including military recruitment. In 1749, Tabellverket was founded to 
coordinate local parish registers, which was subsequently taken over by Statistics Sweden in 
1858.288 Since 1947, each Swedish citizen has a unique personal code based on date of birth 
and four more digits. This provides a framework for register research.289 The Cause of Death 
Register started in 1961 and the National Patient Register began in 1964 and became 
mandatory in 1987.76,290 Today, there are more than 100 national health registries, classified 
as quality registers, in Sweden.291 This provides investigators with robust and complete data 
that few other nations can match. 
Many research projects in Sweden are based on registries, often linked to each other either as 
epidemiological studies or a source to identify patients for recruitment to studies.  
8.5.1 Swedish Pacemaker and ICD Registry 
The nationwide Swedish Pacemaker and ICD Registry has an almost complete coverage of 
all implants throughout the country.292,293 We retrieved data on all patients who had an ICD 
due to HCM since the start. These data were then merged with data from the National Patient 
Register to identify all relevant inpatient and outpatient care for each patient.  
8.5.2 SF-36 
The 36-item Short Form (SF-36) questionnaire is used to assess general health status and is 
designed to assess generic health concepts applied in a broad range of age groups, diseases, 
and interventions across different cultural settings.294,295 This HRQL instrument, which is 
often attributed the term “multidimensional”, was developed in the Medical Outcome Study 
and has been frequently used in studies since the start in the 1990s.296 The extensive 
implementation of HRQL questionnaires in research is based on the assumption that they 
fulfill psychometric prerequisites across a wide range of patient groups and general 
populations. The researchers set up data quality assurance, properties of test scaling, and 
measures of internal consistency for all domains in the validation work Medical Outcomes 
Study. They performed these analyses for thousands of patients, and reproduced them in 
subgroups with various background with regard to demography, underlying diagnoses, and 
degree of severity of diseases. It was concluded that the response rate ranged from 88% to 
95% for each question; notably a bit lower in the elderly, patients with lower educational 
levels, and patients with socioeconomic burdens. In 96% of the cases, there was enough data 
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to calculate a reliable score for each domain. Moreover, 97% of all individual questionnaires 
passed the test with regard to internal item consistency and item-discrimination validity was 
92%. Measurements of reliability coefficients had a median of 0.85, although it varied from 
0.65 to 0.94. The floor-ceiling properties were examined. Overall, the floor-ceiling effects 
were small, but both role disability domains showed floor effects, while ceiling effects were 
noted in both disability scales and the domain SF. Thus, SF-36 rely on a solid base of 
validation work, at least for research purposes on a group level. It is notable that SF-36 is a 
generic instrument for measurement of HRQL, which is not designed for disease-specific 
research questions. Nevertheless, it constitutes a platform for estimation of generic HRQL.296 
The standard questionnaire contains 36 questions but there are simpler versions using 8 and 
12 questions. In the full version, physical health is divided into Physical functioning (10 
items), Role physical (4 items), Bodily pain (2 items), and General health (5 items).296 The 
mental health section includes Vitality (4 items), Social functioning (2 items), Role emotional 
(3 items), and Mental health (5 items). In addition, there is question about general health 
transition based on the general health today compared to a year ago and another global 
question about the perception of current health status. McHorney examined discriminant 
validity, scale homogeneity and reliability using Cronbach´s alpha for internal validity, a kind 
of intraclass correlation.296 The precision of the questions is balanced, typically 3-5 of 
alternatives is enough. Otherwise, it can lead to difficulties distinguishing the different 
categories of answers from each other. Moreover, a large number of items may lead to 
unreliability in validation work using repeated testing because answers tend to be 
inconsistent. If all subjects answer low or high, the test can be said to have floor-ceiling 
effects. The sensibility across different groups are part of validation work.  
The extended applicability of the SF-36 Health Survey into an international context was 
endorsed by the International Quality of Life Assessment (IQOLA) Project. This adoption by 
IQOLA incorporated a standardized translation into several languages, including Swedish. 
The questionnaire was administered through regular mail with a proportion of 68% who 
responded during 1991-92. The 8,930 respondents, 51.8% females, aged 15-93 years (mean 
42.7 years) varied by marital status, education, socio-economic status, and geographical 
area.297 The same psychometric methods used in the validation work in the US were applied. 
More than 90% had complete answers, missing data were more common in the elderly >75 
years. Item consistency was excellent and reliability estimates above 0.80 (highest for Bodily 
pain, above 0.90) and most physical component scales. In summary, this validation work of 
the Swedish version provided a norm population which allowed age- and sex-matched 
comparison with our cohort. We decided to use this version rather than version 2 for the 
purpose of comparison with norm population.298 
8.5.3 PET technology 
PET is a noninvasive imaging modality that depicts the distribution of a radionuclide-labeled 
tracer that is injected in a vessel.299 This technology relies on radionuclide decay by the 
elementary particle positron, an antimatter with opposite charge, but the same mass as an 
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electron. The positron releases from the nucleus and collides with electrons; kinetic energy is 
lost and converted to gamma-ray photons. Based on the formula E=mc2, the energy is 
conserved and the two gamma rays proceed in opposite directions. These rays can be detected 
and their coordinates refer to the point where the original decay of the positron happened.300 
From these coordinates, geometrical volumes of interest are constructed. The spatial 
resolution of modern PET technology is 4 mm. The detectors are optimized for the amount of 
energy generated by the gamma rays (511 keV). The scanner consists of thousands of crystals 
in a cylindrical form of rings.301 
Besides high imaging quality, quantitative accuracy is important in cardiac PET to assess 
distinct anatomical measurements. To achieve accurate measurements, calibrations, 
attenuation, and scatter corrections are needed for reconstructions. Even though standardized 
protocols have been developed, the optimal imaging parameters vary among detectors. ECG-
gated imaging requires more total counts because of the division of counts over multiple 
frames; larger doses and longer scan times may be required. PET technology is integrated 
into CT imaging. Moreover, software application is used to yield final imaging results, 
including quantification. 
8.5.3.1 PET-tracers 
PET provides quantitative assessment of MBF in absolute values rather than qualitative, 
relative findings as in single-photon emission computed tomography imaging.302 The spatial 
resolution of modern PET is far better than SPECT, which allows for regional differentiation. 
This makes this type of imaging advantageous in HCM, because HCM is a heterogeneous 
disease with regional variations in phenotype. The most widely used tracers for quantification 
of MBF are 15O-water, 13N-ammonium, and 82Rubidium. 15O-water is an ideal tracer because 
of free diffusion, metabolic inertness with full complete extraction from the myocardium 
independent of flow velocity.303 In the normal heart 15O-water and 13N-ammonium both show 
high accuracy.304,305 In the presence of scar tissue and altered metabolism, 13N-ammonium 
and 82Rubidium are less reliable because of the discrepancy in kinetic modeling due to 
changes in myocardial tracer uptake.306 However, many tracers, including those used in our 
study, require a cyclotron in close proximity to the PET scanner which limits availability. 
The tracer 11C-acetate is the most commonly used method for accurate noninvasive 
assessment of MVO2. The 2-carbon-chain free fatty acid of acetyl-CoA is metabolized 
through the tricarboxylic acid cycle. The turnover of 11C-acetate based on the coupling of the 
tricarboxylic acid cycle and oxidative phosphorylation corresponds to the oxidative 
metabolism expressed as MVO2. The bi-exponential curve fitting, or a simplified method 
from the directly linear portion of the cardiac activity curve over time, is used to measure the 
kinetics of the tracer in the heart, the rate constant k1, which represents the myocardial 
clearance of 11C-activity (11CO2) and correlates closely with MVO2 under diverse 
conditions.147,307–309 
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PET also provides an assessment of myocardial autonomic innervation.310,311 The tracers for 
presynaptic catecholamine innervation are either biological catecholamines or analogs. The 
former follow metabolic pathways, while the latter may resist certain pathways, for example 
in the vesicular storage inside the nerve terminal part or presynaptic uptake transporters. The 
biological target of 11C-meta-hydroxyephedrine (11C-HED) is presynaptic catecholamine 
uptake.312,313 This tracer is a norepinephrine analog and is probably the most commonly 
applied PET tracer for sympathetic neuronal imaging.311,312 Like norepinephrine, via the 
uptake-1 mechanisms, plasma HED is transported into the terminal ends in the sympathetic 
nervous system and is inert to enzyme activity and remains in the myocardium for 30 
minutes. Thus, the retention of HED is highly dependent on reuptake by the norepinephrine 
transporter.314,315 Autonomic nervous system dysfunction has been elucidated in ischemic 
cardiomyopathy and dilated cardiomyopathy with marked reduction in retention.314,316,317 
8.5.3.2 PET-protocol 
The PET scans were performed at Uppsala University Hospital, Sweden. The scanners were 
two GE Discovery MI (GE Healthcare, Waukesha, WI) which made parallel patient exams 
possible. The procedures started in the morning after fasting overnight and patients refrained 
from caffeine and tobacco use 24 hours before the first scan. Due to the half-time of the 
tracers, the scans were conducted in the following order: 15O-water at rest and then at 
adenosine stress under supervision of a cardiologist, 11C-acetate and finally 11C-HED. The 
isotopes were produced by a cyclotron. In order to achieve an attenuation correction, a low-
dose, respiration-averaged CT was performed before the tracer was injected. A 400 MBq of 
15O-water was given intravenously using an automated injector as a fast bolus and a 6-minute 
emission scan was started. The procedure was repeated at adenosine infusion. The data were 
reconstructed into 22 frames using a standard protocol. Because of the half-time (2.0 minutes) 
of 15O-water, the next tracer started approximately 30 minutes after the first tracer was 
finished. The labelled 11C-acetate (433 SD 84 MBq) was injected by the same technique and a 
27 min scan was started. After these exams, the patient left the machine and had a rest while 
the tracer decayed. In the afternoon, the final exam took place. A second CT was thus 
required before the 11C-HED scan. Again, after tracer-injection (385 SD 70 MBq) a dynamic 
list mode emission scan was simultaneously started, this time for 27 minutes. The data were 
reconstructed using standard protocols including, 22 (15O-water), 31 (11C-acetate), and 31 
(11C-HED) frames, respectively. 
8.5.3.3 Data analyses 
All PET scans were analyzed using the aQuant software.318 The arterial and right-ventricular 
concentrations were automatically obtained using cluster analysis.318,319 The standardized 
myocardial segmentation and nomenclature for tomographic imaging of the LV wall based 
on the 17-segment model was used (Figure 3).320  
The 5 regions were categorized as anterior, septal, inferior, lateral, and apex. The analysis and 
calculation of the PET-variables were performed by two expert physicists who were blinded 
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to the outcome. Their inter-observer repeatability was excellent, i.e. intraclass correlation was 
>0.98 for all parameters. 
Figure 3. The 17-segment model of the left ventricle.320 
 
 
 
The tracer 15O-water was quantified using the standard one tissue compartment model.321 The 
MBF at rest was adjusted for rate pressure product. Based on a previously published method 
for heterogeneity index, this was derived by dividing the maximum MBF by the lowest 
MBF.322 The transmural perfusion gradient (TPG) was defined as the quotient of the 
endocardial/epicardial MBF by splitting the 17 segments each in equal halves based on their 
distance to the LV cavity. To estimate the so-called defect size, the total volume of the LV 
with MBF × perfusable tissue index below 50% of maximum for rest and MBF <69% of 
maximum for stress was calculated. 
The mathematical modeling of 11C-acetate likewise used a one tissue compartment model, 
but with corrections for blood volume fraction and spillover from blood.323 The input 
functions were calculated by applying the average plasma metabolite correction.308 The 
MVO2 was derived from the clearance rate (k2) and conversion factors.
308 The MEE is the 
proportion of MVO2 that is actually used in cardiac work, thus it was possible to calculate 
how efficiently the myocardium could handle energy; the calculations for forward cardiac 
output and LV mass could be derived from PET images.323 The transmural gradient for 
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MVO2 was calculated the same way as MBF. The end-diastolic volume, end-systolic volume, 
and stroke volume were calculated and adjusted for body surface area using ECG-gated 
images.308 The EF of the LV was calculated as stroke volume/end-diastolic volume. 
The kinetics of the 11C-HED can be described using a one-tissue-compartment model, 
corrected for spill-over from both the right and left ventricle, and with average plasma 
metabolite correction.324 The basis for this model is the rate of 11C-HED transfer from blood 
to myocardium and the opposite flow, i.e. the transfer from the myocardium to the blood. The 
parameter K1 represents the influx rate, while the k2 represents transfer from the myocardium 
to the blood or the clearance rate. The ratio K1/k2 (uptake rate/clearance rate) is the volume of 
distribution (VT) and represents the net uptake when the equilibrium between tissue and 
blood has been reached. K1 is dependent on the extraction fraction of C-HED and can be used 
as an index of MBF at rest.325 Retention index (RI) was calculated as the quotient of the late 
uptake activity and the integral of the non-metabolite corrected arterial input function. The 
defect size was defined as the total volume of the LV with RI <75% of maximum. Using the 
principles for calculation transmural gradient mentioned above, RI, VT, and clearance rate 
were calculated. 
8.5.4 Echocardiography 
Echocardiography is a cornerstone in evaluation of HCM patients. Papers Ⅰ-Ⅳ used 
retrospective data from medical records. These data were used in part for validation of 
diagnosis, but they were also used for risk assessment. Due to the retrospective nature of data 
without a standardized protocol for prospective evaluation, several variables were missing or 
not robust. For example, left atrial size was often not included in the echocardiographic 
evaluation and the LVOT gradient assessment was often unreliable.  
In Paper Ⅴ, echocardiography was part of the research protocol with predefined variables. 
Two experienced physicians, blinded to other patient data, independently evaluated all 
echocardiograms. The objective of this study was to verify the HCM diagnoses of the patients 
and compare their PET data. In Paper Ⅴ, it was possible to report the following 
echocardiography variables: left atrial diameter (mm), left atrial size/body surface area 
(ml/m2), LV diameter, diastole (mm), LV diameter, systole (mm), LVOT gradient (mmHg), 
LV outflow obstruction ≥30 mmHg at rest or with the Valsalva maneuver, EF (%), maximal 
wall thickness (mm), tricuspid annular plane systolic excursion (mm), and systolic pulmonary 
artery pressure (mmHg).  
8.6 STUDY SIZE 
Papers Ⅰ-III were based on the Swedish Pacemaker and ICD Registry with national coverage. 
Efforts were made to gather complete data. Compared to many international cohorts, a large 
database was achieved based on all available data. Nevertheless, subgroup analyses are prone 
to both type I and type II errors. Paper Ⅳ was based on 26 conducted interviews, which is 
rather large given the qualitative nature of data from patients with long longitudinal narratives 
of a complex disease. Paper Ⅴ was based on 25 HCM patients with ICDs; a formal power 
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calculation was deemed difficult because of uncertainty of outcome estimates in the design 
phase. Considering the multiple tracers and extensive protocol for selected patients with 
HCM and ICDs, the number of patients included was comparatively large. PET is also costly 
and requires considerable resources, which further limited sample size. 
8.7 STATISTICAL METHODS 
Descriptive statistics is the process of quantitatively describing or summarizing features of a 
dataset.326 In inferential statistics, it is assumed that the dataset is sampled from a larger 
population. The properties of the population are inferred by hypothesis testing and derived 
estimates. 
8.7.1 Descriptive data 
Frequencies were described as numbers (n) and ratios (i.e. proportions) as percentages. When 
a ratio is related to time it was described as a rate. Dichotomized data were used to describe 
variables with binary outcome but also if a variable had certain cut-offs for definitions or 
decision-making. The arithmetic mean is the sum of numeric values divided by the total size 
of sample. The mean uses all the data but outliers may heavily influence this value. If the data 
were deemed skewed, then the median rather than the mean was chosen for a central 
measurement. The median was occasionally used, and it reflects the middle value of ordered 
observations. The median is the 50th percentile but other percentiles could be used to describe 
the dispersion of the data. Typically, the 25th and the 75th percentile were reported and the 
interquartile range. The full variability of the dataset was presented as the lowest and highest 
value, i.e. the range. 
The standard deviation and its CI were used to estimate the dispersion of the assumed true 
parameter within a proposed range. The width of the CI is affected by the data variability, the 
sample size, and the confidence level. In the analyses, a confidence level of 95% was used by 
convention. 
8.7.2 Statistical models 
The distribution of data was categorized as binomial, normal or Poisson. A scatter-plot or 
histogram was typically used to determine the distribution of the dataset.  
8.7.2.1 Comparison of two independent groups 
Fisher’s exact test, or the chi-square test, was used to compare categorical data based on a 
contingency table. 
The t-test was chosen if the data were continuous and normally distributed with similar 
standard deviations. 
In the case of a non-normal data distribution, the Mann-Whitney U test was used. It requires 
the data to be ordinal, i.e. they could be ranked in relation to each other. The null hypothesis 
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H0 assumes that both populations are equal, whereas the alternate hypothesis H1 assumes the 
distributions are not equal.327,328 
8.7.2.2 Comparisons using time-related data 
A Kaplan-Meier estimate was used to model time to event data, including graphical 
presentation. The start of time was initial ICD implantation. In Paper Ⅰ for risk marker 
analysis, follow-up time was censored when it was no longer possible for the patient to 
receive appropriate ICD therapy (death, device explant, downgrade to pacemaker, loss to 
follow-up). In Paper Ⅱ, data were censored for death. In patients who experienced an 
appropriate ICD therapy, the time to first event was used. The Kaplan-Meier estimate is non-
parametric test based on the survival function using a product-limit function.328,329  
 
In this equation, ti is the time when at least one event occurred, di the number of events (e.g., 
appropriate ICD therapy or deaths) that happened at time ti, and the patients known to have 
not had an event up to time ti. In the curve, the x-axis denotes time and the y-axis cumulative 
survival/freedom from event. In the graphical presentation, each horizontal line is the time 
interval and a vertical line denotes that an event did occur. Below the x-axis, the number of 
patients at risk was presented. In Paper Ⅱ, two curves were outlined to represent the 95% CI. 
When two groups were compared, different lines and dots, in addition to color, was used. The 
significance between groups was calculated using Mantel-Cox p-values. 
The Cox proportional hazard model was used to study the association of covariates with 
regard to time, expressed as hazard ratios (HRs). It is used for both binary and continuous 
predictors. In univariable analyses, the predefined predictors were used. The multivariable 
analyses were based on the rationale for including a predictor rather than backward or 
forward elimination. There is a general assumption that for every variable included, a 
minimum of ten events is advisable to ensure regression coefficients with acceptable 
precision. 
Incidence rate was defined as all events that occurred during the total follow-up period. This 
implied that multiple events were counted several times, in contrast to Kaplan-Meier estimate 
where only the first event was counted. The annualized rate was calculated as the proportion 
of patients who experienced at least one event as the numerator and the sum of follow-up 
time of right censoring as the denominator. Cumulative incidence was the proportion who 
reached the outcome at a certain time, often expressed as 1, 3, and 5-year incidences. 
In Paper Ⅱ, crude mortality of the whole cohort was calculated with the number of deaths as 
the numerator and patient-years of follow-up since first ICD implant as the denominator. This 
study followed patients even if they were downgraded to a pacemaker, underwent heart 
transplant, or the device was inactivated or explanted for another reason. The SMR was 
defined as the observed number of deaths in the cohort divided by the expected number of 
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deaths based on Swedish data from the general population. The population data was 
controlled for age, calendar period as the mortality changed in the population, and sex. The 
95% CI for the SMR was based on the assumption of Poisson distribution.  
8.7.3 Significance level 
Significance level, denoted by alpha, is the probability of rejecting H0; when the p-value from 
a test is less than the significance level it can be concluded that this difference is true.330 The 
predetermined alpha level is typically set to 5%. With two-sided distribution, an alpha level 
of 2.5% for each side was applied.  
Type I error is the rejection of a true H0 which implies a false-positive finding. On the other 
hand, the non-rejection of a false H0 leads to false-negative conclusion known as type II 
error.328 The probability of type II error is denoted beta. The conventional value beta=0.2 was 
used. 
We used a p-value of 0.05 for confirmatory approaches and 0.10 for explorative approaches. 
Small cohorts and subgroup analyses are prone to both type I and type II errors, so in these 
cases p-values in the range of 0.05 to 0.10 were described as tendencies. 
8.7.4 Effect size  
In Paper Ⅲ on HRQL, the magnitude of a significant difference between groups was 
expressed as an effect size (ES). The ES of a difference was estimated by calculating the 
mean difference, and then dividing it by the pooled standard deviation using Cohen’s d.331 
We used standard criteria in our descriptions of the ES: 
● trivial (<0.20),  
● small (0.20-0.49),  
● moderate (0.50-0.79), and 
● large (≥0.80).331 
8.7.5 Computer software 
The databases were stored as files in Excel 2010 (Microsoft Corporation, Redmond, WA). It 
was then imported to other statistical software. For statistical analyses and graphical 
presentations, we used Excel 2010 (Microsoft Corporation, Redmond, WA), SPSS version 
22-24 (IBM, Armonk, NY), R (R core team, 2014), and SAS version 9.2 (SAS Institute Inc., 
Cary, NC). Illustrations were done using the software tools Adobe Illustrator 2015.5 (Adobe 
Inc, San Jose, CA) and PowerPoint 2013 (Microsoft Corporation, Redmond, WA). 
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8.8 QUALITATIVE METHODS 
8.8.1 Practical approach to the interviews 
The interview started with information about the study, some initiating background questions 
followed by open-label questions. The intention was to create an environment that facilitated 
the patients’ freely reflective narratives. The interview guide (Table 4) served as a framework 
with both open-ended and specific questions to ensure that all relevant areas were covered. 
This mitigated the risk we might avoid or neglect certain topics and it assured the interviews 
all had a uniform structure. The order of the questions was not important; instead, participants 
were encouraged to speak freely and bring up feelings from their own perspectives. At the 
end of the interviews, the guide was used to check that all areas were covered and sometimes 
some complementary questions were addressed. Most of the time, active listening by the 
interviewer allowed most of the topics to be addressed in spontaneous conversation. 
Often the patients brought up questions about their disease and management. To separate the 
roles of the interviewer and the responsible clinician but at the same time provide service to 
the patient, a contact with the clinician was advised or arranged if requested. 
Each interview was audio-recorded digitally and transcribed verbatim. Notably, the 
interviews ranged from 81-210 minutes and the mean was 135 minutes. In total, this 
generated about 59 hours of recorded interviews. 
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Table 4. The interview guide. Reproduced from Paper Ⅳ, appendix 1, with permission.332 
Topic Questions 
Background • How old are you? 
• Do you live with anybody? 
• Do you have children? 
Early questions • What is it like to live with HCM and ICD? 
• How and when did you get the HCM diagnosis? 
• When did you get the ICD? 
General health • What do you think about your health? 
• How do other people consider your health? 
• In what way does the ICD affect your health? 
• Has your health changed over time? 
• What do you think about your future health? 
Professional life • Are you working/studying? 
• Has your professional life been affected by HCM/ICD? 
• Do you think your future career will be affected by HCM/ICD? 
Leisure time • In what way has your leisure time been affected? 
• Do you exercise? How does that work? 
• Did you get advice on activity levels? Do you follow this advice? 
Family & Friends • Is family life affected by HCM/ICD? 
• How did your relatives know about your HCM diagnosis and ICD? 
• What do your family and close friends think about your having an ICD? 
• What do your family and friends know about your HCM and ICD? 
Driving • Do you have a driver’s license? Which certificates? 
• Are your driver’s licenses affected by HCM/ICD? 
• Did you drive for a living? 
• What advice did you get about driving? 
Insurance • Did your insurance company act differently based on your HCM/ICD? 
Lifestyle • What kind of food do you eat? Alcohol? Smoking? 
Medication • Which pharmaceutical drugs do you take? 
• Do you take these drugs as prescribed? 
• Do think that these drugs relieve symptoms/cause side effects? 
Diagnosis of HCM • What made them suspect HCM? How long did it take to be diagnosed? 
ICD • When and why did they decide about the ICD? 
• What do you think about the information before ICD implant? 
• Did you experience ICD shock (appropriate/inappropriate)? 
• How was the implant procedure? 
• Did you experience any surgical complications? 
• Does the ICD give you a sense of security? 
• Did you ever regret receiving an ICD? 
• Do you know how to turn the ICD off? 
• What is the difference between a pacemaker and an ICD? 
Health care • What could be improved in health care in HCM and ICD? 
• Did you ever contact a patient association? 
• Do you use internet/social media? For HCM/ICD communication? 
• What can the society do to improve care for HCM/ICD patients? 
Sexuality • Is your sex life affected by HCM/ICD? 
• Did you need medication to improve sexual performance? 
Reproduction • What are your concerns about your child getting HCM? 
Pregnancy • Did HCM/ICD affect your pregnancy? 
Genetics • Have they found a mutation causing your HCM? 
• Did the genetic counselling affect the family? 
Sleep • How is your sleep quality? 
• Has your sleep been affected by HCM/ICD? 
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8.8.2 Hermeneutics and content analysis  
Qualitative approaches to content analysis allow for a deeper understanding of a text. They 
aim to analyze a text beyond the sentences to a greater depth, i.e. interpreting the actual 
underlying meaning. This implies that the analysts acknowledge the usefulness of their own 
pre-understanding. The pre-understanding is formed by the socially and culturally 
conditioned background of experiences. Krippendorff refers to this as an interactive-
hermeneutic approach.333 Content analysis is a technique to gain reliable and valid references 
from texts. It should be highly reliable and thus replicable. Berelson originally stated that 
content analysis should be an objective and systematic research technique.334 He argued that a 
systematic approach was crucial, because humans have the tendency to selectively interpret 
texts in order to support preexisting thoughts, rather than question the pre-understanding. To 
improve validity, a systematic approach for handling the texts is needed in order to produce 
replicability and become part of external validation. In fact, results from content analysis can 
be measured, but objectivity is inherently difficult because it is interpretation made by 
humans. However, content analysis can be operationalized as a process toward the meaning 
of a text within a context. Context is crucial and even when one tries to be objective about 
context, it still remains a subjective construct.333 Merten adheres to this thought by claiming 
that content analysis is a way inquiring into social context and is a tool to infer the 
nonmanifest message from the manifest message.335,336 Thus, the analysis needs to handle 
extra-textual phenomena, that is, the meaning and consequences of what was stated. We set 
out a framework of areas for exploration by using an interview guide but were also open to 
the patients leading the interview in specific directions. The empirical grounding of the areas 
to explore was based on the experiences of clinicians treating these patients along with the 
methodological expertise of the group. It was inspired by hermeneutics and content 
analysis.337–339 The basis for interpretation of a text using a hermeneutic approach is the 
hermeneutic circle. This circle encompasses “both as a movement between tradition and the 
movement of the interpreter.”340 The awareness and reflexive approach of the analysts pre-
understanding based on contextual experience provided a solid base for meaningful 
interpretation. The rigor of the study is underpinned by pre-understanding of the area of 
hermeneutics.341,342 At the same time, pre-understanding was balanced by a reflective 
approach and interaction with other in the research group. This was achieved based on a 
framework of trustworthiness, credibility of the interview technique, and rationale for the 
interview guide to facilitate richness and in-depth narratives.343 During the structured analysis 
and comprehensive understanding, interpretation was approached with critical reflection on 
pre-understanding.344 The hermeneutic circle also provided a model for movement between 
the parts and the whole. While a single interview was dissected into parts, it was also built 
into the whole of all of the other interviews. The judgement of transferability of text into 
interpretation used examples of citations and thematization in a stepwise manner. The 
intertwining of narrative and theoretical themes was discussed among the authors. 
The inferences often took an abductive approach from logically distinct domains from one 
kind to another kind, but also inductive approaches from particulars to generalizations.345 
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The main advantage of unstructured data is the preservation of the data´s sources. Because 
the text is context sensitive, it is the responsibility of the interpreter to process the data to be 
meaningful, informative, and representational to the readers.346 Nevertheless, the unstructured 
data need to be handled in structured way. The huge quantity of text in this study had to 
undergo categorization according to a scheme. Importantly, this scheme had to be applied to 
every text unit in the same way.347 
8.8.3 Analysis and interpretation of text 
The transcription of the interviews was written using the software Microsoft Word. The 
practical approach to analyze the data was inspired by the concepts and practical procedures 
proposed by Graneheim and Lundman to organize data and achieve trustworthiness.348 The 
first step was a naïve reading of the text. The guiding principle was to read each interview 
without interruption and to get an overall impression of story from the narrative itself. This 
was done with of all the interviews and followed by discussions with the researcher of 
preliminary interpretations of each interview and the cohort as a whole. In the next step, each 
interview was analyzed using a structured approach in which the text was condensed into 
meaning units based on the aim of study. In this way, unnecessary parts with less relevance 
were removed. Then these condensed meaning units were further broken into shorter phrases 
and labelled with a code. In order to be specific, these codes were diverse. When each 
interview was analyzed this way, these codes could be decontextualized, i.e. brought out from 
each interview and put together. Based on further interpretation and interactive discussion 
among researchers, clear themes emerged based on the narratives. From these narrative 
themes, more generalized theoretical themes could be developed to characterize the main red 
threads in the text. Altogether, this was an attempt to concretize the hermeneutic vision of 
“unfolding the world in front of the text,” as stated by Ricoeur.349 The final determination of 
themes was preceded by another reading of the interviews from a holistic viewpoint. 
8.9 ETHICAL APPROVALS AND LICENSES 
The studies were conducted in accordance with good clinical practice based on the principles 
of the Declaration of Helsinki.350–352 All patients, who were alive, gave their written informed 
consent participation including data acquisition. Papers Ⅰ, Ⅱ, and Ⅲ were based on approval 
by the Ethical Review Board in Stockholm (document number 2012/1301-31/3). The study 
that resulted in Paper Ⅳ was approved by Regional Ethical committee in Uppsala (document 
number 2015/060). Finally, the PET-study, which also needed approval by the local radiation 
committee was approved by the Regional Ethical committee in Uppsala (document number 
2017/021). 
The company Quality Metrics (OptumInsight Life Sciences, Inc., RI) provided the SF-36 
(Swedish version) questionnaire with the license number QM015832. The translation into 
Swedish was validated.  
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9 RESULTS 
This section summarizes the key findings from the scientific projects, upon which Papers Ⅰ-Ⅴ 
were based. 
9.1 VALIDATION OF DIAGNOSIS AND DATA EXTRACTION 
In all papers, the diagnosis of HCM was validated using medical records followed by a 
thorough discussion between the cardiologists Magnusson and Mörner. The extract from the 
Swedish Pacemaker and ICD Registry based on HCM as the underlying etiology yielded 
misclassification in 31 patients (8.3%). In these cases, there was never actually a diagnosis of 
HCM. Instead, other forms of cardiomyopathies, valvular heart disease, malignant 
hypertension and ion-channelopathies were diagnosed. A flow-chart summarizes patient 
extraction and recruitment into each study (Figure 4).  
Figure 4. Flow-chart of patient extraction in each study. 
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9.2 PAPER Ⅰ 
9.2.1 Patient characteristics 
Patients with an unequivocal HCM diagnosis and available medical records with all relevant 
variables were analyzed. The final sample consisted of 321 patients, of whom 225 were men 
(70.1%). The mean age at the time of ICD implant was 52.1 years SD 15.4 with a mean 
follow-up of 5.4 years, which corresponds to a total of 1,733 patient-years. The vast majority 
(n=237; 73.8%) had ICD due to primary prevention and the remaining due to secondary 
prevention. Most patients underwent dual-chamber ICD implantation (n=225; 70.1%), i.e. a 
right atrial lead and a right ventricular lead. In 66 patients (20.6%), a single-lead ICD was 
implanted either because of permanent AF or no need for atrioventricular (AV) synchrony 
based of absence of sinus node dysfunction. A total of 30 patients (9.3%) underwent 
implantation with a LV lead, i.e. CRTD.  
Notably, 42 patients were upgraded from a pacemaker to an ICD/CRTD. Among these 42 
patients, 22 (52.4%) had the first implantation of the pacemaker to alleviate symptoms due to 
LVOT obstruction. The decision to implant an ICD/CRTD was based on risk stratification at 
the time (the five conventional risk factors and EF≤35%) in all except two patients (0.6%). 
One of these patients experienced VF during the implantation of a bradycardia pacemaker 
when the right ventricular lead encountered the apical wall. This induced VF caused the 
implanting physician to switch to an ICD system. It was deemed as primary prevention, as it 
was not a spontaneous VF but rather was induced by catheter manipulation in the right 
ventricular chamber. The other patient who lacked an established risk factor was physically 
active and whose uncle (second-degree relative) suffered from HCM with subsequent lethal 
VF without successful resuscitation. 
The five risk factors were NSVT, unexplained syncope, abnormal blood pressure response at 
exercise test, wall thickness ≥30 mm, and a family history of SCD. In primary prevention, 
these risk factors are typically addressed in the clinical evaluation. In contrast, systematic 
assessment was deemed unnecessary by the clinician in secondary-prevention patients, i.e. 
survivors of cardiac arrest or sustained VT, as the decision to implant an ICD did not require 
such evaluation. In addition to the conventional risk factors, we added a history of AF and 
EF<50%. The clinical characteristics of the whole cohort are reported in Paper Ⅰ. The 
summary of the risk markers among primary and secondary prevention patients is presented 
in Table 5. 
  
  53 
Table 5. Risk markers among HCM patients with primary and secondary prevention 
indication for ICD. Modified from Magnusson et al.283 
Variable 
  
Primary 
prevention 
n=237 (73.8%) 
Secondary 
prevention 
n=84 (26.2%) 
All patients 
                      
n=321 (100%) 
Age at implant, year 51.6 SD 15.6 53.5 SD 15.2 52.1 SD 15.5 
Men 165 (69.6%) 60 (71.4%) 225 (70.1%) 
Risk markers†    
Atrial fibrillation 66 (27.8%) 25 (29.8%) 91 (28.3%) 
Ejection fraction <50% 50 (21.1%) 15 (17.9%) 65 (20.2%) 
NSVT 138 (58.2%)   
Syncope 84 (35.4%)   
Exercise BP response 17 (7.2%)   
Wall thickness ≥30 mm 58 (24.5%)   
Family history of SCD 62 (26.2%)   
BP, blood pressure; †Atrial fibrillation and ejection fraction <50% were risk markers evaluated for all patients, whereas the 
others were solely for primary-prevention patients. 
9.2.2 Outcome 
A total of 45 patients died. The primary outcome, appropriate ICD therapy, occurred in 77 
patients (24%). Using the definition described in the Method section, i.e. that multiple 
treatment of different episodes of VT/VF within 24 hours were counted as one event, the total 
number was 183 appropriate ICD therapies. The distribution is shown in Figure 5.  
Figure 5. Number of appropriate ICD therapy events during follow-up per patient. 
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Among the first episodes in the 77 different patients who experienced an appropriate ICD 
therapy, 40 (52%) required cardioversion while in the remaining 37 (48%), ATP was enough 
to terminate the VT. The overall efficacy of terminating potentially life-threatening 
ventricular arrhythmias was excellent. All VT/VFs were terminated by the ICD, but in one 
case a VT below the programmed detection zone recurred, which resulted in prolonged 
circulatory collapse and subsequent multiorgan damage and finally death.  
The cumulative 1, 3, and 5-year incidences of appropriate ICD therapy were 8.1%, 15.3%, 
and 21.3%, respectively. The time-to-event analysis is graphically shown as Kaplan-Meier 
estimates (Figure 6). Thus, the risk of VT/VF requiring appropriate ICD therapy persists over 
the years. 
Figure 6. Kaplan‐Meier event‐free appropriate ICD therapy for the whole HCM cohort. 
Reproduced from Magnusson et al, with permission.283 
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In patients with a secondary-prevention indication, the time-dependent Kaplan-Meier 
estimate of appropriate ICD therapy was higher than for primary prevention (p=0.044). The 
difference was mainly due to a higher risk in the first year in secondary prevention compared 
to primary prevention (Figure 7). There was a trend toward a higher risk among males than 
females (p=0.073) as shown in Figure 8. 
Figure 7. Kaplan‐Meier event‐free appropriate ICD therapy for primary and secondary 
prevention in HCM. Reproduced from Magnusson et al, with permission.283 
 
Figure 8. Kaplan‐Meier event‐free appropriate ICD therapy for men and women with HCM. 
Reproduced from Magnusson et al, with permission.283  
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9.2.2.1 Risk markers for appropriate ICD therapy in the whole cohort 
In secondary prevention, the decision to implant an ICD was based on a history of a 
spontaneous, life-threatening VT/VF. Thus, a systematic collection of risk markers was not 
considered necessary by the clinicians. Instead, AF, EF<50%, male sex, and age at implant 
were analyzed in a univariable followed by a multivariable analysis in a Cox proportional 
hazard regression model. The result is summarized in Table 6. 
Table 6. Association of clinical variables and first appropriate ICD therapy for the whole 
HCM cohort (77 events in 321 patients). Reproduced from Magnusson et al.283 
Predictor Univariable Multivariable  
HR 95% CI p-value HR 95% CI p-value 
Age at implant, year 1.016 1.000-1.032 0.043 1.009 0.99-1.03 0.273 
Men 1.63 0.96-2.76 0.073 1.54 0.90-2.64 0.113 
Atrial fibrillation 1.83 1.14-2.93 0.012 1.39 0.83-2.14 0.214 
Ejection fraction <50% 3.05 1.89-4.92 <0.001 2.63 1.60-4.33 <0.001 
Notably, age was significant in the univariable analysis (p=0.043) but after adjustment of 
other risk markers, it was not significant in the multivariable analysis (p=0.273). Similarly, 
the risk marker AF showed significant difference in the univariable (p=0.012) but not in the 
multivariable analysis (p=0.214). The risk factor EF<50% was strongly associated with 
appropriate ICD therapy in univariable analysis with a three-fold increase and remained 
highly significant in the multivariable analysis. 
9.2.2.2 Risk markers for appropriate ICD therapy in primary prevention 
In primary prevention, the conventional risk markers were analyzed with regard to the 
outcome appropriate ICD therapy. The risk marker abnormal blood pressure response/ 
exercise blood pressure response was not systematically addressed in some cases, because the 
clinician had enough information to recommend an ICD; the absence of this risk marker was 
assumed when an exercise test was not part of the clinical evaluation. The uni- and 
multivariable variable analyses are summarized in Table 7.  
Table 7. Association of clinical variables and first appropriate ICD therapy in primary 
prevention (47 events in 237 patients). Reproduced from Magnusson et al.283 
Predictor Univariable Multivariable  
HR 95% CI p-value HR 95% CI p-value 
Age at implant, year 1.025 1.004-1.046 0.017 1.001 0.98-1.02 0.915 
Men 1.20 0.64-2.27 0.572 0.93 0.48-1.80 0.833 
Atrial fibrillation 3.60 1.95-6.65 <0.001 2.54 1.25-5.17 0.010 
Ejection fraction <50% 3.70 2.00-6.87 <0.001 2.78 1.39-5.56 0.004 
Nonsustained VT 1.97 1.05-3.69 0.034 1.80 0.88-3.68 0.109 
Syncope 1.13 0.63-2.03 0.688 1.11 0.59-2.10 0.746 
Exercise BP response 1.62 0.64-4.12 0.312 1.40 0.50-3.92 0.520 
Wall thickness ≥30 mm 0.99 0.50-1.95 0.936 1.42 0.69-2.92 0.342 
Family history of SCD 0.60 0.28-1.29 0.190 0.77 0.34-1.75 0.532 
BP, blood pressure. 
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Again, age at implant turned out to be significant in the univariable analysis but not in the 
subsequent multivariable analysis. Both AF and EF<50% were significant in univariable and 
multivariable analyses. Among the conventional risk markers, NSVT had the strongest 
association; it was significant in the univariable (p=0.034) analysis but had a borderline 
tendency in multivariable analysis (p=0.109). 
In patients with any of the five conventional risk markers alone, appropriate therapy occurred 
in 15 out of 52 patients with NSVT; 3 out of 23 with unexplained syncope as a risk marker; 
exercise blood pressure response 0 of 2; wall thickness ≥30 mm 1 of 15; and family history of 
SCD 2 of 26. When patients without a history of AF or EF<50% were excluded, no patient 
with the single risk marker of unexplained syncope (0/15) and family history of SCD (0/15) 
experienced appropriate ICD therapy. In this subset of patients, no one had solely abnormal 
blood pressure response as a single risk marker.  
In another multivariable analysis of the four risk markers NSVT, unexplained syncope, wall 
thickness ≥30mm, and a family history of SCD, but not abnormal blood pressure response at 
exercise, the risk marker NSVT was the strongest (Table 8).  
Table 8. Association of four established risk factors and first appropriate ICD therapy in 
primary prevention. Based on the study by Magnusson et al.283 
Predictor Multivariable  
HR 95% CI p-value 
NSVT 1.97 1.00-3.88 0.050 
Syncope 1.25 0.68-2.32 0.475 
Wall thickness ≥30 mm 1.08 0.53-2.18 0.837 
Family history of SCD 0.78 0.34-1.78 0.557 
 
The corresponding Kaplan-Meier estimate of these four risk markers plus AF, and EF<50% 
is shown in Figure 9. The Mantel-Cox p-values differ slightly compared to Table 8 due to 
methodological difference in Cox regression between the softwares. 
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Figure 9. Kaplan‐Meier event‐free appropriate ICD therapy for primary prevention patients 
with HCM and risk markers: A) atrial fibrillation, B) ejection fraction ≤50%, C) nonsustained 
ventricular tachycardia, D) syncope, E) wall thickness ≥30 mm, and F) family history of SCD 
(FHxSCD). Reproduced from Magnusson et al, with permission.283 
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Clearly, for patients with 2 or more risk markers, compared to a single marker, the time to 
first appropriate ICD therapy was significantly shorter (p=0.012), as depicted in Figure 10. 
Figure 10. Kaplan‐Meier event‐free appropriate ICD therapy for HCM patients with 
primary-prevention indication based on number of risk markers at implant. Risk markers: 
NSVT, syncope, exercise blood pressure response, maximal wall thickness ≥30 mm, family 
history of SCD, EF at implant ≤35%. Reproduced from Magnusson et al, with permission.283 
 
 
 
9.3 PAPER Ⅱ 
9.3.1 Patient characteristics 
This paper was based on the same extract of the Swedish Pacemaker and ICD Registry used 
in Paper Ⅰ with an additional 21 patients, for whom additional data were available, 
specifically age at implant and date of death if appropriate for mortality calculations. 
However, there was paucity of detailed data on clinical characteristics for risk prediction for 
these 21 patients.  
As explained in the Method section, the follow-up time was from primary ICD implant until 
last follow-up (death or alive). The mean age at ICD implant was 51.8 SD 15.5 years and 
70.8% were men. The 25th, 50th, and 75th percentile age at implant was 41.6 years, 53.4 years, 
and 63.9 years, respectively. The age distribution between men and women at ICD implant 
were similar; the mean age was similar overall (p=0.63), and in the oldest quartile (p=0.77).  
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9.3.2 Outcome 
In total, 45 out of 342 patients (13.2%) died during a mean follow-up of 5.4 SD 4.2 years. 
Among the 45 deceased patients, the mean age at death was 68.2 years. The 25th, 50th, and 
75th percentile ages at death were 63.6 years, 69.8 years, and 76.8 years, respectively. The 
age at the time of death is depicted as a bar chart (Figure 11).  
Figure 11. Age at death among 45 patients with a history of hypertrophic cardiomyopathy 
and implantable defibrillator. Reproduced from Magnusson et al, with permission.353 
 
 
 
During follow-up, 15 patients underwent explant of the ICD at the time of heart transplant or 
LVAD and 2 of them died. One of these patients died postoperatively due to circulatory 
collapse caused by a cardiac tamponade. The other patient died from progressive heart failure 
of the transplant. In addition, 5 other patients had their ICDs explanted. The reasons were 
downgrade at advanced age (n=2), extraction after infection without replacement (n=2), and 
recurrent inappropriate shocks (n=1). In the latter patient, despite several attempts and 
strategies to avoid inappropriate therapy delivery, he requested that the ICD device to be 
turned off. Unfortunately, he died from subsequent VF a few years later.  
The cumulative 1, 3 and 5-year survivals were 97.0%, 93.4%, and 89.4%, respectively. The 
estimated mean survival of the whole cohort was 17.3 years.  
9.3.2.1 Mortality 
The crude mortality was 2.44 per 100 patient-years for the whole cohort. Among the 45 
decedents, 30 were men (13.3%) and 15 women (15.6%). In the time-dependent analysis, 
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using Kaplan-Meier survival, the crude mortality was almost identical (p=0.97) between 
sexes as seen in Figure 12. 
Figure 12. Kaplan-Meier survival of 342 hypertrophic cardiomyopathy (HCM) patients with 
implantable defibrillator (ICDs) with regard to sex. Reproduced from Magnusson et al, with 
permission.353 
 
The SMR, i.e. matched for age, sex, and calendar period in relation to the national general 
population in Sweden, increased (3.35 [95% CI 1.5-4.8]; p <0.0001). The Kaplan-Meier 
survival plot including 95% CI and expected survival in the general Swedish population as a 
reference is seen as Figure 10.  
Figure 13. Kaplan-Meier survival of 342 HCM patients with ICDs compared with Swedish 
general population (age- and sex-matched). The log-rank p-value is <0.0001. The dotted gray 
lines represent 95% CI. Reproduced from Magnusson et al, with permission.353 
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Again, there was a similar SMR between men (3.15; 95% CI 2.12-4.49) and women (3.85; 
95% CI 2.15-6.30). Moreover, 12% of the primary-prevention patients died, while 19% of the 
secondary-prevention patients did, which implied similar death rates (p=0.77).  
9.3.2.2 Causes of death 
In three quarters (75.6%) of the patients, the main cause of death was related to the 
underlying HCM. The vast majority died from progressive systolic heart failure (60.0%). The 
other HCM-related causes of death were VT/VF (4.4%) and embolic stroke (11.1%). The 
main causes of death are summarized in Table 9. Notably, in 45.5% of the cases with a non-
HCM-related main cause of death, HCM was deemed a contributing cause of death. 
Table 9. Main cause of death among 45 patients with a history of HCM and ICD. 
Reproduced from Magnusson et al.353  
Main cause of death  Frequency  %  
HCM-related 34  75.6  
   Heart failure  27  60.0  
   Stroke    5  11.1  
   Ventricular arrhythmia    2  4.4  
Non-HCM-related 11  24.4  
   Cancer    3  5.4  
   Myocardial infarction    2  4.4  
   Sepsis    2  4.4  
   Pneumonia    1  2.2  
   Alzheimers disease   1 2.2 
   Diabetes mellitus   1 2.2 
   Ileus   1 2.2 
All deaths 45    100 
 
9.3.3 Prediction of death 
We performed a Cox regression univariable analysis of age at implant, male sex, AF, 
EF<50%, secondary indication, and a history of appropriate ICD therapy, followed by a 
multivariable analysis of all these variables included in the model (Table 10). Age at implant, 
calculated in 1-year increments was significantly associated with death in both the 
univariable and multivariable analyses. AF was strongly associated with death in the 
univariable analysis (HR 3.36; p<0.0001) but less so in the multivariable analysis (HR 1.81; 
p=0.214). EF<50% was strongly associated both in the univariable analysis (HR 5.02; 
p<0.0001) and multivariable analyses (HR 5.00; p<0.0001). 
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Table 10. Association of clinical variables and death in HCM patients with ICDs. 
Reproduced from Magnusson et al.353  
Predictor Univariable Multivariable  
HR 95% CI p-value HR 95% CI p-value 
Age at implant, year 1.101 1.068-1.135 <0.001 1.086 1.05-1.12 <0.001 
Men 1.00 0.54-1.86 1.00 1.04 0.53-2.02 0.113 
Atrial fibrillation 3.36 1.79-6.30 <0.001 1.81 0.93-3.56 0.214 
Ejection fraction <50% 5.02 2.80-9.04 <0.001 5.00 2.57-9.73 <0.001 
Secondary indication 1.10 0.59-2.04 0.77 1.26 0.64-2.48 0.50 
Appropriate ICD therapy 1.04 0.55-2.00 0.89 0.55 0.28-1.10 0.09 
 
9.4 PAPER Ⅲ 
9.4.1 Patient characteristics 
In total, 245 adult HCM patients with transvenous ICD systems returned a complete SF-36, 
which was 82.5% of those eligible. The mean age was 55.9 SD 14.7 years and ranged from 
19 to 88 years. The distribution between age strata were as follow: 18-39 years (15.5%), 40-
65 years (37.6%), and ≥65 years (46.9%). A majority was male (70.2%) and primary 
prevention (73.5%) was more common than secondary prevention. There was a history of AF 
in 35.7% and systolic heart failure in 19.6%. At least one appropriate ICD therapy occurred 
in 22.9% and inappropriate ICD shock in 13.5%. Complications that required an invasive 
intervention occurred in 29.4% during the follow-up since first ICD implant. 
9.4.2 SF-36 score compared to norm population 
The HCM patients with ICD were compared to age- and sex-matched Swedish population 
norms. All domains, except for bodily pain, had a lower score than the norms, which is 
summarized in Table 11. Both component score, physical component summary (PCS) and 
mental component summary (MCS), were likewise significantly lower than norms. In Figure 
14 the score of eight domains are visualized using bar charts. The effect sizes varied from 
small to moderate and even large in one domain (General health). A higher age was 
associated with lower scores on Physical functioning, Role physical, and PCS. On the 
contrary, the domains Mental health and MCS showed higher scores with increasing age 
within the cohort. 
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Table 11. SF-36 score in HCM with ICDs compared to general Swedish population norms. 
Reproduced from Magnusson et al.354  
SF-36 domains  Cohort 
mean 
SD 95% CI Effect 
size 
Norm 
mean 
SD 95% CI p-value 
Physical functioning  66.6 27.6  63.1-70.0  0.62  82.1  22.4  80.5-83.8  <0.0001 
Role physical  57.4 43.6  52.0-62.9  0.46  76.0  37.1  73.2-78.7  <0.0001 
Bodily pain  70.7 29.4  67.0-74.4  0.08  72.9  27.3  70.9-74.9  0.550 
General health  53.7 25.5  50.5-56.9  0.77  72.4  23.1  70.7-74.1  <0.0001 
Vitality  51.8  26.2  48.5-55.1  0.67  68.7  24.4  66.9-70.5  <0.0001 
Social functioning  75.1 26.9  71.7-78.5  0.52  87.7  21.3  86.2-89.3  <0.0001 
Role emotional  70.1 40.8  64.9-75.2  0.35  82.9  32.0  80.5-85.3  <0.0001 
Mental health  71.8 22.9  69.0-74.7  0.47  81.7  18.8  80.3-83.1  <0.0001 
Physical Component 
Summary  
40.8 12.4  39.3-42.4  0.62  47.9  10.5  47.1-48.7  <0.0001 
Mental Component 
Summary  
45.5 12.9  43.9-47.1  0.46  50.8  10.2  50.0-51.6  <0.0001 
 
Figure 14. Bar chart SF-36 score in 245 HCM patients with ICDs compared to Swedish age- 
and sex-matched population norms (n=735). Reproduced from Magnusson et al, with 
permission.354  
 
PF, physical functioning; RP, role physical; BP, bodily pain; GH, general health; VT, vitality; SF, social functioning; RE, role 
emotional; MH, mental health. 
9.4.3 SF-36 score in subgroups 
Subgroups analyses within the cohort are shown in Table 12. Thus, patients with a history of 
AF reported significantly lower score in the domains of Physical functioning, Role physical, 
General health, Social functioning, and borderline value for Bodily pain. As a consequence, 
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the component summary score PCS was significantly lower in those with a history of AF than 
those without. Notably, patients with AF were older (mean difference 7.4 years; p<0.001). 
The differences expressed in effect sizes were typically small. Similarly, a history of systolic 
heart failure implied a lower score on physical domains and its component score (Physical 
functioning, Role physical, General health, and PCS). Heart failure patients were older, with 
borderline significance, with a mean difference of 4.6 years (p=0.053). 
The fact that patients had experienced appropriate ICD therapy resulted in significantly 
higher Mental health and a tendency toward better MCS. Inappropriate shock, on the contrary 
was associated with lower score on Role emotional and a tendency toward lower score 
regarding Vitality, Social functioning, and MCS. 
There were no significant differences in any domain or component score with regard to 
primary and secondary prevention. A tendency of better Vitality (p=0.07; ES 0.28) was seen 
among secondary-prevention patients. 
Table 12. Subgroup analyses of hypertrophic cardiomyopathy patients with implantable 
defibrillators. Reproduced from Magnusson et al.354  
SF-36 domains  Atrial 
fibrillation  
Heart failure  Appropriate 
therapy  
Inappropriate 
shock  
  p-value  ES  p-value  ES  p-value  ES  p-value  ES  
Physical functioning  <0.001  0.47  <0.001  0.68  0.812    0.119    
Role physical  0.002  0.38  0.003  0.48  0.211    0.382    
Bodily pain  0.051  0.26  0.260    0.229    0.188    
General health  0.004  0.38  0.023  0.33  0.864    0.118    
Vitality  0.234    0.075  0.30  0.166    0.080  0.31  
Social functioning  0.004  0.42  0.069  0.36  0.180    0.058  0.37  
Role emotional  0.234    0.195    0.209    0.028  0.42  
Mental health  0.288    0.681    0.033  0.30a  0.242    
Physical Component 
Summary  
<0.001  0.48  <0.001  0.63  0.735    0.252    
Mental Component 
Summary  
0.495    0.884    0.076  0.27a  0.060  0.38  
a Higher mental health and mental health summary scores (all other effect sizes were lower). 
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9.5 PAPER Ⅳ 
9.5.1 Patient characteristics 
All 26 patients who were asked to participate consented and were interviewed. At the time of 
interview, the youngest patient was 27 years, the oldest 76 years, and the mean age was 58 
years. The time since diagnosis of HCM varied from 4 to 45 years with a mean of 16 years. 
The mean time since first ICD implant was 6.7 years. All patients had an ICD at the time of 
interview except one whose ICD was removed during heart transplant. The vast majority 
(76.9%; n=20) had ICD as primary prevention and the remaining due to survived cardiac 
arrest or life-threatening VT/VF requiring external electrical conversion/defibrillation. In 3 
patients, a history of appropriate ICD therapy was reported while 8 experienced at least one 
inappropriate ICD shock. In Table 13 the characteristics of participants are further reported. 
Table 13. Characteristics of 26 interviewed HCM patients with history of ICD. Reproduced 
from Magnusson et al.332  
Sex Age  Civic 
status 
Child Indication ICD 
duration 
ICD shock Diagnosis NYHA 
M  27  Cohabitate 0 primary 4.9 no   9 I 
F  32  Cohabitate 2 primary 2.4 no 17 II 
F  33  Cohabitate 2 secondary 6.3 no 14 I 
M  37  Divorced 1 primary 3.0 no   8 II 
M  42  Married 2 secondary 8.4 inappropriate   9 I 
M  48  Divorced 2 primary 4.8 no 30 I 
M  49  Cohabitate 0 secondary 6.9 appropriate   7 II 
F  54  Cohabitate 1 primary 10.9 inappropriate 20 II 
M  55  Single 0 secondary 8.0 appropriate 37 IIIB 
M  59  Married 2 primary 3.8 inappropriate   4 I 
M  59  Cohabitate 2 primary 1.0 no 32 IV/Ia 
F  60  Married 3 secondary 10.9 inappropriate 20 I 
M  61  Married 2 primary 8.9 no 18 I 
M  61  Divorced 5 primary 11.3 inappropriate 45 IIIB 
M  63  Married 2 primary 16.6 appropriate 17 I 
M  64  Cohabitate 2 primary 3.0 no   4 I 
F  65  Single 1 primary 5.3 inappropriate   8 I 
M  65  Married 1 primary 5.1 no 42 I 
M  65  Married 2 primary 7.6 no   9 I 
M  67  Married 2 primary 3.2 no   4 II 
F  68  Married 4 primary 7.8 no   7 I 
M  69  Married 1 primary 4.5 no   5 I 
M  72  Divorced 7 secondary 3.5 no 20 II 
F  75  Divorced 0 primary 11.2 inappropriate 15 I 
F  75  Married 1 primary 9.8 inappropriate 14 IIIA 
F 76  Single 2 primary 5.2 no   7 I 
M, male; F, female. ICD duration refers to time (years) with an ICD and Diagnosis time (years) since first known diagnosis of 
HCM. a Heart transplant due to NYHA IV, at the time of interview NYHA I. 
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9.5.2 Key findings  
The main findings from the interviews are summarized below in each section. This is further 
elaborated in the Discussion in relation to other studies and clinical implications.  
9.5.2.1 Diagnostic considerations 
There was a variety of diagnostic pathways. Diagnosis was sometimes based on family 
screening, detection of a cardiac murmur, abnormal ECG, symptom evaluation, but in many 
other cases diagnosis was made as a part of clinical work-up for another medical reason, for 
example: infection, surgery, stroke or cardiac arrest. In several cases, the diagnosis of HCM 
was considerably delayed and initial misclassification was common. When patients reported 
the name of their diagnosis, they often used terms other than the established nomenclature. 
Instead of HCM, they said “enlarged heart”, “heart trouble”, and “heart thickness”. They 
also claimed that their health care provider used several descriptions of the disease, which led 
to confusion. This made it difficult for them to search for information on their own. 
9.5.2.2 Pharmacological compliance 
The interview situation created a trustful relation, and patients were asked about their 
compliance with pharmacological treatment. In fact, they told the interviewer that they 
adhered to the prescription regarding the HCM-related regimen, typically beta-blockers and 
calcium-channels blockers. 
9.5.2.3 Inheritance 
Genetic screening was widely accepted and appreciated among the patients. However, the 
cascade screening was sometimes challenging or even impossible due to broken relationships. 
Patients who withheld information exhibited ambivalence but rationalized their decisions for 
several reasons, including protecting their offspring. Parents of very young children pondered 
the consequences of genetic testing for their children. But in several cases the parents talked 
openly to their child about HCM. Even when the inheritance pattern was obvious, no one in 
the study blamed their parents for their HCM. 
9.5.2.4 The patient perspective of the ICD 
The decision to implant an ICD was clear-cut to the patients with a secondary-prevention 
indication. Among those with a primary-prevention indication, the risk factors upon which 
the decision was based were seldom known by the patients, except for SCD in a first-degree 
relative. 
Many patients felt there was a lack of information about the procedure before it took place 
and would have appreciated better communication and a more personalized approach. In a 
few cases, the feeling of isolation was strong before the operation: “When I was waiting for 
surgery, I felt like a chicken going into the slaughterhouse.” Complications were diverse and 
generally accepted, but extraction procedures and long hospitalization resulted in 
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disappointment. Typically, patients recalled the implant procedure as fast and convenient, 
even though it was not completely painless. They had swelling, pain, and discomfort in the 
days following surgery.  
Patients thought of the device as part of their own body, although there were sometimes 
situations where it was evident, they had a device. Being at a public swimming hall or beach 
could be embarrassing, especially in the younger patients who disliked people staring at them. 
Among close family members, it was not an issue and regarded as a reminder of security. 
Children and grandchildren often expressed fascination about the device. The gratitude and 
trust made both the patient and, according to them, also their relatives feel secure. However, 
some patients reported the device as bulky, which could cause localized discomfort when 
lying in bed or carrying a backpack. 
Undoubtedly, the ICD provides reassurance. All patients were grateful to receive an ICD and 
none regretted the decision to get an ICD. It was considered as a true “life insurance” and the 
phrase “my life-saver” was repeatedly said by different patients. 
9.5.2.5 Knowledge about HCM and ICD 
Knowledge about HCM and ICD varied substantially among the patients. Generally, patients 
with a higher educational level knew more, but still lacked basic knowledge. Moreover, many 
patients were concerned about the level of knowledge among health care professionals in 
different settings, i.e. prehospital care, emergency rooms, anesthesia, gynecology, and other 
specialized care outside of cardiology units. For example, one patient received multiple 
shocks that could have been avoided by magnet application to inhibit shock therapy. Even 
among cardiologists, patients noticed that some were not familiar with disease management. 
For that reason, when such patients find knowledgeable health care professionals for ongoing 
care, they put a lot of trust in these clinicians and appreciate them. Simple information, such 
as basic information about the ICD and its function, was considered helpful in several 
situations. The patients who were interviewed were aware of the difference between a 
pacemaker for bradycardia and an ICD, but they did not think this was common knowledge 
in the general population. 
Some patients expressed concerns about the possibility of terminal illness and the risk of 
repeated unnecessary shocks as they neared end of life. Some worried how health care 
providers would manage their ICD and whether or not the ICD shock function would be 
deactivated. 
9.5.2.6 Experience of ICD shocks 
In the event of appropriate shocks, patients had symptoms or even became unconscious. It 
could be a dramatic event for bystanders, but patients somehow were prepared for this to 
occur. One patient explained as, “It was fantastic…I was sitting in a dark room and 
everything turned bright white.” Sometimes they did not seek urgent medical care because 
they felt fine afterward.  
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Patients who experienced inappropriate shocks often had multiple shocks and were fully 
conscious at the events. The unpredictable nature of these shocks and their inability to stop it 
made them feel scared. They remembered these situations as “ghastly”, “painful”, and 
“terrible”. It was described in their own words as “being hit by a stone,” “being shot by a 
revolver”, and “I jumped a foot, and I was like a jumping Jack.” Despite this initial 
experience, they felt reassured, typically after a couple of weeks. They accepted the shocks as 
a side effect of the ICD that nevertheless is a life-saver. Some patients who wondered if the 
device would work in the case of a life-threatening arrhythmia stopped questioning it and 
actually felt more comfortable. Again, bystanders were sometimes profoundly affected by the 
dramatic event. A four-year old child whose father was shocked in her presence avoided 
physical contact with him for a while after the event.  
The ICD as two-edged sword was described by an elderly woman who had several 
complications, including infections, multiple inappropriate, but also appropriate shocks. It 
took her considerable time to come to terms with ICD therapy, but she eventually came to 
accept her need for the device.  
9.5.2.7 Overall health experience 
The patients often considered themselves as healthy, at least in the beginning of the 
interview. They refused to see themselves as victims of a disease. Their core personal identity 
remained the same, although they in fact had made several adaptions over the course of their 
lives. They did not see themselves as being sick but indeed admitted constraints, “My 
husband has energy but I have almost no energy”, and “I learned to live with it”, and “I 
listen more to my body…” They sometimes stopped certain activities and survivors of cardiac 
arrest often needed considerable time before they reoriented themselves. In primary-
prevention patients who not yet experienced an appropriate ICD therapy, there were various 
viewpoints on the necessity of the device, for example, “Maybe I do not need a device. I feel 
healthy”. Even those who thought that way regarded the ICD as an insurance policy that they 
would probably never need. The manifestation of the underlying HCM varied in the cohort. 
In patients with systolic heart failure, AF, and comorbidities, patients recognized that the 
underlying disease, not the ICD, accounted for their symptoms and associated physical 
functional deficits. In professional life, the disease affected their career opportunities and 
sometimes made them dependent on help from others. 
Secondary-prevention patients often had long rehabilitation periods after cardiac arrest. Still, 
they enjoyed life and returned to their former activities. Interestingly, the close relatives of 
SCD survivors kept expressing anxiety for a very long time. Partners could become 
overprotective and there were certain overshadowing worries in families with young children. 
Moreover, younger patients felt more worried and limited than older patients. The older 
patients remembered situations from their youth that caused them to feel like they were 
different. A woman said, “My teenage years were difficult”. Over time, these patients came 
to terms with having HCM, adapted to managing a chronic condition, and accepted their 
situation. 
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The physical constraints of the disease, rather than the ICD itself, restricted leisure time 
activities. Patients sometimes had to quit activities like ice-hockey, badminton, and soccer. 
But more often they continued but adapted the intensity, for example in swimming, dancing, 
and hiking. Many patients were unsure about individualized recommendations. Driving was 
sometimes restricted by authorities, but these restrictions were not always followed. In some 
cases, a spouse reinforced regulations about driving beyond what was required by authorities. 
The restrictions on driving had consequences for both leisure time activities and professional 
life. Physical intimacy was sometimes affected by the underlying disease state, but not the 
device. No patient expressed fear of shocks during sex. 
Professional life was affected by the burden of symptoms, mainly shortness of breath. Young 
and middle-aged patients had to reorient themselves. In the elderly, there was already 
adaptation and acceptance in place. In some specific occupations, the ICD imposed 
restrictions, for example, a welder had to change his main working tasks. 
9.5.2.8 Relationships 
Among cardiac arrest survivors, their relationships somewhat changed. For example: “The 
event has made us better connected but also creates problems…these worries can be really 
tiresome…on the other hand, we have a shared experience that somehow bonds us.” Patients 
were offered support more or less, but the relatives did not receive the same support. Some 
patients claimed that they coped better with the situation than their relatives. Indeed, these 
feelings were shared among relatives and close friends. Nobody attended patient support-
group meetings because they felt it was irrelevant for them with their disease. Some patients 
found a Swedish homepage and web group for ICD patients in general, which they thought 
was beneficial. One patient was member of the specific American HCM patient 
organization.367 In general, the younger patients often went to internet sources for information 
about HCM and ICDs. 
A recurring complaint about the absence of information from health care providers was 
addressed. When they had contact with HCM specialists, they appreciated it very much. 
Many patients were aware of media reporting on athletes who died of HCM, and this worried 
them. For example, a young skier said: “The fact that athletes drop dead…it is not 
advantageous for me.” Occasionally, the media interest in SCD was deemed troublesome. 
“The less you know, the less ill you are” as a young patient said. Patients’ reaction toward 
extensive talks about the disease varied and could be contradictory, depending on the 
situation. A young single said talking about HCM was a matter of distress in new 
relationships and conflicted with the patient’s self-image of being an ordinary normal person. 
In two cases, patients were convinced that the disease had contributed to divorce. Having a 
relative with HCM can affect a patient’s self-perception. For example, a young man 
developed increasing anxiety with age and it culminated when he was about the same age as 
his father was when he died suddenly due to HCM. This was the trigger for the young man to 
request an ICD. 
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9.6 PAPER Ⅴ 
9.6.1 Patient characteristics 
The participants in the study had a mean age of 56.8 SD 12.9 years and a majority were males 
(n=19; 76.0%). An echocardiogram was assessed in all patients. About half of the patients 
were genopositive (n=13; 52%). Most participants had an ICD as primary prevention (n=22; 
88%). A detailed summary of the clinical characteristics was provided in Paper Ⅰ.  
9.6.2 Adherence to PET protocol 
The full PET-protocol, including four PET scans (15O-water at rest/stress, 11C-acetate, and 
11C-HED) was performed in 24/25 patients. In one young woman, 15O-water at stress was not 
possible due to emotional stress. In one 11C-HED scan there were motion artifacts, such that 
analyses beyond RI were not possible. 
9.6.3 ICD interrogation 
The ICDs were interrogated at 12 months for evidence of NSVT. In total, 10 patients (40%) 
reached the endpoint of documented NSVT. Another composite endpoint based on a history 
of appropriate ICD therapy and secondary indication was present in 8 patients (32%).  
9.6.4 PET results 
The PET data were derived and analyzed. Mean MBF at rest after adjustment of the rate 
pressure product was 0.91 ml/g/min and severely decreased at stress 1.59 ml/g/min. The 
mean gradient expressed as the ratio of endocardium to epicardium at rest was 1.14 SD 0.09 
but inversed at stress to 0.92 SD 0.16. The MVO2 mean was 0.088 ml/g/min and the MEE 
18.5%. The mean RI was 0.11 /min. 
The distributions were typically skewed, which is why percentiles are also presented. The 
summary of the results is presented in Table 14. Using polar plots, it was possible to visualize 
individual patients with regard to anatomical distribution. The anatomical view and polar 
plots are depicted in Figures 15, 16, 17, and 18. 
Figure 15. Anatomical visualization of the myocardium using 15O-water exams. 
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Figure 16. Example of polar plots of MBF at rest and stress of two patients from 15O-water 
exams. 
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Figure 17. Example of polar plot of MVO2 of one patient from an exam with 
11C-acetate.
 
Figure 18. Example of polar plots of retention index of one patient from an exam with 11C-
HED. 
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Table 14. PET results from 15O-water, 11C-acetate, and 11C-HED. Modified from Magnusson 
et al.355  
 
Mean 25th percentile Median 75th percentile 
15O-water 
    
MBFREST (ml/g/min)ǂ  0.91 0.77 0.90 1.00 
MBFSTRESS (ml/g/min) 1.59 0.94 1.36 2.29 
Heterogenity indexREST  1.34 1.91 1.26 1.41 
Heterogenity indexSTRESS  1.58 1.31 1.55 1.79 
Coronary flow reserve 1.78 1.28 1.60 2.32 
Defect sizeREST (%) 1.97 0.09 0.27 3.32 
Defect sizeSTRESS (%) 29.51 7.07 30.46 50.80 
TPGREST  1.14 1.07 1.13 1.22 
TPGSTRESS  0.92 0.77 0.91 1.05 
11C-acetate 
    
MVO2 (ml/g/min) 0.088 0.070 0.085 0.10 
MEE (%) 18.5 13.3 16.3 20.9 
LV-mass (g/m2) 109 77 102 129 
EDV (ml/m2) 94 80 96 106 
ESV (ml/m2) 36 22 31 53 
SV (ml/m2) 58 47 56 66 
EF (%) 63.3 49.7 64.4 75.1 
TGMVO2  0.99 0.94 0.99 1.05 
11C-HED 
    
RI (min−1) 0.11 0.090 0.117 0.0126 
Defect sizeRI (%) 14.92 7.19 13.60 20.04 
Heterogenity indexRI  1.73 1.38 1.58 1.75 
TGRI  1.06 1.03 1.06 1.09 
VT 17.43 15.83 17.76 22.35 
Clearance rate 0.019 0.014 0.018 0.020 
TGVT  0.960 0.88 0.99 1.03 
TGclearance rate  1.21 1.06 1.12 1.29 
11C-HED - 15O-water 
    
Defect sizeRI - Defect size 
REST (%) 
12.95 3.88 11.86 17.94 
Defect sizeRI - Defect 
sizeSTRESS (%) 
14.53 −41.60 −13.39 10.39 
ǂ Corrected for rate pressure product; heterogenity index=MBFMAX /MBFMIN; TPG=MBFENDOCARDIUM /MBFEPICARDIUM; 
MVO2 , myocardial oxygen consumption; MEE, myocardial external efficiency; LV, left ventricle; EDV, end-diastolic 
volume; ESV, end-systolic volume; SV, stroke volume; EF, ejection fraction; TG, transmural gradient; RI, retention 
index; heterogenity index RI=RIMAX /RIMIN; VT, volume of distribution. 
 
9.6.5 Hypothesis test 
We explored the variables with regard to the binary outcome of NSVT. The most striking 
result was that the MBF gradient at stress was significantly lower (p=0.022) with NSVT and 
was borderline significant at rest (p=0.059). The results of the Mann-Whitney U test appear 
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in Table 15. The regional differences were analyzed and are shown in Table 16. Of note is 
that myectomy was non-significant between those with and without NSVT. The same holds 
true for genopositivity compared to genonegativity. The composite outcome of appropriate 
ICD therapy and a secondary-prevention indication defines those with a history of sustained 
ventricular arrhythmias and was non-significant for all parameters. 
Table 15. PET results from 15O-water, 11C-acetate, and 11C-HED with regard to presence of 
NSVT. Reproduced from Magnusson et al.355  
 
NSVT (p-value) 
15O-water 
 
MBFREST (ml/g/min)
ǂ  0.405 
MBFSTRESS (ml/g/min) 0.114 
Heterogenity indexREST  0.134 
Heterogenity indexSTRESS  1.000 
Coronary flow reserve 0.320 
Defect sizeREST (%) 0.824 
Defect sizeSTRESS (%) 0.725 
TPGREST  0.059
a 
TPGSTRESS  0.022
a 
11C-acetate 
 
MVO2 (ml/g/min) 0.023
b  
MEE (%) 0.405 
LV-mass (g/m2) 0.579 
EF (%) 0.120 
TGMVO2  0.542 
11C-HED 
 
RI (min−1) 1.000 
Defect sizeRI_75% (%) 0.202 
Heterogenity indexRI  0.120 
TGRI  0.698 
VT 0.089a 
Clearance rate 0.061b  
TGVT  0.380 
TGclearance rate  0.052
a 
11C-HED - 15O-water 
 
Defect sizeRI - Defect sizeREST (%) 0.267 
Defect sizeRI - Defect sizeSTRESS (%) 0.380 
ǂ Corrected for rate pressure product; heterogenity index=MBFMAX /MBFMIN; TPG=MBF ENDOCARDIUM /EF, ejection fraction; 
MBF EPICARDIUM; MVO2 , myocardial oxygen consumption; MEE, myocardial external efficiency; LV, left ventricle; NSVT, 
nonsustained ventricular tachycardia; TG, transmural gradient; RI, retention index; Heterogenity index RI=RIMAX /RIMIN; VT, 
volume of distribution. Comparisons performed using Mann-Whitney U test. a Lower rank in NSVT; b higher rank in NSVT. 
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Table 16. PET results from 15O-water, 11C-acetate, and 11C-HED at regional level with regard 
to presence of NSVT (p-values). Reproduced from Magnusson et al.355  
 
 Anterior Septal Inferior Lateral 
15O-water  
    
TPGREST   0.134 0.244 0.017 0.040 
TPGSTRESS   0.178 0.019a 0.005a 0.101 
11C-Acetate  
    
MVO2 (ml/g/min)  0.052b 0.086b 0.046b 0.027b 
TGMVO2   0.222 0.956 0.059 0.542 
11C-HED  
    
TGRI   0.292 0.824 0.782 0.698 
VT  0.222 0.027a 0.267 0.076a 
Clearance rate  0.007b 0.023b 0.183 0.035b 
 
a Lower rank in NSVT. b Higher rank in NSVT. 
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10 GENERAL DISCUSSION 
10.1 PAPER Ⅰ 
In Paper Ⅰ we validated and analyzed the characteristics of Swedish HCM patients with ICDs, 
and the efficacy and risk profile with regard to appropriate ICD therapy in a nationwide 
cohort. The data collection was done before the HCM Risk-SCD prediction model was part 
of ESC guidelines. Therefore, an extended discussion of the knowledge of risk stratification 
to date, including its controversies, is integrated into this discussion. 
10.1.1 Efficacy of ICD 
In Swedish HCM patients, treatment with ICDs was able to terminate all ventricular 
arrhythmias within the programmed zones. In about half of the cases, ATP was enough, while 
in the remaining cardioversion was required, sometimes after multiple attempts. The 
programming of the ICD should be tailored for the individual.  
Our study confirmed the efficacy of appropriate ICD therapy in unselected HCM patients, 
which is reassuring. This is in line with vast experience from international studies, mostly 
from tertiary/expert centers.208,209 In fact, there was no single case of ICD failure to convert 
an episode of VA, even though ATP was often ineffective and several cardioversions 
sometimes were needed before sinus rhythm was restored. It should be remembered that the 
extended study period included devices spanning several generations of ICD technology. In 
the beginning, there were also a few epicardial systems until transvenous system became 
available. In our cohort there were no S-ICD systems, and implementation thereof has been 
slow in Sweden.292,356  
Nowadays, high-voltage ICDs are standard and sophisticated waveform optimization is 
advantageous. Based on findings from general ICD patients, the tendency in the last decade 
has been to avoid DFT testing. In Sweden, DFT testing is rarely performed and it has become 
much less frequent in Europe and even in the United States.357 The current ICD systems are 
known to be highly efficacious, testing does not provide a clearly relevant clinical scenario, 
and the best available systems are used as standard care. Moreover, induction of VF is not 
without risk and the tolerance for devastating complications is very low, especially in primary 
prevention. Thus, the potential benefit of DFT testing does not justify the risk. 
Historically, because of the increased LV mass in some HCM patients, there has been a 
concern about the efficacy of cardioversion.358 High DFTs have been reported to the same 
extent in HCM and general ICD patients. In a study by Quin et al, 89 HCM and 600 general 
heart failure patients had similar mean DFTs (10.4 SD 5.8 J vs 11.2 SD 5.6 J) and 3.4% of 
HCM patients had a DFT above 20 J.359 In a smaller study of 23 HCM patients compared to 
general ICD patients, the DFT was higher in HCM patients (13.9 J vs 9.8 J; p<0.001) and 
could be correlated to increased LV mass. A DFT of 20 J or more was noted in 22% of the 
HCM patients.359 In another study, prolonged QRS duration was a predictor of higher DFT in 
HCM.360 A recently published substudy of SIMPLE found a similar DFT safety margin in 52 
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HCM patients compared with 1,047 ischemic or nonischemic cardiomyopathy patients 
(p=0.63).361  
The fatal case of the young man who suffered from anoxic brain injury after an arrhythmic 
event and eventually multi-organ failure, described in the Results section, highlights the 
importance of programming. In this physically active patient, a relatively high detection zone 
for ventricular arrhythmias was programmed in order to avoid inappropriate shocks. The 
recurrence of a VT below the detection zone after the vulnerable period of hemodynamic 
collapse due to VT/VF was catastrophic. The patient was taking two antiarrhythmic agents, 
which are known to slow reentry circuits and may have contributed to the VT recurrence.362 
This underlines the importance of an individualized approach to programming. The principles 
of allowing an extended number of intervals, including redetection, will reduce the frequency 
of unnecessary treatments, because VT may be self-terminating. When therapy is delivered, 
ATP attempts should be used first, preferably in the form of bursts.32,34 In the Swedish cohort, 
programmed bursts were standard, but in the early era, ramp was also a common ATP 
strategy. While ICDs effectively terminate VT/VF, they do not prevent the occurrence of 
arrhythmias. The ICD solely rescues the patient from the potentially fatal consequences of 
dangerous arrhythmias. For most patients, an ICD shock is a dramatic event. From reports 
from general ICD patients, it seems that a history ICD shock is a marker for decreased HRQL 
and even mortality.363 Thus, it is important to utilize strategies to prevent arrhythmias and 
avoid therapy as much as possible. In patients with recurrent VT episodes, radiofrequency 
ablation may be considered according to HCM guidelines.15 This is in line with previous 
knowledge from general ICD patients. Antiarrhythmic agents or catheter ablation can indeed 
prevent the recurrence of VT as can shock therapy, even though it has not been proven to 
improve overall mortality on a group level.32,34,364 
In our cohort, among the first episode VT/VF, about half (52%) required cardioversion for 
termination. In the largest ICD study of HCM patients (n=506), 103 patients received 
appropriate therapy (47.6% defined as VF).203 Interestingly, 94 of the 103 first episodes were 
treated by cardioversion and ATP only was used in the remaining 9 episodes. This is 
considerably higher than in the prospective PainFREE trial (ischemic and nonischemic 
cardiomyopathy) that aimed to reduce the numbers of cardioversion by using ATP (80.6% of 
episodes were terminated by ATP) with a zone 188-250 BPM and defining rates above 250 
BPM as VF.365 It should be noted that HCM patients with ICDs are probably more 
heterogeneous than general ICD recipients. Often HCM patients are younger, have longer life 
expectancy, less comorbidity, and different and more active lifestyles. This necessitates 
tailored programming on an individual level.  
In addition to preventing SCD as a consequence of ventricular arrhythmia, pacing may also 
protect the patient from potentially life-threatening bradycardia. Not to forget, bradycardia is 
often present in HCM because of beta-blockade and other antiarrhythmic therapy. In patients 
with substantial LVOT obstruction, right ventricular apical pacing may be considered to 
alleviate gradient and its related symptoms. This should be borne in mind when 
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programming, including the activation and optimization of the rate-adaptive sensor. My 
impression from reading numerous device reports based on interrogations from the cohort is 
that Swedish HCM patient with ICDs are managed by cardiologists with expertise in ICD 
programming and electrophysiology. As a rule, ICDs were programmed using the most 
appropriate strategies at the time. It should be stressed that close collaboration among 
different branches of cardiology is important not only for decision-making regarding ICD 
implant, but also during follow-up, especially for the optimal management of inappropriate 
ICD therapy.366 
10.1.2 Appropriate ICD therapy 
Approximately a quarter of the patients in our cohort experienced appropriate ICD therapy 
over a mean of five years. The annualized rate of appropriate ICD therapy in secondary 
prevention was 7.0% and in primary prevention 4.5%, which is in line with international 
experiences. The risk for a dangerous arrhythmia during the first months after secondary-
prevention ICD implant is pronounced. In primary prevention, the risk is linear and 
continues throughout the study period, which is why device exchange should be standard 
even after years without the need for therapy.  
In our cohort, appropriate ICD therapy occurred in 26% of the patients during a mean follow-
up of 5.3 years. The proportion and rate of appropriate ICD therapy was higher among 
patients with an ICD for secondary rather than primary prevention. In secondary-prevention 
patients, the risk for a dangerous arrhythmia was higher in the first year after implant than 
later on. This is expected because after a cardiac arrest or sustained VT, there is vulnerable 
period in the early months. This is well-known from other ICD patients and can be 
generalized to HCM patients. On the other hand, primary prevention, i.e. prophylactic ICD 
implant, shows a linear event rate over the years. From a clinical perspective, after a life-
threatening arrhythmia, the patient should be continuously monitored by ECG in the hospital 
and, when appropriate, an ICD should be implanted before they are released from the 
hospital. In special cases, a wearable cardioverter defibrillator could be an alternative if the 
implant of a transvenous or S-ICD is not possible before discharge. In primary-prevention 
patients, there is a continuous risk even after several years with no events and no need for 
therapy delivery. This is an important point, because sometimes the question arise that device 
replacement is not necessarily due to the absence of any life-threatening arrhythmias for 
many years. There may sometimes be legitimate reasons not to exchange a depleted ICD, 
especially in the elderly with severe comorbidities and very short life expectancy. However, 
the fact that there has not yet been an arrhythmic event requiring therapy cannot justify 
removing an ICD and not replacing it. 
In our cohort, the annualized rate of appropriate ICD therapy in secondary-prevention 
patients corresponds to 7.0% and in primary prevention it is 4.5%. The rate will depend on 
the underlying risk of the patients. It will also be affected if the rate is not linear over the time 
period. Various follow-up periods within the cohort with patients based on different risk 
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profiles make an analysis even more complicated. For this reason, interpretation can become 
quite complex when several studies are compared.  
10.1.3 Comparison of implantation rates, temporal trends, and selection 
General ICD implantation rates have been modest in Sweden but have increased and are 
similar to other Nordic countries, higher than the UK, lower than Germany and the United 
States. The proportion of primary-prevention ICDs in HCM is higher than stated in a review 
(74% vs 83%). The rate of appropriate ICD therapy is comparable to international 
experience, although slightly higher rates are observed. The burden of established risk 
factors is higher in Swedish patients than in many international studies and age is older, 
which indicates a more conservative approach toward prophylactic ICDs in HCM. The 
unselected nature of the Swedish cohort may account for discrepancies. 
The risk profile and other baseline characteristics may change in clinical practice over the 
years. One must bear in mind the historical context; ICDs have been more frequently used in 
recent years, which was also seen in our cohort. It is likely that less bulky and cheaper 
devices, improved implantation techniques without DFT testing, streamlined follow-up 
including home monitoring, and overall available resources for diagnostics and follow-up 
have led to more implants. Evidenced-based expansion from other indications and the 
availability of surgical facilities have increased implantation rates in general.32–34 Awareness 
of HCM disease and risk stratification may also influence implants. The guidelines and their 
implementation are of course likely to impact the volume of implants. Notably, the general 
ICD implant rate has historically been modest in Sweden although it is increasing. It is less 
than in the United States but comparable to many other European countries. In 2013, the 
median European ICD implantation rate was 82 per million inhabitants. Sweden had 198 per 
million, comparable to other Nordic countries (Denmark 231, Norway 214, Finland 194, and 
Iceland 171), lower than Germany (336) but higher than the UK (92).367–369  
In the largest tertiary center in Sweden, two-thirds (66%) of ICDs in HCM during 2005-2016 
were implanted for primary prevention, and it should be noted that this may indicate a more 
conservative approach toward primary prevention than in published international cohorts.235 
The structure of care may differ among countries but can also vary within countries from 
region to region and even among hospitals, and finally among the prescribing clinicians. 
Since the first case series of HCM patients with ICD, several studies have reported outcome 
with regard to appropriate ICD therapy. Sometimes these cohorts are merged with other 
cohorts or there are multiple reports after extended follow-up and inclusion of more patients. 
There are also cohorts with a mix of HCM patients with and without ICDs. An extract of 
publication from these cohorts reporting annual rate is summarized in Table 17. Cohorts 
based on less than 10 patients or pediatric patients were excluded. 
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Table 17. Studies on HCM patients with ICDs with regard to appropriate ICD therapy. 
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Primo370 1998 13 Belgium, 
Spain 
2.2 48 62 2 2 NR SP & PP: 7.0% 
Begley279 2003 132 USA 4.8 34 61 85 27 13 SP: 11% 
PP: 4.5% 
Almquist371 2005 75 USA 3.6 36 65 71 NR NR SP & PP: 1.9% 
Lawrenz372 2005 3.4 Germany  53 53 6 4 1 SP: 10% 
PP: 5% 
Marin373 2006 45 Spain 2.7c 43 62 27 10 1 SP:11.1% 
PP: 1.6% 
Medeiros374 2006 26 Brazil 1.7 43 46 16 4 1 SP & PP: 11.1% 
Maron203 2007 506 USA, Europe, 
Australia 
3.7 42 64 383 103 55 SP: 10.6% 
PP: 3.6% 
Woo375 2007 61 Canada 3.3 46 66 50 8 NR SP & PP: 4% 
Cuoco250 2008 123b USA 2.9 48 66 100 9 9 PP: 2.8% 
Syska280 2010 104 Poland 4.6 36 45 78 27 13 SP: 7.9% 
PP: 4.0% 
O’Mahony281 2012 334 UK 2.2 40 62 307 28 21 SP: 4.3% 
PP: 2.0% 
Prinz376 2013 87 Germany 3.5 50 60 85 15 NR SP & PP: 16.4% 
Shiozaki377 2013 26 Brazil 3.2 39 46 21 13 NR SP & PP: 15.6% 
Vriesendorp282 2013 134 Netherland, 
Belgium 
4.2 44 66 93 38 20 SP & PP: 6.8% 
PP: 5.1% 
Debonnaire378 2014 92 Netherlands 4.7c 50 69 70 21 16 SP & PP: 4.9% 
Frommeyer379 2016 18a Germany 2.6 35 83 14 1 1 SP & PP: 2.1% 
Konstantinou380 2016 37 USA 3.1c 49 76 37 NR 10 PP: 7.2%  
Lambiase222 
 
2016 99a USA, New 
Zealand, 
Netherland, 
UK 
1.8 42 75 87 3 NR SP & PP: 1.8% 
Magnusson283 
 
2016 321 Sweden 5.4 52 70 237 77 47 SP: 7.0% 
PP: 4.5% 
Rigopoulos381 2016 32b Germany 5.3c 50 53 31 4 4 SP & PP: 2.5% 
Ruiz-Salas382 2016 48 Spain 4.1 44 67 48 NR 8 PP: 4.2% 
Thavikulwat284 2016 135 USA 5.2 48 85 125 25 20 SP: 9.8% 
PP: 2.6% 
Viswanathan383 2016 60 Canada 5.1 44 73 60 9 9 PP: 2.5% 
Weinstock221 2016 16a USA 1.5 40 NR 13 0 0 SP & PP: 0% 
Francia384 2017 66 Italy 4.4 45 62 65 14 NR SP & PP: 4.8% 
Wang285 2017 160 USA 4.0 47 61 155 24 NR SP & PP: 3.8% 
Follow-up was reported as mean if not specifically noted as median. a S-ICD cohort; b ASA cohort; c median. NR, not 
reported; PP, primary prevention; SP, secondary prevention. 
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Schinkel et al published a systematic review in 2012 based on 2,190 patients with HCM and 
ICDs with a mean follow-up of 3.7 years.208 The mean age was 42 years and a majority was 
men (62%). The percentage of primary-prevention ICDs was 83%. The risk factors included 
LV wall thickness ≥30 mm (20%), family history of SCD (43%), NSVT (46%), syncope 
(41%), and abnormal blood pressure response (25%). The average number of risk factors was 
1.8 per patient. The authors pinpoint that in only 7 of the 16 studies there was sufficient 
information about the risk factor profile for further meta-analyses. The annualized rate of 
appropriate ICD therapy was 3.3%. 
A subsequent systematic review of HCM patients with ICDs was published in the beginning 
of 2017.209 It included 3,797 patients with a mean age of 44.5 years and a majority was men 
(63%). Most patients had ICDs for primary prevention, 83% (compared to 74% in our 
cohort). The risk profile was as follows: LV thickness ≥30 mm (10%), family history of SCD 
(26%), NSVT (25%), syncope (7%), and abnormal blood pressure response (22%). This 
burden of risk factors, except for abnormal blood pressure response, is less than in primary-
prevention patients in our cohort. This could be interpreted that it is harder to qualify for an 
ICD in Sweden compared to other geographical areas. If so, it may be in line with the more 
conservative approach in Sweden reflected in the general implantation rate of ICDs overall. It 
could be speculated that this approach implies less sensitivity, which could result in SCD that 
could have been prevented. However, the number of SCD events in HCM patients who did 
not receive an ICD remains unknown. Moreover, the diagnostic pathways of HCM are often 
complicated and many patients may be undiagnosed. In the pooled meta-analysis by Wang, 
the annualized rate of appropriate ICD therapy was 4.8% (95% CI 3.9-5.9).209 It should be 
noted that there was significant heterogeneity between studies I2=84%, reflecting the 
diversity of the cohorts. In our nationwide Swedish cohort of unselected patients without 
tertiary center bias, the corresponding annualized rate of appropriate therapy was 5.3%. This 
is a bit higher than in the meta-analysis, but still falls within the 95% CI. The mean age in our 
cohort was 52.1 years, which is higher than in the meta-analyses. It likely reflects the 
unselected nature of the cohort based on nationwide inclusion, which may be different from 
tertiary centers. 
10.1.4 Appropriate ICD therapy in primary and secondary prevention 
Survival after cardiac arrest or sustained VT in HCM warrants ICD treatment if life 
expectancy and related quality of life is reasonable. The scientific controversies are mainly 
about assessment and judgment of risk factors to decide the eligibility for primary prevention. 
Most studies are from the Western world and the majority of patients are male, as in our 
study. The mean follow-up time of our study was in the upper range compared to other ICD 
cohorts. The baseline characteristics and outcome regarding appropriate therapy from our 
study can be generalized to the findings from tertiary center cohorts of general HCM patients 
with ICDs. The annual rate and 5-year cumulative incidence in our cohort was comparable 
to international tertiary-center data. 
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Secondary prevention is often a straightforward decision when it comes to risk evaluation, 
but challenges arise when it comes to overall risk assessment, because life expectancy and 
estimated HRQL deserve careful clinical judgement. Secondary-prevention patients are at 
elevated risk right after they get an ICD, but this risk subsides over time, which could have 
impacted the total rates found in our cohort, which followed patients for 5.4 years. 
Furthermore, the eligibility criteria for secondary prevention may differ along with ICD 
programming, but these details remain unknown. 
The controversies of risk stratification focus on primary prevention. From this perspective, it 
is interesting to review data on primary prevention and appropriate ICD therapy. Maron et al 
merged data from 506 HCM patients with primary-prevention ICDs from the United States, 
Europe, and Australia.203 This is by far the largest study of this population and patients were 
followed for a mean of 3.7 years. Three-quarters of the total study population (75.7%) was 
men. The annualized appropriate ICD therapy was 3.6% and 10.6%, for primary and 
secondary prevention, respectively. This differed slightly from our study, with higher rates 
for secondary prevention (7.0% vs 10.6%, respectively) and lower rates for primary 
prevention (4.5% vs 3.6%, respectively). At 5 years we reported a cumulative incidence of 
21% for the whole cohort, while Maron reported 23%. 
In primary prevention, the eligibility criteria may differ even more than in secondary 
prevention, as it is based on clinical judgement of risk factors. ICDs are more widely used in 
the United States for general heart failure, which makes a European comparison more 
relevant. Vriesendorp et al reported 134 Dutch HCM patients from two tertiary centers (66% 
males) with ICD with a mean age of 44 SD 17 years over a mean follow-up of 4.2 SD 4.8 
years.282 They reported 6.8% annualized rate of appropriate ICD therapy in the whole cohort 
and 5.1% for primary-prevention patients, which is similar to our results and is also from the 
same period. In a Polish single-center study 104 HCM patients with ICD, who had a mean 
age of 36 years was followed for 4.6 years.280 Notably, a minority of these patients was male 
(45%). Their annualized appropriate ICD therapy rate was similar to our cohort: the whole 
cohort (5.6%), secondary prevention (7.9%), and primary prevention (4.0%). However, the 
differences between the underlying patient characteristics are striking with regard to age, sex, 
and selection. Finally, a large British study on HCM and ICD by O’Mahony et al analyzed 
334 patients (62% men, 92% primary prevention) with a mean age of 40 years from a tertiary 
center during a median follow-up of 3.6 years.281 The outcome measurement was appropriate 
shock, not ATP, and the annual rate was 4.3% for secondary prevention and 2.0% for primary 
prevention. Because of the difference in outcome measurement, comparisons are difficult to 
draw. The ratio between secondary and primary prevention is similar. The lower incidence 
reflects the definition of the endpoint and raises the matter of differentiation between shock 
and ATP. From one perspective, cardioversion and ATP might be considered identical 
because they both terminate life-threatening VT/VF. However, sometimes therapy delivery is 
unnecessary, because the arrhythmia would have self-terminated. The proportion of self-
terminating arrhythmias is likely higher among ATP-treated episodes compared to 
cardioverted episodes. This issue is complicated as programming decisions may come into 
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play that affect when each therapy modality is used: ATP is often programmed for lower 
rates and more intervals than shocks, which, in turn, may be programmed for higher rates and 
only after ATP has failed. In the highest detection zones, some ICDs do not offer an ATP 
programming option, although it is increasingly becoming more standard. Furthermore, ATP 
is only moderately effective for the treatment of monomorphic VTs in HCM patients (69% 
were converted by ATP).385 
10.1.5 Evidenced-based approach to risk stratification 
The evidence for risk stratification relies on observational studies of diverse cohorts and 
expert opinions. Typically, appropriate ICD therapy and potential risk markers are evaluated 
at baseline. In the connection, it is important to note that the evaluation of risk factors is 
prone to measurement errors and misinterpretation of patient history. Every patient with an 
ICD has already been deemed at elevated risk based on known underlying risk factors. In 
both univariable and multivariable analyses, these risk markers compete with each other and 
this confounding effect should be taken into account when considering HRs.  
The decision to offer an ICD for primary prevention is based on the evaluation of established 
risk factors and sometimes markers regarded as modifiers of SCD risk. This task of risk 
stratification is of utmost complexity on an individual level. There are no randomized 
controlled trials, as in many other fields of medicine, including ICDs in heart failure.33 
Instead, the relevant guidelines are based on observational studies and expert opinions. Many 
of these studies are limited by small sample size, methodological inconsistencies regarding 
definitions, and even study design flaws. These cohorts are based on widespread geographical 
areas with different resources and traditions. In Sweden, the health care system provides an 
insurance coverage for the whole population, and by law socioeconomic factors should not 
bias health care decisions for the individual. Because our study was national, it may offer a 
more generalized approach to risk assessment. In addition, we included all patients and we 
are not at risk for the selection bias that may occur at tertiary centers. 
Before comparing our results to other cohorts, the interrelationship of risk factors should be 
highlighted. Risk factors may compete with each other. Thus, an HR >1 means that this 
particular factor is stronger with respect to the other factors. In the same study, an HR <1 still 
represents risk, even though it is not as strong compared to the other risk factors. In theory, all 
patients who receive an ICD are selected because the clinician considered the patient and 
their increased risk for SCD. In reality, risk assessment is not always so straightforward. The 
judgement of some risk factors and markers may be arbitrary and imaging can be imperfect 
with imprecise measurements. The interpretation of an anamnesis can be quite complex, for 
example, determining the cause of a syncopal spell. Typically, studies of outcome 
measurements, for example appropriate ICD therapy, and their association with the risk 
profile relies on baseline values. In such cases, the time of ICD implant is considered as 
baseline. During follow-up or even since evaluation of previous risk factors, things may have 
changed. Although most HCM patients remain stable over a few years, there can be 
measurable disease progression as well as less apparent changes of possible arrhythmogenic 
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substrates, modifying factors of the disease, comorbidities, lifestyle changes, and 
interventions. The concept of long-term follow-up is rather arbitrary and is far from a lifetime 
analysis. This is especially true in HCM patients, who often are younger and have a long life 
expectancy. The occurrence of an arrhythmia can be based on a complex interplay of factors, 
in which each risk factor/marker and possible triggers are largely unknown in the individual 
case. 
We adhered to the statistical methods commonly used in this scientific field. It should be 
noted that multivariable analyses may produce different results than other forms of statistical 
analysis and the associations reported were not always clear-cut and could vary among 
cohorts. The interaction among risk factors can be analyzed, but still requires careful 
judgement. Moreover, there are several approaches as to whether to include a risk factor in a 
multivariable analysis; it may be based on results from earlier studies, backward/forward 
stepwise elimination, or a combination thereof. The predictive power of risk factors depends 
on two things: sample size for one, and for the other, the number of events, which is 
indirectly linked to follow-up time. To increase sample size and follow-up time, data can be 
merged but this approach may increase heterogeneity and make generalization more difficult. 
This is even more pronounced in meta-analyses, where a reduction of information takes place 
when data are pooled. The estimates of such analyses may seem more precise but some 
skepticism is warranted and should not replace clinical judgment. 
10.1.6 Adherence to guidelines 
In our Swedish nationwide cohort, almost all patients had an established risk factor at 
baseline. 
Our study was performed before the HCM Risk-SCD calculator was implemented. Instead, 
clinicians based their decision on the guidelines at that time, possibly with some 
modifications based on their own clinical judgement and interpretation. Only two (0.8%) of 
the primary-prevention patients in our study were considered not to fulfill established risk 
assessment, but they were deemed as high risk by the clinician. From a specificity 
perspective, the Swedish cohort reflects a strong adherence to the established risk 
stratification strategy. There was basically no off-label use. The two exceptions were well 
motivated based on the knowledge at the time. In comparison, a Dutch study reported 15% of 
the recipients did not meet established criteria (notably AV block due to septum reductive 
procedures) and the largest of merged cohorts had 3.5% who did not fulfill these 
criteria.203,282 It is understandable, although not scientifically sound, to prescribe an ICD in 
borderline cases if there is already an indication for permanent pacemaker system. 
10.1.7 Sudden cardiac death outcome measurement  
Appropriate ICD therapy is often used as surrogate for SCD. This leads to an overestimation 
of the benefit of ICDs, as not all ventricular arrhythmias are lethal. This issue is complex as 
ICDs also protect patients from life-threatening bradycardia. In HCM cohorts without ICD, 
SCD is categorized based on anamnesis when ECG is not available. Our cohort adhered to 
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the most widely used definition of appropriate ICD therapy, but awareness of differences in 
outcome measurement is warranted.  
In primary prevention, risk stratification is based on an evaluation of risk factors/markers and 
is related to outcome. The outcome in ICD cohorts is essentially appropriate ICD therapy 
based on the definition described in the Materials and Methods section. The time to first 
endpoint is used. However, there are studies that solely use cardioversion, i.e. ICD shock or 
discharge, and not ATP as an outcome. It can be argued that ICD shock is more likely to 
indicate life-threatening arrhythmias than ATP, but this is not necessarily true and certainly 
not always the case. The use of shock also depends on programming, including detection 
zones and numbers of intervals before therapy delivery is launched. For example, an episode 
detected in the VF zone is often programmed to be treated quickly, usually after only a few 
intervals. While noncommitted systems will abort a shock if the arrhythmia resolves on its 
own during charging, a shock for VF may be delivered so quickly that it cannot be cancelled 
even if the rhythm might have converted spontaneously on its own a few seconds later. With 
ATP, at least one attempt is often used in VF-zones and may be effective. Slower VTs may 
degenerate into VF and result in shock therapy if ATP was not attempted. The tendency to 
avoid shock by programming several ATP sequences in different zones after an extended 
number of intervals has evolved over the years, and this evolution can create a bias when 
comparing studies from different time periods. Since there is no standard ICD programming, 
comparisons of studies are not possible, Furthermore, ICD programming may change, even 
more than once, over the follow-up period. Using appropriate ICD therapy of both ATP and 
cardioversion will lead to a non-differential bias within studies, because all markers are 
evaluated the same way. Comparison with other studies using the same approach is possible, 
but if a study limits outcome to shock therapy only, then this will result in differential bias. 
In HCM cohorts without ICD, SCD or aborted SCD after resuscitation is often used as the 
outcome. This is appealing because it may reflect the actual proportion of SCD. By contrast, 
using ICD therapy delivery as the outcome will overestimate the number of life-threatening 
arrhythmias, as some are self-terminating. Nevertheless, in reality, the definite cause of SCD 
is a matter of judgement and the definition described above is not always easily applicable. In 
retrospective analyses, it can be difficult to access reliable and detailed data to determine 
cause of death. The distinction between SCD and deterioration of heart failure can sometimes 
be challenging to determine. The HCM populations often constitute a mixture of outcome 
measurements, as some patients have an ICD. Thus, the composite endpoint includes 
appropriate ICD therapy. The outcome is typically SCD, survived cardiac arrest, or 
appropriate ICD therapy used as an equivalent. Clearly, this can make comparisons difficult. 
Instead, the relative strength of risk markers within a study or among studies with similar 
design should be interpreted in its context. ICD outcome has the advantage in that it 
correlates with a definite ventricular arrhythmia, even though it will overestimate the benefit 
of an ICD if all therapies are regarded as life-saving. On the other hand, the simultaneous 
protection from bradycardia death offered by an ICD cannot be determined and is therefore 
underestimated.  
  87 
10.1.8 Risk factor evaluation 
We confirmed the usefulness of established risk factors as predictors of appropriate ICD 
therapy. Among these risk factors, NSVT was the strongest while family history of SCD was 
the weakest. There was an increased risk with increased age but this association disappeared 
after adjustment for other factors. Neither was sex related to outcome. AF and EF<50% 
emerged as risk markers, especially in primary prevention. 
The established risk factors for SCD in HCM have been NSVT, family history of SCD, 
maximal wall thickness >30 mm, and unexplained syncope. Abnormal blood pressure 
response at exercise test has been a matter of debate and was missing in some evaluations in 
our cohort. These risk factors were analyzed using Kaplan-Meier estimate and Cox 
proportional hazards in uni- and multivariable analysis. We added AF and EF<50% in both 
the analyses of primary and secondary prevention. In secondary prevention, there was no 
uniform assessment of the established risk factors, because the decision-making physician did 
not deem it necessary, since survivors of cardiac arrest or VT with hemodynamic 
compromise were already eligible for an ICD, regardless of other risk factors. 
In secondary prevention, AF (HR 1.8) and EF<50% (HR 3.1) were highly significant in 
univariable analysis. Increasing age was associated with increased risk of outcome, but with a 
borderline p-value of 0.043. Male sex showed a tendency toward higher risk (p=0.073). In the 
multivariable analysis, EF<50% (HR 2.6) remained significant but age, sex, and AF were not.  
In primary prevention, increasing age was significantly associated with outcome but after 
adjustment in multivariable analyses it turned out to be not significant at all. It seems that 
both low EF and AF increase with age and long-term follow-up, which may explain these 
findings. In univariable analysis, both EF<50% (HR 3.7) and AF (HR 3.6) were strongly 
associated with outcome and remained significant in the multivariable analysis. In fact, these 
risk factors were actually stronger than the established risk factors. Only NSVT was 
significant in univariable analysis (HR 1.97) but weakened in the multivariable analysis. 
Again, it is important to realize the relativity of HR as a measurement, since risk factors 
compete with each other in the analysis. These findings underscore the importance of NSVT 
as a risk marker, even in this population of patients with a higher mean age than many 
cohorts. In an analysis based on only the five established risk factors, the magnitude of risk 
was in the following order: NSVT, syncope, abnormal blood pressure response, maximal wall 
thickness, and lastly family history of SCD. In a subgroup study where all patients with AF 
and EF were excluded, none of the patients with syncope or family history of SCD had 
received any appropriate therapy. While there were only 15 patients in each of these 
subgroups, it nevertheless suggests less of an independent predictive value than expected for 
AF and EF. Based on our findings, we suggest increased attention to further evaluation of 
these risk markers in patients eligible for ICDs.  
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10.1.8.1 NSVT 
NSVT was the most common risk factor in our cohort and its importance, based on several 
studies from diverse populations, is unequivocal. The predictive power seems stronger in 
younger patients. The role of duration, frequency, and rate of the NSVT has not yet been 
completely elucidated. 
NSVT was highly prevalent in the risk profile (58.2%) and emerged in our cohort as the 
strongest single risk factor in primary prevention, which intensifies its strength with respect to 
the other risk factors. While the role of NSVT as a risk factor in elderly patients has been 
questioned even in the guidelines, it seems to make sense to use it in this context as many 
patients in our cohort had multiple risk factors.  
The presence of NSVT is considered an established risk marker for SCD in HCM, even 
though its predictive value seems to differ between age groups. The definition of NSVT also 
may vary, as described in the Materials and Methods section. Typically, a Holter monitor for 
24-48 hours represents the standard evaluation in routine follow-up of HCM patients. 
Nevertheless, telemetry in the hospital ward, exercise ECG, thumb-ECG and other hand-held 
devices, insertable cardiac monitors, and the availability of smart-watches and fitness 
monitors are additional sources for rhythm monitoring. It should be remembered that most 
scientific studies use 24-Holter monitoring at baseline, i.e. before ICD implant, for the 
assessment of this risk factor. The characteristics of patients may vary among cohorts and 
over time, for example, half of the patients in an early study by Fananapazir et al of 230 
consecutive HCM patients (mean age 39 years) had NSVT on Holter.386 In a study using 14-
day Holter monitoring in 77 HCM patients (mean age 53 years), NSVT occurred in 75%; 
23% and 45% during the first 24 and 48 hours, respectively.387 
Prior to the ICD era, a study by Maron et al (99 HCM patients, mean age 38 years) found that 
NSVT on 24-hour Holter was shown to predict SCD (24% vs 3%; p<0.05).388 Spirito et al 
analyzed 151 asymptomatic HCM patients, of whom 27.8% had NSVT and the RR of SCD 
(n=6) was 2.4 compared to those without NSVT (p=0.24) during a mean follow-up of 4.8 
years.389 In a study by Elliott of 368 HCM patients (mean follow-up 3.6 years, 22 SCD), the 
HR for NSVT was 1.8 (p=0.21), which remained unchanged in the multivariable analysis 
(HR 1.9).192 In a later report by Elliott et al of 917 HCM patients (mean age 37 years), 18.8% 
had NSVT and it was the strongest risk factor in multivariable analysis (RR 3.8; p<0.001).133 
Monserrat et al reported that among 531 HCM patients (5.8 years follow-up) who underwent 
a mean of 41 hours Holter monitoring, 19.6% had NSVT, and the proportion increased with 
age. In patients younger than 30 years, freedom from 5-year SCD was lower in those with 
NSVT (77.6% vs 94.1%; p=0.003). The NSVT odds ratio (OR) with regard to SCD was 4.4 
(p=0.006) in the group age ≤30 years and 2.2 (p=0.1) in those >30 years. NSVT increased 
significantly with age (p=0.008), maximal wall thickness, and left atrial size. There was no 
relation between duration, frequency, and rate of NSVT and outcome at any age group.116  
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Wang et al studied 160 HCM patients with ICDs. About half (54%) had had NSVT at 
baseline or at device interrogation. NSVT was significantly associated with appropriate ICD 
therapy (HR 4.0; p=0.009). Notably, NSVT runs at a rate >200 BPM (HR, 15.6; p<0.0001) 
and >7 beats (HR 6.2; p=0.002), and repetitive runs of NSVT (HR 9.2; p=0.001) but not 
slower, shorter or single episodes were associated with outcome.285 This contrasts with the 
previously mentioned study by Monserrat.116  
Dimitrow et al reported on 1,306 HCM patients, of whom 27.0% had NSVT and although the 
study confirmed the significance of NSVT, it did not report HR.390 Their study design was 
different than other studies, because they use time since birth instead of first evaluation of 
HCM. 
Gimeno et al showed that exercise-induced NSVT (mean 221 BPM) was associated with 
SCD/appropriate ICD therapy in a large cohort of 1,380 HCM patients, of whom 24 had 
exercise-induced NSVT (n=24) and exercise-induced VF (n=3).391 Patients with exercise-
induced NSVT/VF had more severe hypertrophy (22.6 vs 19.5 mm, p=0.009) and larger left 
atrial diameter (47.3 vs 43.7 mm, p=0.03). The HR for the combined endpoint of NSVT and 
VF was 3.7 (p=0.002) and the HR for solely NSVT 2.8 (p=0.049) for SCD/ICD discharge.  
Francia et al reported on 51 HCM patients (mean age 48 years) with ICDs, of whom 66% had 
NSVT as a preimplant risk factor.384 During a mean of 3.2 years follow-up, 11 experienced 
appropriate ICD therapy. NSVT length in beats (HR 1.05; p=0.02) but not heart rate (HR: 
1.00; p=0.86) was associated with outcome.  
In the study by Syska et al of 104 HCM patients (mean age 36 years) with ICDs, the HR of 
NSVT was 10.3, which was the only predictor for an appropriate ICD therapy (positive 
predictive value 22%, negative predictive value 96%).280 
In the HCM Risk-SCD cohort (n=3,675), 17.3% had NSVT at baseline and its HR regarding 
SCD was 2.5 (p<0.001). 
The relative impact of NSVT compared to other risk factors is strong based on most studies. 
In the largest study (n=506), Maron et al did not state HR, but appropriate ICD therapy per 
100 person-years was 4.2 for NSVT, which was the strongest of all four established risk 
factors. In an analysis of patients with only NSVT as a risk factor, it remained strong with 4.0 
events per 100 person-years. 
10.1.8.2 Family history of SCD 
The definition of family history of SCD varies, and in our real-life setting we found a 
discrepancy from guidelines. Based on numerous studies, family history of SCD is an 
established risk factor even though its strength independent of other risk factors has been 
questioned.  
In ACCF/AHA guidelines, a family history of SCD is a risk factor that justifies ICD implant 
but in the ESC guidelines, family history is one part of the risk model. Even though it is used 
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as a binary variable, the interpretation of family history is not always straightforward, and 
may depend on the age of the SCD victim, whether a first- or second-degree relative is 
involved, the likelihood of HCM in the fatal case, the surrogate appropriate ICD therapy, the 
number of relatives/proportion and the age of the patients who are to be risk stratified. Other 
potential risk factors and modifiers are also taken into account, either based on the risk model 
or by clinical judgment. 
While a family history of SCD in HCM is well recognized, its role and weight as a risk factor 
is actually more controversial. In Table 18, established risk factors and their HRs are 
depicted, but it should be noted that univariable and multivariable associations may differ due 
to interaction between factors. In high-risk cohorts, for example ICD cohorts in which all 
patients are deemed at high risk, the risk factors then compete with each other. Thus, the 
relative strength of the factors becomes apparent. In most of these studies (Table 18) a family 
history of SCD had an HR >1.0. To achieve absolute incidence, the rate can be used but this 
strategy does not resolve the interaction among variables and modifiers. 
 Table 18. HCM studies on risk markers of SCD. 
Author Year Size (n) 
(% ICD) 
HR/RR, uni-
/multivariable 
NSVT Unexplained 
Syncope 
Family 
history 
of SCD 
LV 
hypertrophy 
Monserrat116 2003 531  
(4.0%) 
HR 
multivariable 
4.0 1.3 1.4 3.5 
Elliott133 2006 917  
(5.9%) 
RR  
multivariable 
3.8 2.3 1.9 1.7 
Gimeno391 2009 1,380 
(unknown) 
HR 
multivariable 
2.6  2.1 1.8 0.9 
Efthimiadis392 2009 166 
(unknown) 
RR 
univariable 
3.5 13.7 1.8 10.1 
Rubinshtein393 2010 424  
(9.7%) 
HR 
univariable 
6.9 0.7 2.4 6.4 
Syska280 2010 104  
(100%) 
HR 
univariable 
10.3 0.9 3.6 1.0 
O´Mahony137 2014 3,675 
(15.2%) 
HR 
univariable 
2.5 2.3 1.8 Not reported 
Ismail394 2014 711 
(unknown) 
HR 
univariable 
1.7 0.8 0.8 1.6 
Debonnaire378 2015 195 
(29.7%) 
HR 
univariable 
2.5 5.6 1.4 3.6 
Magnusson283 2016 237  
(100%) 
HR 
multivariable 
1.8 1.1 0.8 1.4 
Klopotowsky395 2016 328 
(30.5%) 
HR 
multivariable 
3.3 1.8 2.1 3.7 
Todiere396 2019 354 
(unknown) 
HR 
univariable 
1.2 Not reported 0.9 6.3 
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In the largest study, a compelling analysis was made among patients with only family history 
of SCD as a risk factor: the HR was 2.7 (95% CI 1.1-5.1) as seen in Table 19.203  
Table 19. In the study by Maron et al, based on 506 HCM patients of pooled cohorts, the four 
risk factors were established and expressed as appropriate ICD therapy per 100 person-
years.203 
 Appropriate ICD therapy per 100 person-years (95% CI) 
Risk factor All 4 risk factors (n=383) Only 1 risk factor (n=173) 
Family history of SCD 2.9 (1.7-4.7) 2.7 (1.1-5.1) 
Syncope 3.6 (2.2-5.6) 5.2 (2.5-9.6) 
Massive LV hypertrophy 4.0 (1.9-7.3) 2.1 (0.04-11.4) 
NSVT 4.2 (2.7-6.2) 4.0 (1.5-8.7) 
 
In another, smaller study by Bos et al, those with a family history of SCD as a single risk 
factor had appropriate ICD therapy at a rate of 2.2 per 100 person-years.397 In patients where 
all four established risk factors were analyzed, family history of SCD had HR 2.9 (95% CI 
1.7-4.7). Several studies (Table 18) and meta-analyses have confirmed family history of SCD 
as a risk factor.398 The argumentation regarding family history of SCD as a primary indication 
has been emphasized.399 Other experts oppose this view and advocate an overall risk 
stratification using the HCM Risk-SCD calculator.400 They highlight that ICD cohorts by 
definition are high-risk patients and are not necessarily representive of general HCM patients 
when risk stratification has be applied. Based on their algorithm from 3,675 HCM patients 
(558 ICDs), family history had an HR of 1.8 (95% CI 1.2-2.4; p<0.001) as summarized in 
Table 20.137  
Table 20. The HCM Risk-SCD calculator was based on merged cohorts of 3,673 HCM 
patients. In univariable analysis risk markers were evaluated using HR with regard to SCD or 
its equivalent.140 
Risk factor HR (95% CI) p-value 
Age (year) 0.988 (0.979-0.997) 0.007 
Maximal wall thickness (mm) 1.048 (1.025-1.071) <0.001 
Fractional shortening (%) 0.992 (0.977-1.008) 0.334 
Left atrial diameter (mm) 1.035 (1.018-1.052) <0.001 
LVOT gradient (mmHg) 1.005 (1.001-1.008) 0.005 
Family history of SCD 1.76 (1.32-2.35) <0.001 
NSVT 2.5 (1.85-3.47) <0.001 
Unexplained syncope 2.3 (1.69-3.20) <0.001 
 
Of course, the definition of family history of SCD varies across studies, which increases 
complexity. Often it is limited to first-degree relatives and excludes more distant relatives. 
Moreover, the number of affected and nonaffected family members are not taken into 
account. The position is that family history of SCD should be used along with other risk 
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factors and weighted by the use of the risk model. From a perspective of the practicing 
cardiologist, the family history of SCD risk factor gets special attention, because it is part of 
the patient history and it may carry special emotional importance for the patient and their 
family. In real-world clinical practice, the emotional weight of family history is likely to 
affect the decision-making process. 
Family history of SCD has prognostic implications with a delay to the fifth decade of the life 
span according to Dimitrow et al who also showed that multiple cases of SCD in the family 
imply additional risk.390 Dimitrow et al used a different approach and estimated a lifetime risk 
and all 4 established risk factors were confirmed. 
10.1.8.3 Maximal wall thickness 
Maximal wall thickness can be used either as a dichotomous variable with cutoff or as a 
continuous variable. It is an established risk factor based several studies, but careful 
measurement is important in each individual case. Many patients with extreme LV wall 
thickness are likely to be highly symptomatic and will undergo septum reductive treatment, 
which seems to decrease risk of SCD.  
In the early era, Spirito et al evaluated 480 patients over a mean follow-up of 6.5 years. The 
risk of SCD was increased with maximal wall thickness (p=0.001).401 The incidence per 
1,000 person-years (stated in parentheses) with regard to maximal wall thickness divided into 
5 groups was as follows: <15 mm (0), 16-19 mm (2.6), 20-24 mm (7.4), 25-29 (11.0), and 
>30 mm (18.2). Elliott et al identified maximal wall thickness (cutoff 30 mm) as a risk factor 
in multivariable analysis of 368 HCM patients with a follow-up of 3.6 years: the HR was 4.1 
(p=0.001) in univariable analysis and 2.9 (p=0.03) in multivariable analysis.192  
Elliott confirmed this association in a cohort of 630 patients (mean age 37 years, mean 
follow-up 4.9 years), in which 39 patients had an ICD discharge or SCD. For every 5 mm 
increase in maximal wall thickness, the RR was 1.31 (p=0.029).402  
Efthimiadis et al studied 166 HCM patients (mean age 47.9 years, mean follow-up 2.7 years) 
did a multivariable analysis of syncope (HR 10.4; p<0.001), maximal wall thickness 30 mm 
(HR 7.5; p=0.005), and NSVT (HR 1.4; p=0.64).392  
Monserrat et al specifically analyzed patients younger than 30 years and found a significant 
association between maximal wall thickness ≥30 mm and SCD (HR 3.5; p=0.03), which was 
the strongest predictor next to NSVT.116  
The relationship of maximal wall thickness and SCD was non-linear, rather U-shaped, in the 
analysis by O’Mahony et al of 3,673 HCM patients.403 They reported HRs with respect to 
strata: 15-19 mm (HR 0.93), 20-24 mm (HR 1.09), and 25-29 mm (HR 1.21; p=0.02), 30-34 
mm (HR 2.1), and ≥35 mm (HR 0.22). 
Maximal wall thickness is modifiable risk factor. Many of the patients with high wall 
thickness undergo septum reductive treatment. Overall, the prognosis and risk of SCD are 
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low after myectomy and ASA. The current risk calculator is not adapted for risk assessment 
in these subgroups. Discrepancy between CMR and echocardiography may occur in 
individual cases. 
10.1.8.4 Syncope 
Although categorizing syncope as unexplained is based on judgment after careful evaluation, 
it is an established risk factor. In our study, about a third of patients had syncope as risk 
factor at baseline evaluation. Based on guidelines, syncope can be considered a risk factor 
regardless of when it occurred, but recent episodes constitute higher risk of SCD. 
Unexplained syncope is an established risk factor for SCD in HCM that occurred in 35.4% of 
our patients. However, there are several pathophysiological pathways and complex 
mechanism of syncope in general.15 Besides ventricular arrhythmias, atrial arrhythmias, 
complete AV block or sinus node dysfunction can cause syncope. Primary hemodynamic 
mechanisms are attributed to LVOT obstruction, abnormal vascular response, and impaired 
filling due of abnormal relaxation of the myocardium and diminished LV cavity.404 Mostly, 
the cause of syncope is determined from the anamnesis. A careful evaluation is therefore 
warranted. Since an insertable cardiac monitor is indicated for unexplained syncope, it has a 
limited place in studies of HCM patients. From a safety point of view, it should be noted that 
an insertable cardiac monitor is a diagnostic tool and does not offer treatment. Despite the 
somewhat arbitrary judgement of this risk factor, it has been established as a risk factor based 
on several cohorts. 
Spirito et al evaluated 1,511 HCM patients (mean age 70 years; 70% male) and syncope 
occurred in 14% (10% unexplained, 4% deemed as neurally mediated).405 During a mean 
follow-up of 5.6 years, the RR was 1.8 for unexplained and 0.91 for neurally mediated 
syncope. Interestingly, a syncope within the last 6 months had RR of 4.9 compared to those 
without syncope. Remote syncope (more than 5 years earlier) in persons older than 40 years 
had very low risk. 
In fact, in the largest HCM-ICD cohort, unexplained syncope was a significant risk factor 
(3.6 events per 100 patient-years; p<0.001) and the strongest single risk factor among those 
with only one risk factor (5.2 events per 100 patient-years: p<0.001).203 In the HCM-risk 
cohort, unexplained syncope had an HR of 1.76 and was significant (p<0.001) in univariable 
analysis. Dimitrow et al confirmed syncope as a risk factor (28% of the cohort) in the lifetime 
analysis.390 In an early study, Kofflard et al evaluated 225 HCM patients (mean age 41 years) 
of whom 19% had a history of syncope) and in a multivariable analysis only syncope was a 
significant risk factor (RR 4.3; p<0.05).406 In another study by Efthimiadis et al of 166 HCM 
patients (mean age 51.8 years), syncope emerged as the strongest risk factor (RR 13.1; 
p<0.001).393 
Even though syncope is based on the somewhat subjective practices of history taking and 
clinical judgement, it seems valid to use it as a risk factor. The time between when the 
syncope occurred and the patient is evaluated is recognized as a key factor, but guidelines 
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differ in how they interpret this window of time. In the HCM Risk-SCD calculator “history of 
unexplained syncope at or prior to evaluation” is stated, but the ESC guidelines state that 
episodes within 6 months are considered more predictive than earlier episodes.15,137 If a 
syncopal episode was caused by bradycardia (or more rarely by AF) it is likely to recur 
within a shorter period than VT, which carries a higher risk for SCD but occurs far more 
infrequently. Thus, a remote episode of syncope caused by VT may still represent a risk to 
the patient. Syncope from hemodynamic causes without arrhythmia will likely recur within a 
shorter period of time; if it does not, then the history should be reviewed to suggest what 
triggers these episodes. In most cases, “unexplained” syncope describes the risk factor, 
although the definition of the term “unexplained” is admittedly broad and Spirito et al use it 
to describe the majority of syncopal epsiodes.405 Because recent episodes are more predictive 
of SCD than remote episodes, patients should be made aware to seek prompt medical 
attention when syncope occurs.  
10.1.9 Overview of analyses of established risk factors 
The HCM Risk-SCD showed significant SCD outcome for the binary variables NSVT, family 
history of SCD, and unexplained syncope. In addition, the continuous variables maximal wall 
thickness, left atrial diameter, and age reached significance. Several studies report the 
relative impact of these established variables, and the largest study of HCM patients confirms 
their importance when calculated as risk per year. 
In HCM-ICD cohorts, the established risk factors are generally reported even though 
methodologies vary. Some of these studies are summarized below. The relative strength 
within a study is a key to understanding the weight of each factor. However, this was 
complicated by different approaches about what to include in multivariable analysis. To 
overcome the relativity inherent in the reporting of HRs, the outcome per person-years is 
preferable, especially in patients with only a single risk factor at baseline. This approach is 
appealing but requires a large cohort and it does not account for addition of risk factors 
during the follow-up period. 
10.1.9.1 Low EF 
Systolic dysfunction, expressed as EF, is a cornerstone in general risk assessment of heart 
failure patients. In HCM, an EF<50% should be regarded as severe impairment. Thus, we 
included this risk marker in our analyses. Indeed, it turned out to be the strongest risk factor 
for the whole cohort. This hold true in primary prevention and implied an almost threefold 
risk based on multivariable adjusted for age, sex, AF, and the established risk factors. Thus, 
in addition to conventional risk factors, EF<50% should be considered in risk stratification.  
In risk stratification of general cardiomyopathy patients with ischemic or nonischemic dilated 
cardiomyopathy, low EF is a strong predictor of SCD. Current guidelines use a cutoff value 
of 35-40% in these patients for a class I recommendation for an ICD.32–34 In patients with 
bundle branch block, especially left bundle branch block, concomitant CRT is a cornerstone 
in heart failure management even though the necessity of ICD in nonischemic 
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cardiomyopathy in the elderly is subject to debate.407,408 While EF is used to guide the 
management of general heart failure patients with ischemic heart disease and nonischemic 
dilated cardiomyopathy, LV systolic dysfunction is not emphasized in for the risk 
stratification of HCM.15,16,33 
The vast majority of HCM patients have normal or even supranormal EF, but there is 
nevertheless a risk of deterioration into end-stage heart failure. This clinical spectrum has 
been extensively described.84,174,409,410 The risk of SCD in this subgroup has long been 
recognized.411 
In the enhanced ACCF/AHA strategy, low EF, using the cutoff <50%, was considered one of 
the major risk markers to justify prophylactic ICD implant.142 This guidance referenced one 
single study of HCM patients undergoing evaluation for heart transplant. In this cohort, 27 
patients had end-stage heart failure with EF<50% and all of them received an ICD and 8 of 
them experienced appropriate ICD therapy while waiting for transplant.409 In the ACCF/AHA 
guidelines from 2011, the indication for primary prevention ICD in end-stage HCM patients 
was defined by EF≤50% and NYHA III/IV despite optimal pharmacological therapy (IIb, C). 
In ESC guidelines, ICD therapy is not specifically mentioned, but CRT may be considered 
(IIb, C) in nonobstructive HCM patients, drug refractory NYHA II-IV, EF<50%, and left 
bundle branch block >120 ms.  
Begley et al had previously observed that patients with systolic dysfunction are are elevated 
risk for arrhythmias and SCD; 3 out of 11 patients in their study had appropriate ICD 
interventions.279 
Rubinshtein et al studied 424 HCM patients (mean age 55 years, mean follow-up 3.6 years) 
who underwent CMR/LGE with regard to SCD/appropriate ICD therapy.393 In this study, 
the mean EF was 67% and 20 patients had EF<50%, of whom 17 had LGE. In univariate 
analysis, EF<50% had an OR of 3 but was not significant. 
Minami et al followed 346 HCM patients during a mean of 8.4 years. Elevation of brain 
natriuretic peptide levels with a cutoff 312 pg/mL predicts the combined endpoint of SCD 
and appropriate ICD therapy (p<0.001) and also in multivariable analysis with established 
risk factors (HR 5.7; p<0.001). This supports the finding that systolic dysfunction is a 
significant risk factor.412 
O’Mahony et al used fractional shortening (percentage change in LV diameter during systole 
using M-mode in parasternal long axis view).281 When ventricular geometry is normal and 
there are no regional wall abnormalities, there is good correlation with EF. Fractional 
shortening was the only independent predictive marker for an appropriate ICD shock in the 
multivariable analysis (10% decrease in fractional shortening was associated with a 34% 
increase in risk for shock after adjustment). 
Ismail et al reported 711 HCM patients (median age 56.3 years) who were followed for a 
median of 3.5 years.394 They all underwent CMR including assessment of LGE; LV 
dysfunction (CMR EF≤55%) was present in 23 patients (3.2%). Of these 23 patients, 9 
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(39.1%) had SCD or aborted SCD. When cardiovascular mortality was added to this 
outcome, a total of 9 patients (39.1%) reached the composite outcome. In total, 21 of 23 
patients with LV dysfunction had LGE-defined fibrosis. The extent, but not the presence of 
myocardial fibrosis, was a significant univariable predictor of the primary endpoint (HR per 
5% LGE: 1.24, 95% CI 1.06 to 1.45; p=0.007 and HR for LGE: 2.69, 95% CI 0.91 to 7.97; 
p=0.073). Interestingly, on multivariable analysis, only EF reached significance (HR: 0.92, 
95% CI 0.89 to 0.95; p<0.001).394 For the secondary endpoint cardiovascular 
mortality/aborted SCD, the presence and the total amount of fibrosis were significant 
predictors on univariable, but not multivariable, analysis after adjusting for EF and NSVT.394 
They concluded that the predicted value of EF is greater than that of fibrosis and that EF 
should be emphasized in guidelines. CMR signs of fibrosis were seen in two-thirds of 
patients, and the amount of fibrotic tissue turned out to be a predictor of SCD or aborted 
death, however not independently and it did not offer any incremental beneficial information 
in addition to EF. 
Harris reported on 1,259 HCM patients, of whom 44 (3.5%) had LV systolic dysfunction 
defined by echocardiography as EF<50%.84 In total, 29 patients (66%) died of progression of 
heart failure, had SCD events, or underwent heart transplantation. The mortality rate was 
11% per year. Appropriate ICD therapy occurred at a rate of 10% per year in patients 
awaiting transplant. 
It is of utmost importance to recognize and treat HCM patients whose systolic function 
deteriorates. Of course, this is more likely to be observed in long-term follow-up and not risk 
assessment based on baseline characteristics. From vast evidence from other indications, low 
EF is a strong predictor. Perhaps EF<50% in HCM can be regarded as equivalent to EF of 
35-40% in the general heart failure population, which would warrant ICD recommendation. 
Most HCM studies are limited by a low proportion or even outright exclusion of this 
subgroup. As a result, their predictive power is limited. Even though low EF is mentioned in 
the guidelines, it could be highlighted even more in future updates. In addition, merged large 
cohorts specifically addressing low EF and SCD are welcomed. 
10.1.9.2 LGE 
In our cohort, LGE was not systematically assessed and was not routine at the time for 
evaluation before ICD implant. Recent findings suggest LGE with a cutoff of 15-20% to be at 
least a modifying risk marker in risk stratification. The incremental value of LGE has to be 
further evaluated. 
Myocardial fibrosis is pathophysiological substrate for re-entrant ventricular arrhythmia and 
progression to systolic heart failure. There is an association between LGE and NSVT on 
Holter monitoring.413,414 Because patients at risk for SCD may lack the established risk 
factors, CMR has emerged as a tool for risk stratification.415 The early studies provided 
promising results but were not powered to determine the role of LGE as a risk factor.376,393,416 
In an early pooled analysis, LGE trended specifically toward the adverse outcome of SCD.417 
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In a meta-analysis (5 studies, n=2,992 patients, mean age 54.6 years, mean follow-up 37 
months) by Weng et al, the presence of LGE was associated with SCD (OR 3.4; p<0.001) and 
cardiovascular mortality (OR 2.9; p<0.001).418 There was a linear relationship between LGE 
and SCD (HR 1.6 per 10% LGE; p<0.001) and cardiovascular mortality (HR 1.6; p<0.001). 
Based on these findings, LGE should be looked on as a continuous risk marker rather than a 
binary one. The majority of HCM patients, up to 70%, have LGE on CMR which would 
imply a very low positive predictive value, because the prevalence of LGE is high. It is not 
known whether LGE provides incremental value in addition to established risk factors and its 
place in risk assessment of HCM patients in clinical decision-making remains controversial. 
Doesch et al suggested LGE as an additional tool for risk stratification. In the group with an 
ESC risk score (<6%) and LGE ≥20%, the sensitivity for predicting a life-threatening 
arrhythmic event was 84.6%.419 A Kaplan-Meier estimate using this cutoff was significant 
(p<0.0001). Notably, for 11 events in this low-intermediate risk group (n=26), an annual rate 
of 10.5%, was seen. Moreover, among those with a high ESC risk score ≥6%, none of the 
patients with an extent LGE <20% suffered from an event (negative predictive value 100%). 
Based on their findings, the authors argue that the absence of extent LGE (cutoff 20%) may 
corroborate the decision against ICD implantation in selected high-risk patients. 
Mentias et al evaluated 1,423 HCM patients (mean age 66 years) with preserved EF (≥50%) 
and an ESC risk score <6% with LGE at CMR.143 Notably, 686 underwent myectomy and 
ASA patients (n=42) were excluded. The endpoint was reached by 60 patients (40 SCD and 
20 appropriate ICD therapy) after a mean follow-up of 4.7 years. The authors suggested an 
LGE 15% cutoff for patients with either non-obstructive or obstructive cardiomyopathy, but a 
25% cutoff for patients who underwent myectomy.  
Ismail et al evaluated 711 HCM patients (mean age 56.3 years) with CMR and found LGE 
fibrosis in 66.2% (median 5.9% of the LV mass).394 Few patients (3.1%) reached the 
composite endpoint of SCD or aborted SCD over a median time period of 3.5 years. The 
extent of LGE fibrosis (per 5%) was significant in univariable analysis (HR 1.24; p=0.007) 
but not in multivariable analysis. Interestingly, EF remained significant (HR 0.92; p<0.001). 
Regarding the composite endpoint of cardiovascular mortality/aborted SCD, both the 
presence and the amount of fibrosis were significant predictors in a univariable analysis. 
However, this changed after adjustment for EF and NSVT.394 
Chan et al reported 1,293 HCM patients (mean age 46 years) who underwent LGE evaluation 
after a median follow-up of 3.3 years and 37 patients (3%) reached the endpoint of 
SCD/appropriate ICD therapy.141 There was continuous relationship between LGE 
percentage and SCD risk (p=0.001). For every 10% increase of LGE, the HR increased by 
1.46 (p<0.002) for the endpoint, and this also occurred in multivariable analyses. Using the 
cutoff value of LGE 15%, there was doubled risk in patients with ESC risk <6%. Patients 
without LGE had less than half the risk (HR 0.39; p=0.02). Notably, the extent of LGE of 
10% significantly increased the risk of end-stage heart failure (HR 1.8). 
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The discrepancy between these two studies may be due to power, difference in adjustment, 
and the presence of low EF according to Weng et al.418 The incremental value of LGE has 
been described, but its definite role remains to be elucidated in coming guidelines.22,420 
Todiere et al reported LGE in 354 HCM patients (73% males) with a 5-year risk SCD score 
<6%. LGE was seen in 92% of those who experienced the composite outcome of appropriate 
ICD therapy, cardiac arrest, or sustained VT. The receiver operating characteristic cutoff was 
10% LGE extent (area under the curve 0.74). The Kaplan-Meier estimate showed that LGE 
≥10% had a worse prognosis (p<0.0001). Thus, LGE ≥10% represents increased risk for 
individuals with low-to-intermediate ESC SCD risk score.396  
Hen et al reported on 102 HCM patients with ICDs (median age 63 years; 62% males) who 
had undergone CMR. During a median follow-up of 2.8 years, the annual rate of appropriate 
ICD therapy was 10.3% for secondary prevention and 7.4% for primary prevention. In 
primary prevention about half of patients (47%) was LGE positive in ≥4 of 17 LV segments 
(receiver operating characteristic curve cutoff). The annualized rate of appropriate ICD 
therapy was higher above that cutoff (11.1% vs 4.6%; log-rank p=0.038).421 
In a systematic review of risk markers for SCD in HCM, including both ICD cohorts and 
other cohorts, confirmed the classic four risk markers: family history of SCD (RR 1.8), severe 
LV hypertrophy (RR 1.9), syncope (RR 2.3), NSVT (RR 2.8), and abnormal blood pressure 
response (RR 1.5).398 Using myocardial fibrosis as a binary variable, an association between 
the presence of LGE-detected fibrosis and SCD outcome was found in 4 studies, of which 
one study had all of the risk markers present.141,394,395,414 The RR from the effect model was 
3.4. 
10.1.9.3 Age 
In our cohort outcome was independent of age after adjustment for other variables. This is in 
line with many studies, including the largest merged ICD cohort. Nevertheless, HCM Risk-
SCD has introduced age into the algorithm, but otherwise it is probably integrated as part of 
the clinical judgment in the selection of eligible patients. 
Many studies have not found age to be an independent risk factor for SCD, including the 
largest ICD cohort (p=0.64).203 In the ESC HCM Risk-SCD calculator, younger age implies a 
higher risk score based on the cohort. Here, age is an integral part of the algorithm, while in 
cohorts based on judgment of risk factors and modifiers, age may also come into play. In 
individual cases, it is likely that clinicians integrate age with other findings to assess risk. As 
described, some risk factors seem to be highly important, i.e. the presence of NSVT, 
unexplained syncope, and severe LV hypertrophy in younger patients.15 
10.1.9.4 Left ventricular apical aneurysm 
In the rare case of an aneurysmatic left ventricle there is an increased risk of SCD. 
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A few patients, approximately 2-5% of HCM patients will develop LV apical aneurysm, 
which indicates worse prognosis and has been associated with SCD.399 Rowin et al reported 
on 93 patients with LV aneurysm from a cohort of 1,940 HCM patients (mean age 56 years, 
69% male). The composite endpoint of SCD or appropriate ICD therapy rate was 4.7% per 
year and HCM-related death/aborted death was threefold higher than in other HCM 
patients.422 
10.1.9.5 Genotype 
The genotype itself was never used as a risk marker in our cohort, which is in line with 
guidelines.  
Although SCD can occur in clusters in relatives with HCM, the genotype itself has not been 
clearly demonstrated as a risk factor in sarcomeric HCM. Currently genotype information is 
not used for routine risk stratification of SCD. There may be indirect associations, as Lee et al 
reported AF in a cohort of 1,040 HCM patients with genotype; MYH7 had a higher incidence 
of AF after adjusting for age, sex, left atrial size, and maximal wall thickness (HR 1.7; 
p=0.009) after a mean follow-up of 7.2 years.423 
10.1.9.6 LVOT gradient 
The LVOT gradient is based on various clinical conditions and attributable to treatment. It 
was not systematically assessed in our cohort, nor was it evaluated as a risk predictor. 
The LVOT gradient was rarely assessed systematically in our cohort. Often the quality of 
gradient measurement was poor and it varied substantially from time to time. Medication and 
invasive procedures can influence the gradients. It must be considered a modifiable risk 
factor. 
Elliott et al reported a prevalence of LVOT gradient >30 mmHg at rest in 31% of 917 HCM 
patients. During a median follow-up of 5.1 years, the 5-year survival (or heart transplant) was 
lower (86.5% vs 90.1%) in those with obstruction. The risk was 2.4 times higher for SCD or 
ICD discharge in those with obstruction. The incremental RR for every 20 mmHg was 1.4.133 
However, there are also reports where survival in those with an LVOT gradient ≥30 mmHg 
was the same.392  
Maron et al reported on LVOT obstruction, defined as rest peak instantaneous gradient of ≥30 
mmHg as a risk marker (RR=1.9; p=0.014).424 This risk marker was also linked to all-cause 
mortality (RR=1.6; p=0.02) and the composite of progression to NYHA III/IV, death from 
heart failure, or stroke (RR=2.7; p<0.001).  
In the validation work of HCM Risk-SCD, this risk factor has been re-established and is 
included as a continuous variable.137 Notably, the measured value of gradient from either rest 
or the Valsalva maneuver can be used in this model. 
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10.1.9.7 Abnormal blood pressure response 
Abnormal blood pressure response at exercise test was analyzed in our cohort, but it was not 
performed systematically in all patients. The definitions vary among studies and the interest 
in this risk marker has diminished. 
This risk factor has been controversial. The definition varies among studies. Sadoul et al 
evaluated 161 HCM patients <40 years and 37% had abnormal blood pressure response and 
15% in the group with this risk factor had SCD compared to 3% SCD in the group with 
normal blood pressure response.425 Since this early study, this risk marker has been 
diminished in importance and is no longer part of ESC guidelines. In the ACCF/AHA 
guidelines it can be taken into account when associated with another risk factor or modifier. 
10.1.9.8 Left atrial diameter and atrial fibrillation 
AF was a significant univariable risk marker for appropriate ICD therapy in our cohort. In 
primary prevention, AF was significant in both uni- and multivariable analysis. AF was a 
stronger risk marker than any of the established risk factors. It may be suggested to include 
AF as part of risk stratification. AF is closely linked to left atrial size. In fact, left atrial 
diameter has been included in HCM Risk-SCD.  
In our cohort, AF was associated with appropriate ICD therapy in the univariable analysis of 
the whole cohort, but in multivariable analysis it was no longer significant. In primary-
prevention patients, AF was associated with an HR 3.6 (p<0.001) in univariable analysis and 
remained significant in the multivariable analysis (HR 2.5; p=0.010). In fact, it was more 
strongly associated with appropriate ICD therapy than the established risk factors. We did not 
collect data on left atrial diameter, since the numerical value was not always stated in the 
reports. 
AF is associated with increased mortality based on a meta-analysis of 104 studies with a total 
of almost 10 million persons.426 A history of AF was associated with all-cause mortality (RR 
1.46), cardiovascular mortality (RR 2.03), stroke (RR 2.42), and SCD (RR 1.88). 
An early study by Robinson et al could not demonstrate a mortality difference between HCM 
with and without AF, but SCD was not specifically addressed.427 AF was associated with the 
risk of heart failure and stroke.125  
In a systematic review (n=27 studies) including meta-analyses by Rattanawong et al, AF in 
the general population was associated with SCD (pooled risk ratio 2.04; p<0.01).428 They 
reviewed 4 studies of HCM and the pooled risk ratio for AF was 2.05 (95% CI 1.2-3.4; 
p=0.01). Except for the study by Kofflard, the other three studies showed a significantly 
higher risk of SCD in HCM patients with AF.125,406,429,430  
Minami et al analyzed the left atrial diameter in 564 HCM patients over 10.8 years.429 SCD 
was higher in those with left atrial diameter ≥48 mm (19.8% vs 8.2%; p=0.002). Enlarged left 
atrium was an independent determinant of SCD (HR 5.2; p<0.001), but there was no 
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difference regarding those with known AF or not (p=0.567).429 In another publication of an 
overlapping cohort, paroxysmal AF (but not other forms of AF) was associated with SCD 
(HR 4.7; p=0.002).430 Sorajja et al showed that among 433 HCM patients with epicardial 
coronary disease and normal EF, AF increased risk of SCD.125 
Woo et al identified age <30 years at the time of implant (HR 3.0; p=0.03) and AF (HR 3.1; 
p=0.02) as risk markers of appropriate ICD therapy.375 
Siontis et al evaluated 3,673 HCM patients (55% men) between 1975 and 2012 with a 
median follow-up of 4.1 years and 18% had AF.431 AF was associated with left atrial 
enlargement and also increased risk of death (annual mortality 6.9% vs 4.4%; HR 1.48; p 
<0.001), which remained unchanged after adjustment for age and sex. The mortality was 
increased compared to a US age- and sex-matched population. Specifically regarding SCD, 
AF trended for increased risk (HR 1.73; 95% CI 0.96-2.92) and was similar after age- and sex 
adjustment. 
Spirito et al identified left atrial size, measured as diameter, as a significant variable for SCD 
in a multivariable model (RR 1.03 per mm). In another study by Spirito of 653 HCM patients 
(mean age 46 years) with mean follow-up of 5.3 years without known risk factors and with 
low symptomatic burden, annualized SCD was 0.6% per year (heart failure 0.2% per year, 
stroke 0.1% per year).432 The annual rate of SCD in patients with an left atrial diameter <40 
mm was 0.3% per year, but increased to 3.1% with an left atrial diameter of 41-50 mm and 
above 50 mm it was 8.0% per year. 
In the HCM Risk-SCD model, the association was similar (HR 1.035) and established the use 
of left atrial size as a continuous variable.137 It was decided to use left atrial size instead of AF 
due to less missing data. 
Since the guidelines were published, another study added more evidence in support of left 
atrial size, but used the left atrial volume index as assessed by two-dimensional 
echocardiography as a marker in 427 HCM patients (66% men mean age 52 years) with a 
mean follow-up of 6.7 years. In multivariable analysis the left atrial volume index but also 
global longitudinal strain were associated with the composite endpoint of death, transplant, 
SCD, or appropriate ICD therapy. They suggested 34 ml/m2 for the left atrial volume index 
and -15% for the global longitudinal strain for incremental value to standard risk evaluation 
(C-index increased from 0.68 to 0.73).433  
Left atrial enlargement is common among HCM patients as a result of the dysfunctional 
relaxation of the LV, LVOT obstruction, mitral insufficiency, and atrial myopathy.434 The left 
atrial volume index is superior to diameter for estimating left atrial size.435 In a small study of 
81 HCM patients, left atrial volume index was an independent risk marker for cardiovascular 
events, which was also seen in another study of 140 HCM patients.134,436  
Debonnaire et al reported that left atrial volume index, using the cutoff 34 ml/m2,was 
associated with appropriate ICD therapy in 92 HCM patents (69% men, mean age 50 years) 
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during 4.7 years follow-up.378 A total of 21 patients experienced ICD therapy, but none with 
both left atrial volume index <34 ml/m2 and global longitudinal strain <-14%.  
The link between left atrial diameter and AF in HCM was recently further reinforced by 
Klopotowsky et al, who evaluated 546 HCM patients, aged <65 years, with regard to a 
history of AF.437 In addition to age, NSVT (HR 2.7; p<0.001), left atrial diameter at baseline 
(HR 1.065; p=0.001), and left atrial diameter at the last assessment before AF occurrence 
(HR 1.10; p<0.001) were identified as risk factors for AF. 
Even though the association between AF and SCD has been demonstrated, the mechanisms 
are not completely elucidated. There is anecdotal evidence of a direct causal link between AF 
and VF; Favale et al reported a case of rapidly conducted AF as a trigger of recurrent VF.438 
But, in general, the causal pathways are complex. The underlying pathology of heart failure 
and ischemic heart disease may play a role and the irregular, often rapid cardiac conduction 
through the AV node may cause unfavorable changes in action potential, leading to 
proarrhythmic propensity.439–441  
10.1.10 Hypertrophic cardiomyopathy risk calculation 
In 2014, the ESC endorsed a novel risk evaluation based on an algorithm which intregrates 
several risk factors. It uses age, maximal wall thickness, left atrial diameter, LVOT gradient, 
family history of SCD, NSVT, and unexplained syncope. It was developed to improve 
discrimination between high, middle, and low risk.  
To improve risk stratification in primary prevention, a new risk assessment tool was 
developed and endorsed by the 2014 ESC guidelines.15,137 It was claimed that previous 
guidelines overestimated risk and resulted in ICD implants in patients with low risk.442 
This new prognostic tool was based on retrospective analyses of six European centers.137 In 
total, 3,675 HCM patients (mean age 48 SD 17 years; 64% males) were evaluated during a 
median of 5.7 years. The outcome was reached by 198 patients (5%) with a 5-year 
cumulative incidence of 3.8% (annual rate 0.81%). The outcome consisted of 118 cases of 
SCD (60%), 53 appropriate ICD shocks (27%), and 27 aborted SCD events (14%). At 
baseline, 1% had an ICD but during the study period, a total of 15% underwent ICD implant. 
The continuous variables were checked for linear correlation with outcome using a 
univariable Cox regression model. If a correlation was deemed non-linear, a quadratic term 
was used instead in the multivariable model. In addition, a 15% significance level was used in 
a backward elimination before the final risk model was chosen.442 The HRs for the selected 
variables in the univariable model were as follows: Age in years (HR 0.988), maximal wall 
thickness in mm (HR 1.048), left atrial diameter in mm (HR 1.035), LVOT gradient mmHg 
(HR 1.005), family history of SCD (HR 1.760), NSVT (HR 2.533), and unexplained syncope 
(HR 2.326).137 Based on calculations from this validation cohort, the number needed to treat 
(ICD implant) was 16 for every life that could be potentially saved during the 5-year period 
in patients with ≥4% 5-year SCD risk. Patients who did not reach the 5-year SCD endpoint 
  103 
(n=2,982) had a mean predicted 5-year SCD risk score of 3.7%, while those who fulfilled the 
SCD endpoint (n=84) had a risk score of 7.3%.137 
The previous guidelines provide a rough estimate.16 The new guidelines incorporate the 
relative weight of each risk factor using a multivariable analysis.15 Risk factors that are 
continuous variables were handled to reflect the actual proportional risk rather than being 
dichotomized. In addition, age was part of the model. Compared to using four conventional 
risk factors, the new model has a C-index of 0.54, which was deemed superior as 
discrimination. Even though the formula is complex, there is a calculator on the web that may 
be used by clinicians as a part of the evaluation.443  
Although an improvement, the current risk calculator is imperfect. In fact, around one-third 
of the cases of SCD in HCM patients have no known risk factor. The risk calculator will 
identify some of them, but the authors admit “…the performance of the model in this patient 
subgroup is not optimal.” Moreover, patients with extreme LV thickness (≥35 mm) or septum 
reductive interventions (ASA or myectomy) require special attention and the calculator is not 
fully applicable according to guidelines.15,137,443 However in a recent study of 844 ASA 
patients of whom 46 experienced SCD during a mean of 6.5 SD 4.2 years (another 20 patients 
who had SCD during the 30-day post-procedure period were excluded), the C-index for the 
use of the HCM Risk-SCD model was 0.61 (p=0.02), the 2003 ACCF/ESC guidelines was 
0.59 (p=0.051), and the 2011 ACCF/AHA guidelines was 0.58 (p=0.054).444 Importantly, the 
analyses excluded 20 SCD cases during the first months. 
Notably, EF and abnormal blood pressure response to exercise were not prespecified. The 
reason for this was that these factors were not clearly associated with SCD in multivariable 
analyses in previous studies.116,133,192,392,445 
Left atrial size was chosen as predictor instead of AF because of less missing data regarding 
left atrial measurement. Indeed, both left atrial size and AF are considered risk factors.125,405 
AF was used as minor risk factor in US guidelines from 2003.35 The pathophysiological 
rationale and association between left atrial size and AF is well established.446,447 
10.1.10.1 External validation of the HCM Risk-SCD model  
The validation and usefulness of the HCM Risk-SCD model has been established in several 
studies. However, severe criticism regarding its sensitivity in the identification of patients at 
risk of SCD must be addressed. 
The HCM Risk-SCD model has been validated in several studies. This validation work was 
conducted in several ways, from simple descriptive data on sensitivity/specificity, to 
positive/negative predictive values, to measurements like area under curve, C-index, and D-
statistics. Indeed, an effective sample size is needed for external validation.448 
The C-index is a measure of discrimination between high and low risk in a mathematical 
model. An ideal situation would be a C-index of 1.0, meaning there is perfect discrimination, 
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while 0.5 is poor discrimination.449,450 The D-statistics quantify the observed discrimination 
based on log HR for the outcome and a score of 0 means no separation at all while higher 
values are improved results. 
The usefulness of the HCM Risk-SCD has been further established by EVIDENCE-HCM 
collaboration.451 In this study, 3,703 HCM patients from different continents were evaluated 
and the 5-year incidence of SCD (or equivalent outcome) was 2.4%. The C-index was 0.70 
and D-statistics 1.17. This study supported that when the 5-year risk ≥6%, an ICD should be 
offered and <4% did not merit an ICD, while the range of 4-6% should be regularly assessed. 
With the 6% cut-off, the number of ICDs needed to prevent one case of SCD over 5 years 
was 13. 
Despite the solid evidence for the HCM Risk-SCD as a helpful tool in risk stratification in 
adult HCM, severe criticism has been expressed by Maron et al.452,453 They point out the lack 
of sensitivity of the algorithm.  
Wang et al did a meta-analysis of 9,651 patients followed for a mean of 5 years. The 
discriminatory model showed a C-index of 0.75. The sensitivity ranged from 41% to 71% to 
predict SCD over the time period.209 The Tufts experience showed inadequate sensitivity 
when the ESC model was adopted according to the Maron et al.142 Instead, they advocate for 
the 2011 ACCF/AHA guidelines based on the risk marker profile and incorporating 
additional risk markers based on more recent findings in an individualized strategy.16,142 In 
2019, they published data on 527 ICD patients from among their HCM population of patients 
without a history of SCD at baseline (n=2,094).142 Of this ICD population, 15.6% had 
appropriate ICD therapy and the cumulative 5-year probability of appropriate ICD therapy 
was 10.5% (95% CI 8.0-13.5). They argued that when retrospectively applied to study 
patients, the ESC risk score was much less sensitive than the ACCF/AHA criteria (34% [95% 
CI 22-44] vs 95% [95% CI 89-99]). 
Wang et al recently published a systematic review of 13 studies (mean age 52 SD 6.3 years, 
mean follow-up 5.4 SD 2.2 years). The global C-index was 0.75 (95% CI 0.67-0.83). Using 
the cutoff 4%, area under curve was 0.69 (95% CI 0.62-0.75), while using 6% cutoff area 
under curve was 0.65 (95% CI 0.59-0.72). This study confirmed high specificity but the 
authors regarded sensitivity as poor and discrimination as moderate. Notably, the predictive 
power was slightly lower in US publications.454 There was no heterogeneity regarding age, 
sex, follow-up period, and publication year. 
The validation of the model by O’Mahony et al, based on 3,703 HCM patients from different 
countries, confirmed the accuracy of the model.451 In patients with a risk <4%, the 5-year risk 
was 1.4%, while 8.9% of patients had a risk ≥6%. Using the cutoff ≥6% would yield 13 ICD 
per life potentially saved. The C-index was 0.70 and D-statistics 1.17. In cohorts from 
Europe, China, and South America, the ESC model performed better than previous 
approaches.455–457 However, in the US cohorts, the model seems less robust, but differences in 
comparison measurements deserve greater scrutiny.452,458 It seems that regional difference is a 
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key factor to explain this heterogeneity. There may be several explanations for this 
discrepancy. Firstly, there are underlying differences in the HCM cohorts regarding baseline 
characteristics and management during follow-up; for example, the proportion of myectomy. 
The risk calculator already recognized the potential limits in this subgroup of patients. 
Secondly, ICDs are more frequently used in the United States in general compared to Europe 
and this also holds true in these HCM cohorts. Maron reported 28% ICDs in the population. 
In the validation study, 3.3% had ICD at baseline and 10.7% received ICDs during follow-
up.451 In the independent validation by Maron of 1,629 HCM patients, 460 had ICDs (28.3%) 
and 10% of ICD patients experienced appropriate ICD therapy. The majority (59%) of 
appropriate ICD therapy occurred in low risk, i.e. <4% per year based on the HCM Risk-SCD 
score. The higher proportion of ICDs in a cohort will imply a higher sensitivity of detecting 
VTs that would be self-terminating. This, in turn, will overestimate the actual benefit of ICD. 
The proportion of patients who reached the outcome SCD may be partly a result of how SCD 
was defined. 
In a recently published study on Korean HCM patients (n=730), 7/11 (64%) of endpoint SCD 
or appropriate ICD shock had a low ESC risk score (<4%), but specificity was high (C-index 
0.72).459 This may be added to the previous criticism addressed by Maron et al, who 
advocates a strategy based on enhanced ACCF/AHA guidelines.142 They claim that extensive 
LGE, systolic dysfunction (EF<50%), and LV apical aneurysms should be considered as they 
constitute one quarter of appropriate ICD therapies.459,460 Lui et al compared the enhanced 
ACCF/AHA strategy, 2011 ACCF/AHA strategy, and ESC Risk SCD cutoff of 6% in 1,369 
Chinese HCM patients (mean age 50 years) of whom 39 reached SCD endpoint, with a yield 
of 67%, 51%, and 13%, respectively for each guideline.461 
Recently, a systematic review by O’Mahony et al of 7,291 HCM patients based on 6 
publications reported the 5-year risk for primary-prevention patients.129,137,451,455,457,462,463 In 
their pooled analysis, the SCD endpoint at 5 years from baseline evaluation in low (<4%), 
middle (4-<6%), and high risk (≥6%) patients was 1.0%, 2.4%, and 8.4%, respectively, which 
was interpreted as accurate risk estimation.462 About half (51%) of SCD endpoints occurred 
in high-risk patients, and 68% in middle-high risk patients which comprised 30% of the 
merged cohort. C-index ranged from 0.69 to 0.92. Notably, ATP was excluded from the SCD 
endpoint. Some smaller studies which lacked 5-year data, included ATP, or constituted pure 
ASA cohorts were excluded from the meta-analysis.284,381,382,444,464 Moreover, the systematic 
analysis did not include the data from Maron et al.452 The authors of the systematic review 
recognized LGE as a predictor for future endeavours to further improve the risk model.419,465 
In addition to the systematic analysis, Nakagawa et al reported on 289 HCM patients with 
≥50% and 81 patients with EF<50% during a mean follow-up of 5.2 years.466 In patients with 
EF≥50%, Risk-SCD score was higher in those with outcome, 6.8% vs 1.8% 5-year risk, and 
60% of those with outcome were classified as high risk. In the group EF<50%, 16 out of 81 
(19.8%) experienced SCD outcome. There was not a significant HCM Risk-SCD score in 
patients with EF<50% and the authors suggested insufficient accuracy in this subgroup. 
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Ommen et al has proposed using the principles established by Maron et al as a highly 
sensitive screening, but also integrate the 5-year score from the HCM Risk-SCD calculator.366 
Rather than using cutoffs for strict decision-making, these values can be looked on as pieces 
of evidence. This could provide a basis for shared decision-making with the patient. They 
describe this challenge as not for the “cognitive miser” but for the “domain of healers.”366 
The decision to implant an ICD is a turning point in the management of the HCM patient.467 
After careful evaluation of risk factor/markers and potential modifiers by a qualified 
physician, preferably after discussions with colleagues, the recommendation needs to be 
shared with the patient in trustful communication.468 Patients, and often also relatives, need to 
be extensively informed about complications of ICDs and consequences for lifestyle. Even 
though inappropriate shocks and device-related infections can be devastating, they should not 
be a reason to refrain from the obvious benefits of preventing SCD. Like any other ICD 
indication, there will always be individuals who will not benefit from device implantation. 
From a health economy perspective, ICDs in general based on the indications established by 
current guidelines are advantageous. For a long time, there has been limited health economy 
analysis regarding other forms of cardiomyopathy.469 Recently, a health economy analysis 
using a Markov model showed excellent cost-effectiveness from both a health care sector 
viewpoint and a societal viewpoint based on our published Swedish data.470,471 No risk 
stratification model can ever be perfect, and SCD is inherently unpredictable.472 Thus, the 
decision to implant an ICD should be based on an overall assessment, with a holistic 
approach, but always with the guiding principle to avoid SCD, after shared decision-making 
with the patient. 
10.1.11 Single vs multiple risk factors 
Our study confirmed that multiple risk factors imply higher risk than single risk factors. 
There has been an ongoing debate whether multiple risk factors imply higher risk than a 
single risk factor. The question could also be turned to ask if a single risk factor is enough for 
a patient to be eligible for an ICD. Already in 2001, Elliott et al noticed that a higher number 
of risk factors (one, two, or three) was superior to predict SCD or ICD shock compared to 
maximal wall thickness (RR per additional risk factor 2.00; p=0.058) based on 630 HCM 
patients.402 However, many early studies were not powered to detect a difference between the 
numbers of risk factors. ESC guidelines have overcome the problematic binary approach of 
regarding risk factors and the ACCF stress the use of a more refined judgement of multiple 
risk factors in conjunction with modifiers and elaborate on the interpretation of each factors, 
although ACCF does not quantify risk assessment. In our comparatively large study, we were 
able to confirm that multiple risk factors do indeed imply higher risk. This does not address 
the related question as to whether a single risk factor is enough to justify ICD, because that is 
a matter of acceptable sensitivity and specificity. However, in borderline situations it could 
sometimes be useful to take more risk factors into account. 
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10.1.12 Special situations in risk stratification 
Long-term results, including SCD, after septum reductive procedures have showed low risk of 
unfavorable outcome. Genetic profile does not yet play a role in risk stratification. 
The HCM Risk-SCD states precautions in patients who have undergone septum reductive 
procedures. Desai et al studied 1,809 HCM patients with obstruction. In 65% of the patients, 
there was no risk factor, 1 risk factor in 26%, and ≥2 in 8%. The HCM Risk calculator 
categorized 65% of the patients as low risk (<4%), 18% as intermediate risk (4-6%), and 17% 
as high risk (>6%). A total of 64% underwent myectomy.458 On multivariable competing-risk 
analysis, myectomy (HR 0.69; p<0.01) was associated with lower risk of SCD events while 
ESC SCD risk score was not (HR, 1.31; p=0.36). Thus, myectomy seem to mitigate risk of 
SCD. 
Liebregts et al evaluated 844 ASA patients (mean age 56 years, 54% men) without a 
secondary indication for an ICD. Periprocedural 30-day mortality, occurred in 20 patients. 
Another 46 patients reached the composite endpoint of SCD or appropriate ICD therapy 
during a mean follow-up of 6.5 years.444 The C-index for HCM Risk-SCD was 0.61 (p=0.02), 
and using the 2011 ACCF/AHA guidelines was 0.58 (p=0.054). They concluded that the ESC 
model was applicable for ASA patients. 
In the systematic review from 2015 (16 myectomy cohorts and 11 ASA cohorts) long-term 
mortality was similar, myectomy 1.4% per year, and ASA 1.5% per year (p=0.47). SCD, or 
appropriate ICD shock, was also similar (myectomy 0.5% per year, ASA 0.4% per year).247 
Genetic profile should not be used for risk stratification. The clinical expression is relevant 
and not the specific gene mutation. However, from the Portuguese HCM Registry (only 51% 
underwent testing, 28% genopositive, 9% had variants of unknown significance) the MYH7 
gene was associated with a risk of LV systolic deterioration. This indirectly warrants 
attention to clinical deterioration and subsequent risk of SCD, but not the genotype per se. 
10.1.13 Limitations 
Often data are presented as crude annual event rates which does not imply completely 
accurate representation of the incidence data. Instead, the time to event analysis is beneficial, 
but often not reported.209 
Risk stratification in HCM is inherently limited by the unpredictable nature of ventricular 
arrhythmias. A high sensitivity can be achieved at a cost of lower specificity and vice versa. 
Many studies are hampered by limited power and there are difficulties in adjusting for known 
and unknown risk markers. Moreover, modifiers and changes in risk since baseline prove 
difficult to take into account. Typically, long-term risk is relative and does not always align 
with life expectancy. Most studies use both ATP and cardioversion in their outcomes, but 
some studies omit ATP, which can underestimate the benefit of device therapy. At the same 
time, an unknown proportion of ventricular arrhythmias are self-terminating, with the result 
that the benefits of device therapy are overestimated. Cohorts may contain different 
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proportions of ICD patients which will affect outcome, typically defined as the composite of 
SCD, aborted SCD, and appropriate ICD therapy. Moreover, the generalizability of studies 
may be influenced by setting, tertiary center bias, and changes in risk stratification over time. 
10.1.14 Summary 
In the Swedish nationwide cohort of HCM patients an excellent efficacy of appropriate ICD 
therapy was confirmed. In other words, in a clinical setting the device was able to convert 
potentially life-threatening ventricular arrhythmias. An individualized approach to 
programming is important to assure efficacy in addition to avoiding inappropriate shocks. A 
quarter of the patients in our cohort experienced appropriate therapy, and there is continued 
risk over the years. This underlines the unpredictable nature of VT/VF in HCM. Therefore, 
device exchange should be advised even if the patient received no appropriate therapy for 
several years. The burden of risk factors in the Swedish cohort was comparatively high 
compared to other cohorts. Sweden has a conservative approach to ICD therapy compared to 
many other high-income countries which was evidenced here with a lower proportion of 
primary-prevention patients and older age at implant, resulting in a higher annualized rate of 
appropriate ICD therapy. There was a majority of male patients who had ICD due to HCM as 
seen in other studies but outcome with regard to appropriate ICD therapy is similar between 
sexes. There is a strong adherence to risk factors in the decision-making. AF and EF<50% 
emerged as risk markers, especially in primary prevention. Age is not an independent risk 
factor in this unselected cohort. NSVT is the strongest conventional risk factor. Our study 
was performed before the implementation of the HCM Risk-SCD calculator and which 
makes comparisons impossible. Several studies have confirmed the benefit of this new 
algorithm, but controversies remain regarding its sensitivity. Complementary risk factors like 
LGE are promising for improving risk stratification. Left atrial size enlargement is part of 
current ESC guidelines and our findings about AF likely reflect such risk. Importantly, our 
data suggest that EF<50% implies an increased risk and should be taken into account to 
improve risk assessment. In individuals with deteriorating systolic function, there is a 
substantial risk for SCD. 
10.2 PAPER Ⅱ 
10.2.1 Mortality among general hypertrophic cardiomyopathy patients 
Mortality in general HCM patients depends on the underlying characteristics of the cohort. 
Merged cohorts from tertiary centers show a doubled SMR while unselected cohorts of 
middle-aged patients seem to have mortality comparable to the general population, but this 
has been questioned. NYHA III/IV, AF, possibly female sex, but not necessarily obstruction, 
seem to be associated with an increased risk of death. Over extended periods of follow-up, 
heart failure seems to be the main culprit, but there may be advanced treatment options 
available. 
Over the decades diagnosis and treatment have improved within the field of HCM. Kofflard 
reported an annual mortality of 1.3% in 225 HCM patients between 1970 and 1999 with a 
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mean age 41 years at first evaluation.406 By 2006, Elliott et al showed historical trends toward 
improved survival.473 With the contemporary treatments, the HCM-related death rate is low 
and many patients are believed to have a normal or near-normal life expectancy without 
major adverse events.80 Maron et al reported low cardiovascular mortality among middle-
aged HCM patients (range 30-59 years, mean 45 years) over 7.2 years follow-up with 5 and 
10 years freedom from HCM-related death estimated to be 98% and 94%, respectively.80 
Surprisingly, this was comparable to the general US population, which included all deaths 
(p=0.25). In a later comparison, they stated superior 5-year survival rates for HCM patients in 
relation to myocardial infarction, heart failure, and many forms of cancer.474 Even though this 
is somewhat reassuring, at least for middle-aged patients, and, indeed, the treatment of HCM 
patients has improved, it does not unequivocally answer the question of differences in 
survival compared to the normal population, because populations should also be matched 
with regard to age, sex, and calendar time. 
In 2017 Liu et al published a meta-analysis regarding HCM and survival.268 Their search 
yielded 19 studies and a total of 12,146 patients (62.5% males) but many studies did not 
report data for all analyses. The pooled 1, 3, and 5-year cumulative survivals were 98.0% 
(95% CI 97.4-98.6%), 94.3% (95% CI 93.1-95.6%) and 82.2% (95% CI 75.2-89.2%), 
respectively.268 Few studies reported 10-year data, but based on 4 studies it was 75.5% (95% 
CI 71.1-78.9%). It should be pointed out that there was substantial heterogeneity, which may 
involve age, comorbidity, treatment, and time period for the cohort. The natural course of the 
disease and follow-up interventions may likewise differ among cohorts. In a heterogeneity 
analysis, publication year (cutoff 2005), sample size (cutoff 1,000), and geographical area 
were not statistically significant. NYHA III/IV was the strongest risk factor for 
cardiovascular death (HR 2.5) and all-cause death (HR 2.0). Regarding cardiovascular death, 
the average age, NYHA functional class, NSVT, family history of SCD, syncope, AF, 
maximal LV wall thickness, and obstruction were significant prognostic factors. Family 
history of SCD showed strong predictive power for cardiovascular death (HR 2.4), but no 
significant correlation with all-cause death was observed. NSVT, LVOT obstruction, and 
syncope were risk predictors for cardiovascular death (HR 2.5; HR 1.5; HR 2.4, respectively). 
Syncope was also associated with all-cause death (HR 1.4). Left atrial diameter and EF were 
not determined to be significant prognosticators based on the limited data in their analyses. In 
regression analyses, age at first evaluation of HCM is often used rather than actual calendar 
age. Meta-analyses in a heterogeneous disease like HCM must be regarded with some degree 
of caution.475 
Notably, Autore et al found that AF was the strongest predictor of cardiovascular mortality 
(HR 4.3; p<0.001) both in uni- and multivariable analysis.476 There has been a debate 
whether obstruction implies worse prognosis. This was also addressed in another meta-
analysis (n=20 studies) of 7,731 HCM patients comparing annualized mortality with and 
without LVOT obstruction (1.8% vs 1.6%; p=0.40).477 Spirito et al also evaluated death from 
any cause with regard to maximal wall thickness: the incidence per 1,000 person-years with 
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regard to maximal wall thickness divided into 5 groups was as follows: <15 mm (11.7), 16-19 
mm (15.9), 20-24 mm (21.4), 25-29 mm (27.5), and >30 mm (28.6).401 
Late November 2019, Lorenzini et al from the HCM Outcome Investigators reported 
mortality data from a dataset of 4,893 patients (63.9% males, mean age at first evaluation 
49.2 years) with a median follow-up of 6.2 years.275 Of note, the data were confined to 
tertiary centers and covered the time period of 1980-2013. A composite endpoint of all-cause 
mortality, aborted SCD, and heart transplant (but not appropriate ICD therapy) was used in 
the main survival analysis. They used strata of time intervals for calculation of SMR. Patient 
age at the end of the follow-up period was used for comparison of expected mortality, based 
on yearly mortality rates by age in the general population. Indeed, HCM patients had 
excessive mortality (SMR 2.0, 95% CI, 1.5-2.6) compared to the general population. The 
SMR was significantly higher among women than men (2.6; 95% CI 2.4-3.0 vs 1.7; 95% CI 
1.5-1.9; p<0.001). The categories of outcome were: SCD or ICD shock (not ATP) 3.4%, 
heart failure 2.6%, transplant 1.7%, other cardiovascular causes 2.2%, and unknown causes 
0.5%. As the authors admitted, Eurostat data do not contain specific causes of death. The 
study highlighted the high mortality among women, whereas men aged 65 years or more had 
mortality rates similar to general population. The authors suggested higher prevalence of 
heart failure and advanced disease due to tertiary center bias. At the same time, patients with 
much comorbidity, especially the elderly, are probably not referred to tertiary centers. In 
another study, registry data from HCM patients compared to the general population showed 
an excessive amount of SCD, heart failure, and AF.478 
Also, in November 2019, Rowin et al reported the US experience of 2,123 patients (38% 
women) with HCM from a tertiary center.272 Women were diagnosed at an older age than 
men (55 SD 18 vs 44 SD 16 years; p<0.001) and more often developed NYHA III/IV 
symptoms. EF<50% was similar between both sexes (5% among men and 4% among women 
p=0.33) but heart failure with preserved EF was three times more common in women 
(p=0.001). Appropriate ICD therapy was similar in women and men (0.9 vs 1.0% per year; 
HR 0.92; p=0.73). HCM mortality was infrequent, 0.3% per year in both sexes, p=0.25. The 
age-adjusted all-cause mortality rate also did not differ between women and men (1.7% vs 
1.3% per year; HR 1.32; p=0.13). 
In the SHaRe study, 4,591 HCM patients (2,763 genotyped) with a mean age of 45.8 years at 
diagnosis were followed for a mean of 5.4 years.27 The composite outcome was SCD, 
appropriate ICD therapy, heart transplant, all cause death, AF, stroke, NYHA III/IV, or 
EF<35%. Patients aged <40 years at the time of diagnosis had a 77% cumulative incidence of 
achieving the endpoint before the age of 60 years. Patients with a positive genotype had a 
doubled risk. Patients 20-29 years of age had a fourfold mortality rate compared to the 
normal population and more than a threefold higher rate of HCM patients who were 50-69 
years of age at evaluation, but this study did not adjust for sex and time period. In a merged 
cohort of Italian and British patients with HCM including phenocopies, the prevalence of rare 
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phenocopies was associated with a nine-fold prevalence of LV dysfunction. Amyloidosis is 
often associated with low EF and poor prognosis.478 
The vast majority of patients with HCM due to sarcomeric mutations have normal or above-
normal EF values due to their small LV cavity. Using the echocardiographic definition <50%, 
the prevalence is about 2-5% and the annual incidence less than 1%.83,84,479 The transition to 
end-stage HCM can occur at any age but typically occurs at least 10-15 years after 
symptoms.83 Traditionally, the risk of death in HCM has largely focused on SCD. Due to the 
efficacy of ICDs, there is now improved long-term survival, with new concerns arising over 
disease progression into heart failure. US data for 1, 5, and 10-year survival after transplant 
due to HCM are 85%, 75%, and 61%, respectively, which compares to other underlying 
diseases.178 Transplant or LVADs should be considered in HCM patients with end-stage 
disease.409 CRT may be considered but should not delay transplant/LVAD.237 Recently, 
Songsirisuk et al evaluated 161 HCM patients (mean age 66 years, 42% males), of whom 25 
(16%) died of HCM-related causes during a mean follow-up of 6.8 years.480 These deaths 
could be attributed to heart failure (52%), SCD (44%), and stroke (4%). Geske et al reported 
sex differences in a tertiary center cohort of 3,673 HCM patients.273 Females were the 
minority (45.2%). The age at first evaluation was higher in females than males (59 vs 52 
years; p<0.001) and females were more symptomatic based on NYHA III/IV class (45.0% vs 
35.3%; p<0.001). A Kaplan-Meier estimate showed lower survival in females than males 
(p<0.001). In a multivariable analysis, female sex was associated with a higher risk of death 
adjusted for age, NYHA class, and cardiovascular comorbidities.  
Age-matched data from Iceland showed similar all-cause mortality rates for patients with 
HCM and those of the general population (HR 0.98; p=0.9).72 The HCM-related mortality 
was 0.78% per year with a mean age of 68 years compared with 81 years for non-HCM-
related mortality (p=0.02). Importantly, they did not include individuals who died before a 
clinical diagnosis of HCM. Genetic evaluations of patients found pathogenic mutations in 
67% of subjects, of which MYBPC3 mutations were most prevalent, but seemed to be 
associated with a relatively benign course of HCM. 
A British population-based cohort of 3.3 million people found 0.035% with HCM (median 
age 57 years, 59% men). During a median follow-up of 4.0 years, the risk of cardiac 
arrest/SCD was higher than in the matched general population (incidence rate ratio 23.5; 
p<0.001). This was also seen with regard to AF (HR 3.8; p<0.001). Using Kaplan-Meier 
estimates, at 3 years, the risk of cardiovascular death or heart failure was 8.8%. This 
underscores the increased risk and unmet need for the implementation of evidenced-based 
medicine in HCM.481 
10.2.2 Mortality and cause of death among HCM patients with ICDs 
In our nationwide study of HCM patients with ICDs, the SMR was 3.4 which was 
significantly higher (p<0.0001) than the normal population, even adjusted for age, sex, and 
calendar time. Risk of death increases with age. Patients with EF<50% had five-fold risk of 
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death in both uni- and multivariable analysis with regard to death. AF is also associated with 
death, but is weaker in multivariable analysis. Death from SCD do occur in end-stage heart 
failure. This warrants careful attention to deterioration of systolic function in patients with 
HCM.  
In 2018, in a study of 486 HCM patients with ICD (mean age 51 SD 16 years) from 8 tertiary 
centers in the United States, Europe, and Australia, 94 experienced appropriate ICD therapy 
with a mean follow-up of 6.4 SD 4.7 years.482 Among these 94 patients, one died suddenly 
because of device malfunction and 3 died of end-stage heart failure. In the meta-analysis by 
Schinkel et al, mortality based on 13 studies was reported. Cardiac death was 0.6% per year 
and non-cardiac death 0.4% per year.208 Only 5 studies reported heart transplantation as an 
outcome, which occurred in 2.3% with an annualized rate of 0.5%. In this meta-analysis, the 
largest ICD cohort was included and reported more details on cause of death. Out of 507 
HCM patients with ICDs, 39 died (7.7%) during the mean follow-up of 3.7 years.203 About 
half (n=20) died from HCM-related causes: end-stage heart failure (n=12), embolic stroke 
(n=7) and SCD (n=1). The single SCD event occurred in a young man whose ICD device 
malfunctioned.483 The remaining causes of death in the other 20 patients were due to cancer, 
renal failure, coronary artery disease, and trauma. Wang et al, who analyzed 16 studies, found 
an all-cause mortality of 1.3% (95% CI 0.9-1.9) divided into cardiac 0.9% and non-cardiac 
0.8% per year.209 Table 21 summarizes mortality in HCM patients with ICDs. 
Table 21. Mortality in HCM patients with ICDs. 
First author Year Size 
(n) 
Follow-up, 
mean (years) 
Age 
(years) 
HCM-related 
mortality (%) 
Non-HCM-related 
mortality (%) 
Primo370 1998 13 2.2 48 0 0 
Begley279 2003 132 4.8 34 3.0 1.5 
Almquist371 2005 75 3.6 36 2.7 0 
Lawrenz372 2005 15 3.4 53 6.7 13.3 
Marin373 2006 45 2.7a 43 4.4 0 
Medeiros374 2006 26 3.7 43 3.8 0 
Maron203 2007 506 3.7 42 4.0 3.8 
Woo375 2007 61 3.3 46 1.6 0 
Syska280 2010 104 4.6 36 3.8 0 
O’Mahonyb,281 2012 334 2.2 40 2.7 1.2 
Vriesendorp282 2013 134 4.2 44 8.2 2.2 
Lambiase222 2016 99 1.8 42 0 0 
Magnusson353 2015 342 5.4 52 9.9 3.2 
Rigopoulos381 2016 32 5.3a 50 0 3.1 
Ruiz-Salas382 2016 48 4.1 44 0 0 
Thavikulwat284 2016 135 5.2 48 Not reported 7.4 
Viswanathan383 2016 60 5.1 44 0 Not reported 
Francia384 2017 66 4.4 45 1.5 0 
Wang285 2017 160 4.0 47 6.9 3.8 
a median. b additional 0.9% mortality of unknown cause. Stroke was not clearly discernable among non-cardiac deaths in a 
few cases, which implies some uncertainty regarding HCM-related mortality.  
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Our cohort of HCM patients with ICDs represents patients with a high proportion having an 
EF<50%. The crude mortality was 2.44 per 100 patient-years. In the meta-analysis by 
Schinkel et al the annualized mortality was 1.0% per year (0.6% cardiac, 0.4% noncardiac). 
In the meta-analysis, the mean age at implant was 10 years younger, follow-up was shorter 
(3.7 years), and patients were selected from highly specialized centers.  
The SMR in our cohort was 3.4 which was significantly higher (p<0.0001) than the normal 
population adjusted for age, sex, and calendar time. There is no other comparable study with 
this measurement in a nationwide cohort. In older, general HCM patients, but not necessarily 
ICD patients, Maron found an SMR of 1.5 compared to general US population.484 The 
cumulative survival in our cohort was 97.0% at 1 year, which supports a highly selected 
cohort based on the guidelines of offering ICDs in patients with at least one year of life 
expectancy. The 5-year survival rate of 89.4% indicates a substantial proportion of death with 
longer follow-up. There was no significant survival difference between men and women in 
our cohort. Neither was there a sex difference in the cohort with respect to age or calendar-
matched data. From this perspective, there seems to be no selection bias in candidates for 
ICD, as survival rates are similar. Interestingly, primary and secondary prevention patients 
had similar survival. This also reflects the selection of patients with acceptable long-term 
prognosis after cardiac arrest and sustained VT.  
The excess mortality in our cohort was due to HCM-related causes. In fact, three-fourths of 
all deaths could be attributed to HCM. Interestingly, this is higher than the largest HCM-ICD 
study, in which 51% of deaths were HCM related. In that study, investigators attributed 31% 
of all deaths to heart failure. The likely explanation for this discrepancy is the higher 
proportion of low EF in our cohort, including patients with CRT. Our data support EF<50% 
to be the critical level that marks a transition toward end-stage heart failure. The unfavorable 
prognosis of low EF in HCM is well-known.83,172 Patients with EF<50% have a five-fold risk 
of death in both uni- and multivariable analysis.  
The detailed interpretation of main and contributing causes of death confirms that underlying 
systolic deterioration is the culprit. This underscores the importance of attention to end-stage 
heart failure in HCM. It requires a multidisciplinary effort to provide optimal treatment in the 
individual case.  
Not surprisingly, AF was likewise a predictor of death in our study. There was a three-fold 
increase in univariable analysis, which diminished to a doubled risk with borderline 
significance after adjustment of other variables. There is an association with embolic stroke, 
but this can effectively be prevented by anticoagulation. Of note, ICDs can monitor AF 
episodes and most patient also have remote monitoring systems, which can be helpful when 
prompt anticoagulation is deemed indicated. AF is also a consequence to heart failure and 
may lead to or worsen heart failure, which may explain the difference in HRs in uni- and 
multivariable analyses. 
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The efficacy of ICDs in terminating ventricular arrhythmias has been demonstrated in Paper 
Ⅰ. This is in line with massive evidence from diverse cohorts. In a survival analysis, the 
potential life-saving benefits of bradycardia pacing should also be taken into account. The 
exact benefits of bradycardia treatment cannot be quantified.  
Paper Ⅱ also offers insights with respect to the risk of the consequences if the ICD is 
removed. In Paper Ⅰ, the analysis was performed based on time until right censoring, for 
example, removal of the device. Here we analyzed the overall survival and not just 
appropriate ICD therapy, which acts as a surrogate for SCD. As reported in the Results 
section, there can be catastrophic results when an ICD is inactivated, as occurred in the 
patient who had the device disabled after several inappropriate shocks. This highlights how 
important it can be to avoid inappropriate therapy delivery so that the patient is motivated to 
keep the device activated.  
From other studies, it is obvious that a holistic view of patient management is of utmost 
importance to improve survival. It should include alertness of signs of developing heart 
failure, prompt evidenced-based pharmacological treatment, and LVAD or transplant in 
selected cases.485 CRT may be beneficial, but long-term survival benefits from CRT seem 
modest.173,177 ICDs are indeed beneficial due to high efficacy, but there can arise certain 
complications, including inappropriate shocks that may undermine device acceptance among 
both patients and health care providers. Therefore, it is crucial to take action against the risk 
of complications and carefully handle them from several perspectives, including the patient’s 
emotional response. Based on Papers Ⅰ and Ⅱ it should be stressed that the risk of life-
threatening arrhythmias persists over the years and ICDs offer excellent protection from 
SCD. Indeed, ICDs almost eliminate SCD, which can occur suddenly in heart failure. This is 
reassuring, and should be emphasized in the long-term management of HCM patients.  
10.2.3 Limitations 
Many cohorts of HCM patients with ICD are from tertiary centers of selected patients, while 
our nationwide study is without referral bias. We also reported relatively long-term follow-up 
periods compared to other studies, but still far from the estimated life expectancy. The 
challenge with long-term data is that treatment changes over time with improvements in 
disease management, with the patient’s underlying condition and disease progression, and 
with comorbidities. Home monitoring of the device and anticoagulation may be of benefit in 
ICD patients and further reduce mortality. More available options for advanced heart failure 
therapy are likely to emerge in this disease, due to the fact that many patients have otherwise 
long life expectancy. 
10.2.4 Summary 
The natural history of HCM varies enormously. It covers asymptomatic disease, mild 
expression, disease of moderate severity, but also end-stage heart failure or SCD. Even 
though there has been a decline in death rate, efforts are still needed to reduce adverse disease 
manifestations and offer effective treatment. Given the clinical heterogeneity of the disease, 
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individuals need to be stratified for risk of SCD, heart failure, and embolic stroke. The 
contemporary treatment options have led to a paradigm shift in the natural history of the 
disease. Nowadays, many patients can expect a near-normal life expectancy, but each 
individual needs to be carefully managed, including risk stratification for SCD. Complete 
reassurance can never be applied since each individual must be treated holistically with 
evidence-based management strategies. ICD patients with HCM constitute a group who is at 
increased risk of adverse outcome with a more than threefold SMR. Our nationwide cohort of 
HCM patients with ICDs show that SCD can occur quickly in heart failure, making 
monitoring of any deterioration in systolic function of crucial importance. 
10.3 PAPER Ⅲ 
Our paper was the first one specifically addressing HRQL in HCM patients with ICD. 
This was the first paper on HRQL specifically in HCM patients with ICD. It is essential to 
address this patient group, because they are younger than typical ICD patients and thus there 
is less burden of age-related comorbidity. The underlying disease is also different than other 
ICD patients, including risk factor profile. We decided to use the widely recognized SF-36 
questionnaire, which has been used in tens of thousands of publications throughout different 
medical fields. The importance of HRQL assessment in heart failure patients in general is 
widely recognized, as poor HRQL predicts adverse outcomes, including death.486 
10.3.1 The concept of HRQL 
Patient-reported outcome measurements reflect subjective well-being. Generic 
questionnaires reflect general HRQL from a holistic perspective and cover multiple aspects. 
In addition to the traditional evaluation of outcome in both observational and randomized 
controlled studies, patient-reported outcome measurements are often used to reflect subjective 
well-being. Quality of life in its broadest sense is often used interchangeably with other 
terminology, but we prefer the term HRQL, which is widely used to stress the health 
aspects.295 Still, HRQL has resisted strict definition. Instead, its meaning may vary from 
study to study, but it is generally agreed that it includes general health, physical functioning, 
emotional functioning, symptoms, cognitive functioning, social functioning, and well-being. 
It may reflect spiritual issues, coping strategies, and satisfaction with life.295 Because HRQL 
covers multidimensional constructs, a single, global question is likely going to be ambiguous, 
unreliable and unspecific. Thus, multi-item measurements scales are used for each part of the 
overall concept. Generic HRQL includes both health status and domains reflecting quality of 
life and is thus more general, i.e. holistic, but are not as sensitive as questionnaires developed 
for a certain, specific diseases.  
10.3.2 Choice of HRQL questionnaire  
SF-36 is a highly validated, widely accepted instrument for general health status in many 
patient groups and there is a Swedish population norm for comparison. 
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The SF-36 determines the general health status and is designed to assess generic health 
concepts applied in a broad range of age groups, diseases, and interventions across different 
cultural settings.296,487 This broad HRQL assessment tool was developed in the Medical 
Outcome Study and is frequently used in studies since the early 1990s.296 
The major advantage of these questionnaires is that its generic measures may allow for 
comparisons with the general population, which was possible in our study where we used the 
36-item SF-36 Health Survey. Therefore, we decided to use version 1 based on its solid 
psychometric foundation, Swedish contextualization, and the availability of a norm 
population for comparison purposes.297,488,489 Despite extensive and robust validation work 
carried out to make this questionnaire suitable for use in Swedish populations, the Swedish 
SF-36 pioneers have brought up issues relating to the PCS and the MCS scores. They 
performed simulations to pinpoint the impact of the scoring model to discrepancies between 
subscale profiles and summary component scores. Notably, significant correlations were 
found between PCS and MCS scores at their upper scoring intervals, which should be 
interpreted to mean that they are not highly independent. Moreover, regression analyses 
showed that within these ranges, PCS mainly measures of mental health (57% of variance) 
and MCS measures physical health (65% of variance).297,488,489 Nevertheless, PCS and MCS 
are widely accepted as summary scores, but it should be emphasized that all 8 domains 
constitute the basics of interpretation. 
When we used the SF-36 version 1, the norm population was collected more than 20 years 
ago.297 It is unknown whether this influenced the score. Most other validation studies are 
from respondents of the same age and without renewed follow-up of the general population. 
Differences could be interpreted as reflecting improvements in the general population’s 
HRQL due to improvements in their overall welfare.  
Even though SF-36 was validated as a single questionnaire when posted by regular mail, it is 
often used in conjunction with other questionnaires and metrics. We followed the practical 
approach of distribution by mail in our study. In addition, we had phone reminders to 
improve response rates and eliminate missing data. We dispensed with the use of multiple 
questionnaires as they risked a reduced response rate plus there can be carry-over effects in 
the questionnaires as patients get tired of the tedious work involved in completing the many 
forms. In our national cohort, we had actual clinical contact with only a few of the included 
patients and we anticipated the risk of low response rate. Fortunately, the response rate was 
82.5%. We believe these patients with chronic disease and ICDs were grateful toward the 
health care sector in general and willing to contribute to research by answering questions. 
Often patients wrote additional sentences of the paper sheets or included an extra sheet with 
personal reflections about their HRQL. This could not be addressed quantitatively in this 
study but became a motivating factor to conduct the study that resulted in Paper Ⅳ. 
There is no HRQL questionnaire specifically for HCM. We could have included a more 
general heart failure questionnaire like the Kansas City Cardiomyopathy Questionnaire 
(KCCQ) and possibly the Hospital Anxiety and Depression Scale (HADS).490,491  
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There are device-specific questionnaires, but they are not widely used. Instead, we had 
validated clinical data from medical records that could be used for comparisons of subgroups 
using the SF-36 and its norm population. The age- and sex-matched sample was randomly 
selected from the normative data base (n=8,930). The sample of 735 persons (516 males) had 
the same mean age and was used for comparisons. 
10.3.3 HRQL in relation to population norms 
Swedish HCM patients with ICDs reported a poor HRQL compared to population norms. 
Our study demonstrated a poor HRQL in patients with ICDs. Compared to Swedish age- and 
sex-matched population norms, 7 of 8 domains showed significantly lower SF-36 scores. The 
only non-significant domain was Bodily pain, otherwise the differences were highly 
significant (p<0.001). A graphical presentation using bar charts is shown as Figure 14. Effect 
sizes (ES) varied from small to moderate. General health had the highest effect size (0.77), 
followed by Vitality (0.67) and Physical functioning (0.62). The PCS score (0.62) was more 
affected than the mental component score (0.46). The moderate effect size of physical 
domains contrasted with the smaller effect size of mental domains.  
10.3.4 HRQL in relation to other studies 
A British tertiary center study of younger HCM patients before the ICD era showed poor 
HRQL. In a small Norwegian study on HCM patients, SF-36 score was lower than in the 
population norm. An Australian cohort of HCM patients reported a lower PCS but similar 
MCS score compared to population norms. A recent international study of HCM patients 
with ICD, without population norms, showed similar scores between patients with and 
without ICD therapy using the SF-12. 
In a study by Cox et al published in 1994, a total of 137 HCM patients returned completed 
SF-36 data (response rate 80.1%).492 Similarly, scores were coded and transformed to a scale 
between 0 and 100, where 100 indicates the best possible health. All 8 domains scored 
significantly lower than the UK norms, but no ESs were reported. The comparison group 
comprised of 144 patients with serious cardiac conditions included in the Medical Outcomes 
Study. Interestingly, these results are similar to the findings in our cohort, but there are three 
important differences between our study and the British study. First, the British study was 
performed in the early 1990s, before the era of efficient therapy options. Secondly, patients 
were recruited from a tertiary center, likely representing patients with advanced HCM. 
Thirdly, the British patients were comparatively young, with a mean age of 43 years, i.e. 
more than 10 years younger than our cohort and 54% were males (in our cohort 70%). The 
results we obtained in terms of similarities in comparison with a group of seriously ill cardiac 
patients and significantly lower scores than norms in all domains imply that HCM patients 
have poor HRQL (Table 22). 
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Table 22. SF-36 score of UK patients, norm and serious cardiac conditions. Modified from 
Cox et al.492 
Domain HCM Serious cardiac 
conditions294 
UK norm493 
Physical functioning 60.9 SD 25.3 57.4 SD 28.1 88.4 SD 18.0 
Role physical 55.9 SD 42.9 43.9 SD 39.7 85.8 SD 29.9 
Bodily pain 66.1 SD 27.2 65.1 SD 24.7 81.5 SD 21.7 
General health 47.2 SD 24.4 49.1 SD 21.6 73.5 SD 19.9 
Vitality 43.6 SD 24.2 47.8 SD 21.8 61.1 SD 19.7 
Social functioning 70.2 SD 26.3 80.0 SD 24.4 88.0 SD 19.6 
Role emotional 64.2 SD 40.7 76.2 SD 37.3 82.9 SD 31.8 
Mental health 65.6 SD 21.1 77.6 SD 15.8 73.8 SD 17.2 
 
A Norwegian study published in 2010 compared HCM patients (n=19) referred for genetic 
counselling to the general population using the SF-36 (Table 23).494 The eight domains were 
significantly (p<0.05) lower for HCM patients or had a tendency (p<0.10) to lower scores in 
all domains except for bodily pain and mental health. 
Table 23. SF-36 score of Norwegian patients UK patients compared to norm. Modified from 
Hamang et al.494 
Domain HCM Norwegian population norm p-value 
Physical functioning 73.2 SD 19.5 84.9 0.021 
Role physical 50.0 SD 43.3 73.3 0.024 
Bodily pain 62.0 SD 30.8 72.9 0.127 
General health 54.1 SD 23.9 73.2 0.004 
Vitality 44.5 SD 19.5 61.9 0.001 
Social functioning 61.4 SD 43.4 74.1 0.068 
Role emotional 61.4 SD 43.4 81.5 0.054 
Mental health 76.3 SD 14.0 79.9 0.245 
 
In an Australian study on cardiogenetic studies and HRQL (response rate 55%), 208 patients 
with the HCM phenotype (mean age 54 SD 15 years, 62% males) were evaluated by SF-36 
version 2 (Table 24).495 The evaluation took place between 2007 and 2010. A majority had no 
shortness of breath (NYHA I), and the remaining were in NYHA II (36%) and NYHA III 
(3%). A quarter (25%) had an ICD. Predictors of worse HRQL on physical domains were 
female sex, presence of comorbidities, and lower NYHA functional class. The PCS score was 
significantly lower in HCM while the MCS score was indistinguishable from the general 
Australian population. 
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Table 24. SF-36 score of Australian patients compared to norm. Modified from Ingles et 
al.495 
Domain HCM Australian population norm p-value 
Physical functioning 70.1 SD 25.9 83.3 <0.001 
Role physical 72.3 SD 27.9 81.8 <0.001 
Bodily pain 72.3 SD 25.3 76.2 0.037 
General health 55.4 SD 23.0 71,8 <0.001 
Vitality 53.3 SD 21.7 74.9 <0.001 
Social functioning 79.5 SD 24.2 86.4 <0.001 
Role emotional 83.7 SD 22.3 84.7 NS 
Mental health 74.5 SD 16.9 76.2 NS 
NS, non-significant 
In 2018, a study on 486 HCM patients with ICD (mean age 51 SD 16 years) at 8 tertiary 
centers in the United States, Europe, and Australia addressed HRQL as part of the research 
question.482 They used three questionnaires. The Florida Shock Anxiety Scale (10 items, 5-
point Likert scale; higher score implies more anxiety) is a validated ICD shock-related 
anxiety questionnaire, especially relevant with regard to the fear of triggering a shock and the 
consequences of a device discharge, including cognitive, behavioral, emotional, and social 
impact.496–498 Patients who experienced appropriate ICD therapy (cardioversion n=64; ATP 
n=30) or inappropriate shock reported slightly higher levels, with borderline significance of 
anxiety than did patients who were free of ICD therapy (17.4 SD 6.7 vs 15.9 SD 6.2; p=0.05). 
There was no difference in the level of anxiety experienced when patients with appropriate 
ICD therapy (n=94) were compared with patients who experienced inappropriate shocks or 
major device complications. Hospital Anxiety and Depression Scale (HADS) is frequently 
used across diverse populations.491,499 There were no significant differences in HADS scores 
among the ICD patient subgroups. Patients with ICD therapy (either appropriate or 
inappropriate) had similar scores (5.2 SD 3.7 vs 5.5 SD 3.9; p=0.51). Only 20.6% of patients 
with appropriate shocks (13/63) had HADS scores with an abnormal psychological profile 
(≥8). The SF-12 version 2 showed similar scores among patients who had experienced either 
any ICD therapy compared to no ICD therapy (50.5 SD 10.2 vs 52.0 SD 8.4; p=0.52).500 
There were no comparisons with population norms.  
10.3.5 Septum reductive treatment and HRQL 
ASA and myectomy relieve symptoms, and smaller studies suggest they can improve HRQL. 
ASA is known to relieve symptoms in obstructive HCM and this seems to translate into better 
HRQL. In a study by Serber et al, 22 HCM patients were assessed before and at 3 months 
follow-up after ASA. They used 6 HRQL questionnaires, including the SF-12. The overall 
interpretation was that ASA reduces psychological distress and improves well-being. The 
short time period implies the risk of cognitive dissonance, a psychological theory that patients 
choosing to undergo a procedure will perceive their post-procedure health status favorably so 
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that it is congruent with all that they have experienced (i.e., disease severity and 
procedure).501 
Myectomy effectively reduces symptoms and may be the preferred choice over ASA, 
especially in younger and middle-age patients. A preference for myectomy has been 
advocated.245,502 Still, formal analyses of HRQL would be beneficial, in addition to the 
evidence of improvement of physiological parameters. 
In HCM, pacing can alleviate obstruction and improve outcomes.225 Studies have shown 
patient-reported improvement in both physical and mental SF-36 domains during the first 
year of pacing treatment.230,503,504 The long-term effects of pacing with regard to HRQL are 
less known, even though a study of 50 patients (mean age 62 SD 11 years) with a mean 
follow-up of 5.0 SD 2.9 years, indicates long-term benefits.234 
In our study, only 3% of the patients had their ICD implanted in the last year. Thus, these 
patient reports likely reflect a chronic state rather than temporary changes at the time of ICD 
implant. Because HCM patients have comparatively long life expectancy, this seem relevant. 
10.3.6 Hypertrophic cardiomyopathy-related comorbidities and HRQL 
10.3.6.1 Heart failure 
Heart failure is associated with worse HRQL in HCM. This is consistent with findings from 
other cardiomyopathies. 
Our HCM patients with ICDs and a history of heart failure scored lower in HRQL than those 
without heart failure. The score was lower in the following domains: Physical functioning 
(ES 0.68), Role physical (ES 0.48), General health (ES 0.33), Vitality (ES 0.30), Social 
functioning (ES 0.36), which resulted in a low PCS score (ES 0.63). Heart failure patients 
were older (mean 4.6 years), but the t-test p=0.053 value indicates that age has only a minor 
influence. Heart failure-related symptoms, mainly shortness of breath, are a key feature of 
HCM. Symptoms are due to LVOT obstruction, mitral regurgitation, diastolic dysfunction, 
AF, and comorbidities. The limited physical capacity, especially at exertion, is likely to affect 
younger patients and their lifestyle. Even though these causes can be attributed to poor 
HRQL, a history of heart failure (defined as EF<50%) is detrimental. This finding is 
consistent with patients who receive an ICD due to dilated or ischemic cardiomyopathy.505–507 
10.3.6.2 Atrial fibrillation 
AF is associated with worse HRQL in HCM. 
AF is common in HCM, and in our cohort 36% had a history of AF. This included 
paroxysmal, persistent, and permanent forms of AF. Patients with HCM often suffer from 
highly symptomatic AF. Heart failure can be caused by LV systolic dysfunction, but AF can 
cause a further decrease in EF due to rapid AV conduction and the lack of the atrial 
contribution to ventricular filling. AF may also reflect an underlying comorbidity. The 
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association of AF to stroke is well-known and HCM patients seem particularly vulnerable to 
embolization stroke, which warrants anticoagulation even without a single CHA2DS2-VASc 
risk factor.15 In HCM patients with ICD, AF is the most common cause of inappropriate 
shocks.211 In our study, patients with a history of AF were older (mean 7.4 years) than those 
without AF. In a subgroup comparison, the presence of AF affected mainly the physical 
domains: Physical functioning (ES 0.47), Role physical (ES 0.38), Bodily pain (ES 0.26), 
General health (ES 0.38), Social functioning (ES 0.42), and the PCS (ES 0.48). AF is main 
culprit in worsened HRQL, which is in line with findings from other patient groups.508 
Indeed, this is a challenge, because the burden of AF is common during the clinical course of 
HCM. Interestingly, patients with ICDs have continuous cardiac monitoring and device 
home-monitoring systems make early detection and intervention possible. For AF patients in 
general, there is ongoing debate about the cut-off for clinically relevant AF that warrants 
anticoagulation.509 The fact that HCM patients are prone to embolization may be taken into 
account in reaching anticoagulation decisions in individual cases. 
10.3.6.3 Appropriate therapy 
Appropriate therapy is not associated with more unfavorable HRQL in HCM, which is 
reassuring. 
Patients with at least one episode of appropriate ICD therapy reported significantly better 
mental health (p=0.033; ES 0.27) when compared to the subgroup who did not receive any 
appropriate therapy. All other domains showed no significant difference. The MCS was 
borderline significant (p=0.076; ES 0.27) driven by the domain Mental health. This is 
somewhat reassuring. An arrhythmic event which leads to appropriate ICD therapy can result 
in anxiety, may impose restrictions on the patient, such as driving, and can interfere with 
lifestyle. Despite these concerns, the negative ramifications of appropriate therapy may be 
outweighed by a psychological impact of feeling secure, and even a relief that the ICD 
system is reliable. In paper Ⅳ, using qualitative assessment, this was further elaborated. The 
impression is that patients with appropriate therapy are grateful to be alive and get a more 
pronounced feeling of the life-saving capability of the ICD.  
10.3.6.4 Inappropriate shock 
Mental health is worse among HCM patients with inappropriate shocks, which warrants 
careful attention. 
Inappropriate ICD shocks often come unexpectedly, may be multiple, and typically lead to 
emergency actions. If appropriate therapy is a confirmation of the benefit of the ICD system, 
the opposite is the case with inappropriate shocks. This distress is likely difficult for patients, 
but the small effect sizes indicate that they do eventually cope with it. Mental health was 
significantly lower (p=0.028; ES 0.42), and Vitality (p=0.080; ES 0.31) and Social 
functioning (p=0.058; ES 0.37) showed a tendency toward worse score. The MCS was 
borderline (p=0.060; ES 0.38). Our cohort had a similar rate of inappropriate shocks as other 
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studies, which suggests that these findings have external validity, i.e. can be generalized to 
other cohorts, even though none of these studies addressed HRQL.208,211 
10.3.6.5 Other subgroup analyses 
In our study HRQL scores were similar in both primary- and secondary-prevention ICD 
treatment. Other ICD cohorts without cardiomyopathy have HRQL scores similar to the 
normal population, which leads to our speculation that it is the disease of cardiomyopathy 
rather than the ICD device, which accounts for poor HRQL. Symptoms and risk perception 
seem to be major determinants of HRQL in HCM. 
HCM patients who received an ICD due to cardiac arrest or sustained VT had scores similar 
to those of primary-prevention patients (tendency toward better vitality in secondary 
prevention). In another study of general ICD patients, primary-prevention patients had lower 
scores in all domains except Bodily pain).510 The typical primary-prevention patients in 
cohorts of ischemic or nonischemic cardiomyopathy are based on EF<35-40%, and these 
patients are typically in NYHA II/III. The worse HRQL likely reflects underlying heart 
failure and comorbidities. Nevertheless, primary-prevention patients, including HCM 
patients, express low HRQL which should be addressed with a holistic view of disease 
management.  
It is interesting to compare patients with and without structural heart disease. A French study 
of Brugada patients with and without ICDs reported better physical performance than the 
norm population, Bodily pain and Social functioning were similar to the general population, 
but Role physical, General health, Vitality, Role emotional, and Mental health were all lower 
compared with the general population.511 The SF-36 scores were non-significantly different 
between Brugada syndrome patients with and without ICDs. 
A Dutch study of HCM mutation carriers (response rate 87%) confirmed that symptoms and 
risk perception are major determinants of HRQL (Table 25).512 In patients with the phenotype 
and symptoms, HRQL was worse than those who were genopositive-phenonegative. Patients 
with manifest HCM scored significantly worse than the general population in 4 of 8 domains 
and PCS. This supports the assumption that symptoms are the main determinant of poor 
HRQL in HCM. 
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Table 25. SF-36 score of Dutch patients compared to norm. Modified from Verkerk et al.512 
Domain HCM-
genotype 
Dutch population norm p-value 
Physical functioning 74.0 SD 25.1 83.2 SD 22.6 <0.05 
Role physical 69.1 SD 34.8 76.6 SD 36.1 NS 
Bodily pain 77.5 SD 25.8 75.0 SD 23.3 NS 
General health 58.5 SD 22.6 70.9 SD 20.6 <0.05 
Vitality 59.6 SD 21.5 68.6 SD 19.3 <0.05 
Social functioning 78.7 SD 25.4 84.2 SD 22.3 <0.05 
Role emotional 79.7 SD 34.8 82.5 SD 32.8 NS 
Mental health 76.4 SD 16.1 76.9 SD 17.4 NS 
Physical component score 47.0 SD 10.5 50.0 SD 10.0 <0.05 
Mental component score  48.9 SD 9.7 50.0 SD 10.0 NS 
NS, non-significant 
Patients who experienced complications requiring a surgical intervention had similar scores 
as those without such complications. This is reassuring, in that at least on a group level, 
patients cope well with complications in the long-term. Further analyses did not reveal 
significant differences in ICD patients with a risk factor of SCD in a first-degree family 
member. 
In a study of general ICD patients in the INTRINSIC RV trial, HRQL, using SF-36, revealed 
improvements from baseline until 1-year follow-up in all domains.513 That confirmed the 
previous findings from the ENHANCED-ICD trial, using EQ-5D, which showed that the 
level of distress and perceived health status were lowest at the time of implant and gradually 
became better at 2, 6, and 12 months follow-up.513 
Moreover, in a Swedish survey study (n=3,067, response rate 55%) of general ICD 
indications, it was concluded that ICD-related problems exert a larger impact on 
psychological distress than the experience of an actual shock. This underlines the importance 
of handling ICD-related concerns as an integrated part of follow-up. The concerns should be 
addressed in all ICD patients, not just in patients who received ICD shocks.514 
In our study, there was no difference with regard to sex except for PF, which showed a 
tendency to slightly lower values in women. In a large study of general ICD patients, a lower 
score on PF and VT were seen among females, while sex-related differences in the other 
domains were non-significant. It should be recognized that comorbidities, rather than sex, is 
the determinant of poor HRQL. Importantly, the decision to implant an ICD should be 
reached because of the individual risk profile and not sex. 
HCM patients with ICDs are a heterogeneous group with a complex pattern of comorbidities 
and risks of complications. In addition to specific pharmacological regimens surgical 
interventions, and device programming strategies, a holistic view is crucial, including 
targeted information and individualized socially relevant approaches in order to achieve 
patient satisfaction and possibly improve HRQL.515–519  
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10.3.7 Limitations 
At the time this paper was published, it was the largest study on generic HRQL in HCM 
patients with ICDs. SF-36 was used and the sample was compared with an age- and sex-
matched Swedish norm population. Patient data were validated using medical records. 
However, the assessment of the norm population was older, and it cannot be ruled out some 
aspects expressed in the SF-36 score might have changed over the years. It should be 
remembered that HRQL was assessed in a cross-sectional design and does not take the 
natural course of disease progression into account. The benefit of a generic instrument like 
SF-36 is its inherent lack of sensitivity to disease-specific concerns for the patients. 
Moreover, the use of SF-36 in a group is not the same as an individual assessment, especially 
in a condition with such high heterogeneity. Finally, associations of variables should be 
interpreted with caution, as causal relationships cannot be assumed. 
10.3.8 Summary 
Our study of HCM patients with ICD represents a nationwide cohort, without tertiary center 
bias, and a high proportion of responders. It demonstrated poor HRQL compared to the 
Swedish norm population, despite advanced treatment, including pharmacological and 
interventional options, and also treatment of diverse comorbidities. In all SF-36 domains, 
except Bodily pain, there were significantly lower scores than in the norm population. The 
physical components are even more severely affected. It seems that HCM, especially when 
heart failure or AF complicates its natural course, are the main determinants of HRQL. Both 
primary- and secondary-prevention patients score similarly. Complications requiring surgery 
do not affect HRQL. HRQL results are similar in men and women. A history of appropriate 
ICD therapy is not associated with poor outcome, but inappropriate shocks implies worse 
mental health. In order to improve HRQL in HCM patients with ICDs, several approaches are 
needed both regarding disease management and device optimization.  
10.4 PAPER Ⅳ 
10.4.1 Narrative and theoretical themes 
In our cohort, the following themes emerged: awareness, adaptation, acceptance, gratitude, 
and hope. The awareness of the disease and ICD varied among patients and their interaction 
with other people, including health care professionals. Both the HCM and the ICD required 
some adaptation by patients. They were grateful toward their cardiologist contacts and 
device, which gave them hope for the future. Despite restrictions and limitations to their lives, 
acceptance was generally high. 
From the narratives, the condensed meaning units could be categorized as themes. These 
themes could be used to label the codes from diverse areas of the narratives. On a more 
abstract, theoretical level, the meaning of content of these narrative themes could be 
summarized as red threads through the intertwined expressions from the texts. Even though 
individual aspects cannot be reduced without losing details and there were some extreme 
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views and anecdotes, five common themes emerged: awareness, adaptation, acceptance, 
gratitude, and hope. These main themes are depicted in Figure 19. It should be noted that 
these themes appear to be influenced by the respondent’s personal traits; their knowledge of 
their condition and therapeutic response; the degree of support they receive from family, 
friends and colleagues; and their perceived limitations based on their personal life situation 
and measured against their expectatations. 
Figure 19. Theoretical themes emerging from narratives of HCM patients with ICD. 
Reproduced from Magnusson et al, with permission.332 
 
The awareness of HCM seems to vary among patients. The nomenclature of HCM has 
historically been a hodgepodge and it is still confusing to the patients. Because of diffuse 
descriptions, many patients could not communicate effectively about the disease, and few of 
them searched for information about the disease. They were not prepared for visits with 
health care providers. Even though HCM is the most common cardiogenetic disease, there is 
no specific HCM patient organization in Sweden. Indeed, there are internet groups for ICD 
patients and these are considered helpful. Often patients were ambivalent about discussing 
their disease. Instead, they were often left alone with their thoughts. The genetic transmission 
of the disease was well-known to some of the patients, while others claimed they were never 
told about it. Indeed, there was missing genetic testing for some patients, but even in the case 
of genetic counselling, patients did not recall much. From a clinical perspective, there seems 
to be a demand for repeated, individualized information. Outside of cardiology care, patients 
often felt misunderstood and reported that they thought that many health care providers had 
limited knowledge of HCM and were unable to meet their needs.  
At the same time, patients who often felt misunderstood expressed gratitude for contact with 
their cardiologist. Often, they had long-term relationships with their cardiologist, based on 
trust and support. Because these patients have a long history of disease, they appreciated the 
continuous, long-lasting relationship with their cardiologist and associated professionals. 
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However, patients also said that clinicians would focus mainly on device function and 
medical evaluation, leaving only limited time for other concerns. Patients often lacked 
information about their prognosis and did not receive much guidance on lifestyle matters. The 
ICD was genuinely appreciated, and patients said they felt grateful to have been selected for 
this potentially life-saving treatment. Nevertheless, the pre-implant information these patients 
received was sometimes scanty. Remote monitoring was appreciated for its technical safety, 
but it could not replace information about the ICD in the form of a dialog with the physician. 
Beyond the information from health care professionals, patients were often left on their own 
to manage their emotional and existential issues. They turned to their closest relatives with 
these inner feelings, which could be complicated and confusing. It was reported that family 
members were often helpful when the symptomatic burden prevented patients from doing 
ordinary or household tasks. 
The burden of the disease also meant patients had to adapt, including dealing with 
restrictions. They reduced workload or changed employment. They had to limit social 
activities and contend with worse economic situations and status. Younger patients in 
particular sometimes felt isolated. On the other hand, fewer working hours meant more time 
for relationships with family members and friends. Over the years, patients adapted and 
accepted their situation. Their inner identity remained the same, and they navigated the path 
through their new life course. The symptomatic burden of the underlying HCM was the 
limiting factor over time, not the ICD. The device could lead to restrictions and younger 
patients often suffered frustration in certain situations, but it faded away over time.  
The ICD sometimes required some adaptation, but it actually gave them hope. They felt 
relief. They trusted the device as a life-saver. In fact, many patients thought bystanders were 
more concerned about arrhythmia episodes than they were, at least in secondary prevention. 
In primary prevention, patients were likewise grateful and highly motivated, especially if 
SCD ran in the family. Patients who received appropriate ICD therapy were particularly 
grateful, as expected. Surprisingly, even with a history of inappropriate shocks, patients were 
grateful. They admitted fear and concern during the immediate period after inappropriate 
shocks. Indeed, inappropriate therapy delivery was a scary and painful experience, but they 
were able to cope with the situation. Complications, even inappropriate shocks, were 
accepted as a side effect of the treatment. Here the pre-understanding based on our clinical 
experience had to be changed. From the perspective of the device physician, who is involved 
in the care and possible reprogramming or intervention immediately after an inappropriate 
shock, it was reassuring that patients are able to cope with the situation. Typically, soon after 
such an event, patients returned to their normal state and continued their ordinary life. This 
long-term perspective is valuable and must be recognized in contrast to the emergency 
situation when patients experience pain, fear, and anxiety. 
Overall, despite chronic disease, patients in our cohort reported satisfaction. Although 
adaptation and acceptance were needed to handle many obstacles in life, the overall 
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interpretation was that patients with HCM and ICDs had a strong spirit and a robust will to 
live. Their joy, appetite for life, and hope was a lodestar for their future expectations. 
10.4.2 Findings in relation to other studies 
HCM patients with ICDs likely represent more advanced disease manifestation than HCM 
patients without an ICD. The physical constraints seem to be the limiting factor and require 
adaptation of professional and leisure activities, which have been seen in other HCM studies. 
Recent studies confirm that, perceived from a patient perspective, there are important 
knowledge gaps among health care professionals. Educational efforts regarding both ICD 
and HCM are crucial and should include health care professionals, patients and their 
relatives, friends, and colleagues. Individualized information about ICDs before and during 
follow-up should be part of care. Knowledge of genetic aspects of HCM have often been 
identified as weak. 
HCM is a heterogeneous disease and ICD patients generally represent more severe 
manifestations of HCM. Our study is the only qualitative study to date that focuses on the 
subset of adult HCM patients with an ICD. There is one other qualitative study with 15 HCM 
patients (interview length 35-180 minutes), but the number of ICD patients in this population 
was not reported.520 They recruited from a patient organization by word of mouth using a 
convenience sampling method. This may create a bias compared to our selection of 
participants. Subasic described three themes that arose; “it is in the family,” “finding a new 
normal”, and “HCM and relationships.” HCM affected not only the individual patient, but 
also family members, and created worries at home. Indeed, we recognized this situation 
among our patients. There were concerns for disease transmission, especially for parents in 
relation to their children. Concerns were typically shared among family members, but were 
communicated much more selectively outside the family, for example to their employer. 
Again, our impression was the same, namely that patients, especially younger patients, 
carefully selected who they trusted when sharing information. In this regard, the alteration of 
identity and finding a new normal were necessary. Here our interpretation was somewhat 
different, possibly due to varying views on the concept of personal identity; among our 
patients, their notion of identity remained the same, even though they had to adjust their 
lifestyle. Patients in this other study also reported having to adapt to physical limitations, 
which were caused by the underlying HCM rather than the device. These adaptations 
sometimes required support and adjustments from others. As in our study, the misdiagnosis 
of HCM and its latency were commonly encountered. In the other study, patients with ICDs 
reported being concerned about inappropriate shocks, but gratitude outweighed this; we made 
this same striking finding in our study, too. In the US cohort, patients reported struggles with 
insurance companies to get rehabilitation after cardiac arrest. While this was different from 
national health care insurance in Sweden, Swedish patients with private insurances also had 
to argue with companies to get coverage. The different insurance system in the US created 
stress, while in our Swedish cohort this was less of a concern. However, in both studies, it 
appeared that career opportunities were hampered. Relationships were changed in the 
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families. Often it caused overprotection, and while some families became closer to each 
other, it could also cause tension, anger, and weakened relationships. There was often 
frustration of not being able to participate in sports or other activities. Our data adhered to 
their findings, but the general impression in our study was things became better over time due 
to coping strategies. During the younger years, patients seem to be more affected by not 
“being normal”, but later in life, they found a way to move forward, feel joy, and have hope 
despite their limitations.  
Subasic claimed that “the possibility of death and dying moved to the forefront, igniting 
added fear and concern.”520 This was not the case in our study. Their patients were afraid that 
physical activity would trigger ICD shock therapy, while our patients typically felt reassured 
and conducted physical tasks with more confidence, even though they were limited by the 
disease. Like our study, HCM patients had to accept modified plans when it came to travel, 
work life, and hobbies. In our study, patients with a family history of SCD described fear 
before they got the ICD, but a sense of calm afterwards. This contrasted somewhat to the 
Subasic conclusion that HCM stayed in the foreground. In our study, the ICD contributed to 
less anxiety and facilitated a reorientation of life, giving these patients new hope. 
The poor knowledge about HCM and inheritance pattern has been described previously by 
Fitzgerald-Butt et al.521 In the study by Subasic, only 47% of the patients were aware of the 
possibility of genetic testing for HCM. We also noticed poor understanding of disease 
transmission, but this may be complicated by the fact that genotype is not required for 
diagnosis and information from health care professionals is likely to be individualized.  
Burns et al qualitatively investigated attitudes and knowledge of genetic findings in HCM.522 
They found that results of testing varied and were sometimes poor. The reason for 
undergoing genetic testing was altruistic, and these patients often did not recognize the 
implications for the cascade screenings in their family. This pinpointed the importance of 
individualized communication about the need for and ramification of genetic counselling. 
A disease may change the life experience of a person, who has to make adaptations in 
lifestyle and future plans. Disease can alter body perception, identity, relationships, and life 
course. Indeed, everyday life situations, cultural patterns, social norms, and practical abilities 
may require change and adaptions.523 There is inherent uncertainty in genetic disease with 
regard to prognosis and how it will affect life.524 This is certainly true in patients at risk for 
SCD, which has been described in HCM and long QT syndrome.525 Smart conducted 
interviews on HCM genetic counselling and found that most patients welcomed more 
knowledge, which alleviated uncertainty, but there was also resistance to share information, 
which could have social, psychological and other lifestyle effects. In fact, the genetic test for 
HCM does not predict the course of the disease, and there remains uncertainty. Fortunately, 
these concerns seemed to fade away with time, and the disease was no longer the primary 
focus for the individuals and their relatives. For these reasons, Geelen et al advocated an 
individual approach to genetic counselling in HCM and the involvement of the families.526 
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In a survey study by Baskar et al of 538 HCM association members (54% males; mean age 
58 years; 59% response rate), the vast majority of patients perceived the ICD in a favorable 
way.518 In about 5% of respondents, there were concerns that questioned the value of ICD 
therapy, i.e. that patients perceived the drawbacks outweighed the benefits. Importantly, 
patients reported dissatisfaction with the explanation about their indication for ICD therapy 
and never had a thorough discussion about ICD with their physician. In another study based 
on focus groups, 33 of 41 patients (80%) did not recall any discussion of either 
periprocedural or long-term device complications.527 In a review of patient perspectives on 
ICD decision-making, investigators pinpointed the influence of a shared decision-making 
paradigm as a key for satisfaction.528 Baskar et al showed that lead dislodgement was 
associated with poor satisfaction, which suggests that more extensive pre-implant information 
is welcomed. This approach is endorsed by AHA.529 To improve this counselling, tools have 
been developed to aid the patient and facilitate this discussion with the clinical team.530 
The awareness of the ICD as a protection from SCD is widely recognized in general ICD 
patients.531–533 This leads to a sense of gratitude for the technology and health care 
professionals involved in its management. Patients feel secure and the ICD gives them hope 
for a longer life according to other qualitative studies.531–533 This powerful message was 
particularly strong in our cohort, and it may reflect that many HCM patients are younger and 
have a better life expectancy than other ICD groups. 
Physicians’ knowledge of ICDs in general has been tested in a large Swedish survey with 432 
respondents working in internal medicine, geriatrics, and in cardiology clinics.534 Because 
ICD patients are encountered throughout the health care system, this poor knowledge of ICD 
therapy is worrisome. Many patients reported situations in their own health care in which 
poor knowledge translated into worse care and a loss of trust.  
10.4.3 Limitations 
This qualitative study shares the inherent characteristics of an explorative approach. Still, 
despite maximal sampling variation and relatively large sample size, all combinations and 
shades of the lived experienced cannot be covered. Moreover, condensation implies reduction 
of information; interpretation is subjective. So, despite the action taken to structure data 
objectively and promote reflexivity and trustworthiness, our study could not encompass all 
experiences. A patient’s self-reported view may differ from the view of other persons; 
relatives, friends, employees may have markedly different perspectives than those reported by 
the patient. Even though the narrative design of our study allowed participants to reflect on 
their experiences, it is not the same as longitudinal follow-up with several interviews. This is 
not necessarily a limitation, but should be borne in mind. Our sample was recruited from two 
Swedish regions and all who were asked to participate consented, which avoided selection 
bias. Nevertheless, the external validity should be addressed with respect to other settings of 
geographical, cultural, and different health care systems. 
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10.4.4 Summary 
HCM patients with ICDs express health complaints due to their underlying cardiomyopathy, 
mainly physical limitations and functional deficits. HCM affects their professional life, 
leisure time activities, family dynamics, and sometimes restricts their activities or make them 
dependent on others. Nevertheless, they accepted their condition, adapted, and felt renewed 
hope. At a younger age, being different seemed to be more problematic and often had 
consequences for lifestyle, but over the years, patients coped with their situation. There was a 
reorientation with respect to professional and competitive activities toward supportive 
relatives. Patients showed a wide spectrum of knowledge of the disease and considered the 
knowledge and skills of health care providers to be quite varied, depending of the setting. The 
ICD was deemed as a life-saving device and, after implant, they gradually considered it as an 
integral part of their body. It facilitated a forward-looking attitude and created a hope for the 
future. Complications, including inappropriate shocks were generally well tolerated, but 
emotional response varied, although after a short time period, life returned to normal. 
Appropriate ICD therapy increased the awareness of SCD and reinforced the feeling of 
reliance on the device and thus gratitude. Improvement of health care should be based on a 
holistic view of the patient’s underlying HCM and not limited to just the technical aspects of 
the ICD. Health care providers need to anticipate the emotional concerns of the HCM patient 
in particular, but also consider the concerns of their relatives. The knowledge about HCM and 
ICD need to be improved both within and outside the cardiology community. Continued 
relationships with health care providers specialized in the field were appreciated by the 
patients and provided a solid basis of care, but several other specialties are likely to be 
engaged during the course of the disease. There needs to be an individualized approach as 
patients have different prerequisites and perspectives. The optimal communications model 
would encourage patients to share their inner thoughts and may improve their awareness of 
their limitations and possibilities, help them adapt to lifestyle changes, encourage an 
acceptance of their new situation, and promote hope for the future. 
10.5 PAPER Ⅴ 
In our PET study of HCM, patients with ICDs were selected because of the uniform 
assessment of arrhythmia outcome. All patients had the same timeframe during which the 
outcome could occur. The period of 12 months was deemed appropriate, because it was long 
enough to assess the outcome but not too long so that the underlying myocardial substrate 
would not change substantially. The ICD provides continuous monitoring of arrhythmias that 
can be retrieved by interrogation of the device electrograms. Studies with various follow-up 
periods and temporary ECG monitoring lack this standardized outcome evaluation. 
The selected sample likely represents typical ICD patients due to HCM in terms of age, sex, 
time since first ICD implant, and proportion of primary prevention. This subset of HCM 
patients likely constitutes more advanced disease than HCM patients without ICDs. 
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The PET exams, using triple tracers, were performed during the same day for all patients, 
starting in the morning and in the same sequence. First 15O-water at rest followed by 
adenosine stress, then 11C-acetate, and finally 11C-HED. This approach is beneficial because 
other physiological variables basically remain constant. All tracers were used under resting 
conditions and 15O-water was also used at stress induced by adenosine.  
The main findings are discussed in relation to the respective tracer in following discussion. 
The PET characteristics of our cohort are compared with those from other studies. One 
should bear in mind that most PET studies have a small sample size, differ in methodological 
approach, lack standardized reference values, and have composite outcomes. Moreover, the 
occurrence of an arrhythmia is end product of a intricate interaction of many factors. The 
PET technology we used was probably the most advanced to date and provided highly 
detailed quantitative information about the cardiac substrate and its propensity to act as an 
arrhythmogenic prerequisite vulnerable to one or more triggers, which remain unknown in 
the individual case. 
Despite the shortcomings of PET studies and constraints due to statistical power, PET 
technology provides an opportunity to explore pathophysiological features and elucidate 
potential pathways for ventricular arrhythmias. Indeed, PET technology has contributed to the 
understanding of HCM and translated knowledge from other diseases. HCM is known as a 
heterogeneous disease with various expression and prognosis. In our study, we explored 
HCM patients with ICDs using the established 15O-water at rest and stress to assess MBF, 
oxidative metabolism using 11C-acetate, and, for the first time in HCM, the 11C-HED that 
reflects sympathetic innervation. 
The potential value of our study has been recognized by Schindler et al, who recently stated, 
“Magnusson et al provide unique information of some association between a stress-related 
endocardium/epicardium flow gradient and the prevalence of NSVT in HCM that may 
suggest such flow gradient as potential novel risk biomarker.”163 
10.5.1 Global 15O-water at rest and stress 
In our cohort, the mean MBF at rest was 0.91 SD 0.23 ml/g/min and ranged from 0.47 to 1.70 
ml/g/min. At adenosine-induced stress the mean MBF was 1.59 SD 0.77 ml/g/min and varied 
from 0.64 to 3.50 ml/g/min between the patients. Thus, even though the sample represents 
HCM patients with advanced disease, it shows a considerable spread of MBF values and 
implies heterogeneity.  
Most previous studies on MBF, based on other groups than HCM, used 13N-ammonia and in 
a review (23 studies) of 363 healthy controls, the weighted mean was 0.71 ml/g/min at rest 
and 2.58 ml/g/min at stress.535 Notably, both rest and stress values differ due to 
methodological differences in protocol, tracer kinetic models, software usage, and adjustment 
for cardiac workload (rate-pressure product).535–541 There is an obvious need for 
standardization in order to facilitate comparison between studies.542 Typically, MBF values 
reported in women have been slightly higher.536,543,544 In a pioneering work of the tracer 15O-
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water from 1989, normal subjects had homogenous flow through the myocardium and the 
mean value was 0.90 SD 0.22 ml/g/min at rest and 3.55 SD 1.15 ml/g/min at stress induced 
by dipyramidole.545 In a validation work of 330 patients (not HCM) published 2014, using 
15O-water and invasive coronary angiography in conjunction with fractional flow reserve, the 
cutoff value of 2.3 ml/g/min at adenosine stress for hemodynamically significant coronary 
stenosis was advocated.546,547 It was deemed superior to CT-angiography and single-photon 
emission computed tomography in ischemic heart disease. This is in line with a previous 
study but offers somewhat higher values than in another study.548,549  
The PET technology has been applied in HCM.550 A few PET-studies of HCM, reporting 
MBF at rest and stress, have been conducted and are summarized in Table 26. As can be seen 
from these results, HCM patients have slightly lower MBF at rest but considerably lower 
values at stress compared to healthy controls. 
Table 26. Myocardial blood flow at rest and stress in HCM patients in PET studies.  
First author Year Tracer/stressor Sample size Rest MBF 
ml/g/min 
Stress MBF 
ml/g/min 
Choudhury156 
 
1999 15O-water 
Dipyramidole 
15 HCM 
No controls 
1.02 SD 0.28 1.39 SD 0.31 
Cecchi157  
 
2003 13N-ammonia 
Dipyramidole 
51 HCM 
12 Controls 
0.84 SD 0.31 
1.0   SD 0.23 
1.50 SD 0.69 
2.71 SD 0.94 
Knaapen159  2008 15O-water 
Adenosine 
18 HCM 
10 Controls 
0.92 SD 0.25 
1.30 SD 0.38 
2.26 SD 0.97 
2.93 SD 0.64 
Timmer158  2011 15O-water 
Adenosine 
15 Phenonegative 
11 Controls 
1.19 SD 0.34 
1.18 SD 0.32 
3.87 SD 0.75 
3.96 SD 0.86 
Timmer160  2011 15O-water 
Adenosine 
15 HCM pre-ASA 
15 HCM post-ASA 
0.94 SD 0.23 
0.98 SD 0.15 
2.25 SD 0.91 
2.94 SD 1.18 
Bravo161  
 
2011 13N-ammonia 
Dipyramidole 
33 HCM 
No controls 
1.04 SD 0.33 1.58 SD 0.49 
Sciagrà162 
 
2017 13N-ammonia 
Dipyramidole 
18 HCM, normal 
EF reserve 
16 HCM, abnormal 
EF reservea 
0.86 SD 0.20 
 
0.89 SD 0.18 
1.86 SD 0.41 
 
1.93 SD 0.56 
Magnusson355 
 
2019 15O-water 
Adenosine 
25 HCM 
No controls 
0.91 SD 0.23 1.59 SD 0.77 
a Abnormal EF reserve was defined as reduction of more than 5 percentage units at dipyramidole stress. 
10.5.2 Transmural global 15O-water at rest and stress 
The global TPG, defined as MBF endocardium/epicardium ratio with each part as a half of 
the wall thickness throughout the entire LV, was 1.14 at rest and 0.92 at stress. The positive 
ratio, i.e. >1, during rest implies a higher MBF of the endocardial than the epicardial layer. 
Analogously, a negative ratio, i.e. <1, is the consequence of lower MBF in the endocardial 
rather than the epicardial layer. Knaapen et al and Choudhury et al reported a similar mean 
TPG at stress as in our cohort.156,159 Sciagrà et al reported a higher TPG at stress but a 
subgroup in their cohort had a negative ratio as well; following dipyramidole, both groups 
(normal vs abnormal EF reserve) reached a similar level of subendocardial MBF, while the 
epicardial MBF remained significantly higher in the group with abnormal EF reserve.162 The 
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number of segments per patient with TPG <1 was 3 in those with normal EF reserve 
compared to 6 in the abnormal EF reserve group.162 
Subendocardial ischemia seems to reflect functional impairment in HCM patients during 
maximal coronary vasodilatation. Previous findings using single-photon emission computed 
tomography suggest involvement of the subendocardial layers, but the lower resolution and 
lack of detailed quantitative assessment needed confirmation by modern imaging 
techniques.551,552 CMR with perfusion assessment and LGE has confirmed this phenomenon 
in HCM.553,554 Finally, this was assessed using modern PET technology.159,555 
Knaapen et al compared 18 HCM patients with 10 age-matched controls using 15O-water at 
rest and stress using adenosine. As summarized in Table 26, MBF at stress was blunted in 
HCM compared to healthy controls. The endocardial-epicardial gradient was unchanged 
among controls (1.38 SD 0.15 vs 1.25 SD 0.19; p=not significant) at rest and stress, 
respectively. On the contrary, in HCM patients the gradient decreased significantly (1.20 SD 
0.11 vs 0.88 SD 0.18; p <0.01). This was seen in both the hypertrophied septum and the non-
hypertrophied lateral wall. Hyperemic MBF is more severely affected at the subendocardial 
level in HCM patients. The impairment correlated with increased LV loading conditions and 
LV mass. In this study, CMR was used for the assessment of LV mass and heart 
catheterization for invasive measurement of LVOT gradients. From these findings, it can be 
suggested that extravascular forces, in addition to reduced capillary density, explain 
microvascular dysfunction.159 We used the same measurement of endocardial-epicardial 
gradient by diving ROIs with a central line and reported very similar ratios. 
10.5.2.1 Mechanisms of transmural perfusion gradients 
Consistent with Laplace's law, wall stress decreases from the subendocardial to the 
subepicardial layer, which is why an opposite transmural gradient can be observed.159 
Interestingly, MBF at stress in the epicardial layer did not differ between the control group 
and HCM patients. The absence of impairment in the epicardial layers, which are at least 
influenced by wall tension, strongly suggests that extravascular compressive forces contribute 
as a factor in the elevated vascular resistance of the subendocardial layers in HCM patients. 
10.5.2.2 Pharmacological interaction of microvascular function 
Beta-blockers or calcium-channel blockers act on diastolic functions and do not relieve 
microvascular dysfunction.156,556 These drugs were not discontinued for ethical reasons and 
because we wanted to have clinical representative situation. 
10.5.3 Microvascular dysfunction and outcome 
As early as the 1990s, Dilsizian et al showed an association between myocardial ischemia 
and the composite of cardiac arrest, syncope, and NSVT on Holter monitoring in a 
retrospective analysis of 23 HCM patients aged 6-23 years, using thallium scintigraphy.557 
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A decade later, Cecchi et al published a landmark trial of 51 HCM patients (NYHA I or II at 
baseline) who underwent PET with 13N-ammonium at rest and dipyridamole-induced 
stress.157 The composite outcome (cardiovascular death [n=9], progression to NYHA III/IV 
[n=6], sustained VT/VF requiring ICD [n=3]) was reached by 16 patients during a mean 
follow-up of 8.1 SD 2.1 years. MBF at stress was categorized into three groups: low (n=18; 
0.59-1.11 ml/g/min), middle (n=16; 1.13-1.57 ml/g/min), and high (n=17; 1.62-3.77 
ml/g/min). Patients in the lowest group had an HR of 20.1 (p=0.003) after multivariate 
analysis, compared to the other groups combined. Notably, all 4 patients who died from 
progressive heart failure were in the low-flow group and 3/5 of those with SCD were in the 
low-flow group. Another striking fact is that no single event happened the first two years, and 
the mean time to first event was ≥5 years. This underlines the fact that PET markers are 
sensitive and early signs of adverse outcome.  
Another decade later, Castagnoli et al reassessed the association of microvascular dysfunction 
in HCM.558 Dipyramidole was used to induce stress MBF in 100 HCM patients (follow-up 
4.0 SD 2.2 years), who were then categorized into three groups: low (0.73-1.53 ml/g/min), 
middle (1.54-2.13 ml/g/min), and high (2.14-5.89 ml/g/min). In a similar analysis, the RR 
was 7.1 for the low-flow group compared to the other groups. The authors, partly the same as 
in the previous paper, concluded that previous cutoffs were extreme and 1.53 ml/g/min was a 
better threshold. This was also seen by Lu et al. Interestingly, MBF stress in the lateral wall 
(but not the septal wall) predicted adverse outcome.322 This may be interpreted that when the 
disease is in the lateral wall, it represents a more widespread, severe disease state. In our 
study of TPG at stress, septal and inferior segments were associated with positive NSVT 
outcome, while the lateral wall showed a p-value of 0.101. 
Olivotto et al showed that 42 genopositive HCM patients had significantly lower MBF at 
stress (dipyramidole) than genonegative patients (1.7 SD 0.6 ml/g/min vs 2.4 SD 1.2 
ml/g/min; p=0.02) despite similar clinical profiles. Patients with sarcomere myofilament 
mutations display more severe impairment of microvascular function compared with 
genotype-negative individuals, which suggests a link between mutations and adverse 
remodeling.586 
10.5.3.1 Global 15O-water at rest/stress and outcome 
The main finding of the PET-study involves TPG at stress and its association with NSVT. 
The fact that a borderline significance of TPG (p=0.059) turned into significance (p=0.022) 
during MBF at stress is striking and is explained by a more pronounced microvascular 
dysfunction in the endocardial layers in HCM. The association of a pure arrhythmia outcome 
measurement, even though a surrogate for life-threatening VT/VF, may emerge in further 
studies.  
10.5.3.2 Regional 15O-water at rest/stress and outcome 
The segments for the heart, grouped as regions, showed that septal and inferior parts were 
most strongly associated with outcome with regard to TPG at stress while the inferior and 
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lateral regions were significantly associated with MBF at rest. The mechanistic explanation 
for this is unclear but lateral involvement likely represents patients with more advanced 
disease. The fact that 8 patients had undergone myectomy may affect results, but this group 
did not have a significantly different risk of outcome. The sample was too small to build a 
multivariable model where several factors could be taken into account. 
In HCM, MBF at rest is typically within normal mean values for the entire LV, even though 
regional values may be lower, especially in hypertrophied segments.550 At induced 
vasodilation, MBF at stress is often reduced.152 In HCM, the arterioles of the coronary vessel, 
rather than epicardial coronary vessel, are the level of disease, which is supported by 
histological findings.152,154,157 This microvascular dysfunction explains the reduced MBF at 
stress both globally in the LV but also in segments without hypertrophy.152 
10.5.3.3 Defect size and outcome 
The concept of defect size has been used in other quantitative assessments using PET in 
ischemic cardiomyopathy.325,559 The heterogenic scar zone may contain vital myocytes and 
fibrosis adjacent to each other. In fact, CMR has shown scar-related features in ischemic 
cardiomyopathy associated with SCD.560–562 The size of the scar seems to be correlated to the 
risk of ventricular arrhythmias.560–563 The defect size increased markedly between rest and 
stress. However, in our sample, neither defect size at rest nor stress was associated with 
outcome. 
10.5.3.4 Heterogeneity index and outcome 
Regional ischemia can lead to action potential shortening of the myocyte, dispersion of 
ventricular repolarization, and subsequent conduction from the substrate to reentry circuits. It 
could be speculated that marked disparities in the regional perfusion might promote 
ventricular arrhythmias.564 This pathophysiological pathway provided a rationale for the 
heterogeneity index used by Lu et al in 133 HCM patients (23 with ICD).322 The 
heterogeneity index was defined as dividing the highest regional MBF by the lowest regional 
MBF value at rest and stress in every individual patient. A high heterogeneity index using the 
cutoff ≥1.85 derived from the receiver operating characteristic curve (area under curve 0.64) 
implied a sensitivity of 35% and specificity of 94%. The outcome in that study was the 
composite of ventricular arrhythmia (appropriate ICD therapy, NSVT at Holter monitoring or 
ICD interrogation) during a mean follow-up of 3.3 SD 1.6 years. This outcome was reached 
by 53% of those with a high heterogeneity index and 13% of those with a low index. Based 
on this predictive potential, we did the same calculation using our outcome with uniform 
assessment. Neither MBF at rest nor MBF at stress in our sample were associated with 
outcome. The two studies differ in methodological approach and patients in our sample likely 
represent HCM patients with more advanced disease. 
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10.5.3.5 Arrhythmia substrate mechanisms  
In an autopsy study by Tanaka et al, the external diamater of the intramyocardial small 
arteries were similar in HCM specimens than in normal hearts, whereas the lumen was 
significantly reduced in HCM specimens.153 In another necropsy study, the wall thickening 
was due to proliferation of medial and/or intimal components, especially smooth muscle and 
collagen.154 
The arrhythmogenic substrate for ventricular arrhythmias is highly complex with both fixed 
and dynamic properties. Sarcomeric dysfunction may lead to hypertrophy, disarray, fibrosis, 
altered ion channel expression, and abnormal gap junctions. Altogether this may slow down 
conduction velocity heterogeneously, and it creates pathways for reentry mechanisms and 
promotes triggered activity that can cause arrhythmias.83 The architectural and 
electrophysiological remodeling is affected by reduced arteriolar density and the structural 
wall of vessels, at the arteriolar level.565 The microvascular dysfunction becomes more 
apparent at vasodilator stress. During stress, the reduction of oxygen delivery leads to 
adenosine triphosphate depletion, activation of adenosine triphosphate sensitive K+ channels, 
action potential shortening, and makes these vulnerable as reentry circuits.564 
10.5.3.6 Treatment principles to reduce gradients 
Microvascular dysfunction in HCM, which causes decreased MBF at stress, is expressed in 
both hypertrophied and non-hypertrophied segments.553,566 Thus, this pathophysiological 
phenomenon is widespread over the entire left ventricle. Histological findings of intramural 
vessel remodeling throughout the myocardium provide a basis of explanation.154 Hypertrophy 
in itself seems to play a role, as myocardial hypertrophy due to hypertension or aortic stenosis 
also shows decreased MBF at stress, presumably due to lower capillary density.567,568 
Moreover, the microvascular resistance may be elevated due to compression exerted by the 
increased pressure within the cavity due to LVOT obstruction.159,569 
It has been demonstrated that reduced MBF at stress may appear in segments without delayed 
contrast enhancement using CMR. This has been interpreted as microvascular dysfunction, 
which precedes ischemic injury and chronic tissue responses.570 Indeed, replacement and 
interstitial fibrosis are characteristic features of end-stage HCM.154 Myocardial fibrosis is thus 
believed to play a role in the deterioration of systolic function, likely by interfering with 
myocardial shortening.571,571–573 Altogether this may imply that in HCM with severely 
decreased perfusion there is an increased risk of systolic heart failure and life-threatening 
arrhythmias.553 
This provides a rationale for beta-blocker therapy.574 For the same reasons, septum reductive 
procedures, ASA, or surgical myectomy seem to be effective and grounded in this treatment 
principle.566 From this perspective, calcium-channel antagonists are not equally beneficial 
regarding MBF.156 
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In patients with LVOT obstruction and impaired diastolic relaxation, this microvasculature 
dysfunction may be more pronounced.159 Based on Laplace's law, the wall tension increases 
from subepicardial to subendocardial layer, which leads to an inverse TPG.159 This may be 
more pronounced if the LV loading conditions are elevated.  
In 15 patients with HCM who underwent ASA, MBF at rest was unchanged (0.94 SD 0.23 
ml/g/min vs 0.98 SD 0.15 ml/g/min; p=0.45) but coronary vascular reserve increased (2.55 
SD 1.23 ml/g/min vs 3.05 SD 1.24 ml/g/min; p=0.05).160,575,576 Before ASA, the 
endocardium/epicardium MBF ratio was lower during stress than at rest (0.80 SD 0.18 vs 
1.18 SD 0.15; p<0.001). After ASA, MBF at stress increased to 1.03 SD 0.26; p=0.02. The 
MEE using acetate increased from 15 SD 6 to 20 SD 9%; p=0.04. Thus, ASA alleviates the 
LVOT gradient which, in turn, affects loading conditions and, in so doing, improves 
microvascular function and myocardial energetics. 
10.5.4 11C-acetate 
The myocardium relies on the oxidation of metabolic substrates in the Krebs cycle. 
Therefore, the early clearance rate of 11C-acetate correlates with myocardial oxygen 
consumption (MVO2) under various conditions.
159,308,577 In HCM, MVO2 per gram of 
myocardial tissue was found to be within normal range in two studies or slightly reduced. In 
hypertrophic segments where the MVO2 per gram seems to be reduced compared to non-
hypertrophic segments, i.e. the lateral wall; this differs from the results obtained from healthy 
controls.575,578–580 In hypertrophied segments, hypokinesia, decreased systolic wall 
thickening, increased diffusion distance, and lower capillary density may reduce oxygen 
uptake.154,566,572,581 
Myocardial energy efficiency, expressed as myocardial external efficiency (MEE), is based 
on the proportion of energy produced by the LV in relation to the energy consumed, both 
expressed in Joules. Thus, the MEE is the ratio of conversion of MVO2 into actual cardiac 
work.  
The study by Ishiwata et al from 1997 claimed lower oxygen consumption in hypertrophic 
and non-hypertrophic segments, but this was not adjusted for per gram tissue and the spatial 
resolution was poor (about 7.5 mm).575 Tadamura et al found lower K mono values in HCM 
compared to controls, but these studies share methodological shortcomings with the 
previously mentioned study.580 In HCM, MVO2 is relatively robust and is similar to control 
values, at least at rest. In contrast, MEE is substantially affected. Some studies using 11C-
acetate are summarized in Table 27. 
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Table 27. Oxidative metabolism in HCM and miscellaneous diseases in PET studies. 
First author Year Tracer/ 
stressor 
Sample size MVO2 
ml/g/min 
MEE 
% 
Timmer578 
 
2010 11C-acetate 
 
20 HCM 
11 Control 
0.13 SD 0.05 
0.12 SD 0.04 
21 SD 10 
35 SD 8 
Timmer160  2011 11C-acetate 7 HCM pre-ASA 
7 HCM post-ASA 
0.12 SD 0.03 
0.13 SD 0.03 
15 SD 6 
20 SD 9 
Timmer158  2011 11C-acetate 15 HCM genotype (no 
phenotype) 
11 Controls 
0.14 SD 0.06 
 
0.13 SD 0.04 
27 SD 10 
 
36 SD 8 
Harms323  
 
2018 11C-acetate 
 
33 Aortic stenosis 
20 Mitral regurgitation 
10 Control 
0.12 SD 0.04 
0.11 SD 0.03 
0.10 SD 0.02 
17 SD 4 
18 SD 5 
24 SD 4 
Clemmensen582 
  
2018 11C-acetate 
 
25 Amyloidosis 
15 Control 
0.09 SD 0.02 
0.10 SD 0.02 
13 SD 5 
24 SD 5 
Magnusson355 
 
2019 11C-acetate 
 
25 HCM 
No control 
0.088 SD 0.025 18.5 SD 8 
 
Our results are comparable with the Dutch studies of HCM with a phenotype. Notably, even 
in carriers without phenotype, MEE is decreased, and this variable seems to be a sensitive 
marker of early signs of disease.  
The LV mass correlated with reduced MEE in HCM in the study by Timmer et al.578 In a 
study by Crilley et al, using magnetic resonance spectroscopy, a lower (around 30%) 
PCr/adenosine triphosphate ratio was shown in patients with HCM-associated mutations 
(n=31) than controls (n=24).583 Notably, these parameters of deteriorated energy metabolism 
were similar, irrespective of degree of hypertrophy and including those without hypertrophy. 
This adds to the evidence that cardiac energy handling is impaired in the disease expression. 
The resting energy abnormalities are a primary sign, rather than secondary to hypertrophy. 
Functional studies of HCM with sarcomeric mutations have shown inefficient adenosine 
triphosphate utilization, which increases the cost of contractility.584–586 
Microvascular dysfunction is also likely to play a role in reduced MEE. Carriers of the 
MYBPC3 mutation exhibit reduced MEE in the absence of perfusion defects.158 The 
hypertrophy, fibrosis, disarray, and microvascular dysfunction limit oxygen delivery in a 
viscous circle. 
There is a pathophysiological pathway in myocardial fatty acid metabolism and LV 
hypertrophy. Early observations in children with genetic defects were later confirmed 
regarding abnormalities in regulatory subunits of adenosine monophosphate-activate protein 
kinase, a key part of the beta-oxidation cascade known to cause HCM.587,588 This is supported 
by animal models of hypertrophy.589 In patients with hypertension alone, MVO2 per gram is 
elevated, but when hypertrophy develops, there is a normalization in MVO2 per gram of 
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tissue. However, this adaptation comes at the expense of reduced myocardial efficiency, 
which possibly makes the heart prone to systolic heart failure.590 
In the paper by Timmer et al 15 carriers of the MYBPC3 mutation without phenotype 
underwent 15O-water and 11C-acetate evaluations and were compared to 11 healthy controls. 
LV mass was similar (93 SD 25 gram vs 99 SD 21 gram; p=0.85). Mean MBF at rest was 
also similar, and at stress, MVO2 was similar but MEE was significantly lower (27 SD 10% 
vs 36 SD 8% in controls p=0.02). Thus, MEE seems to be an early component of HCM 
pathology before hypertrophy occurs.158 Increased energy expenditure, i.e. mechanical work 
inefficiency, is a characteristic feature of HCM. This is clearly displayed already as an early 
feature in the clinical course.575,578,579,591 
10.5.4.1 The benefit of myectomy and ASA 
Septum reductive procedures, myectomy, or ASA can alleviate symptoms. In a small study of 
7 patients who underwent ASA, the procedure did not affect mean MVO2, but after 6 months 
the amount work per gram of tissue increased the MEE significantly from 15 to 20%.160 This 
confirms early findings, using invasive catheters, that showed improvement of coronary flow 
and metabolism (lactate) after myectomy.590  
10.5.5 11C-HED 
Abnormalities in the autonomic nervous system have been associated with VT/VF.592,593 Our 
study is the first study of sympathetic innervation using the tracer 11C-HED in HCM. The 
mean RI was 0.11 /min in our cohort. Because there are no standardized reference values, our 
results can be compared to the largest study using 11C-HED, the PAREPET study.594 In the 
PAREPET study, 204 patients eligible for a primary-prevention ICD due to ischemic 
cardiomyopathy with EF≤35% were enrolled. The RI defined as the segment with maximal 
uptake was 0.136 SD 0.037 in PAREPET compared to 0.11 SD 0.042 in our study. The 
outcome in the PAREPET study was SCD or appropriate ICD therapy due to VT/VF at a rate 
of 240 BPM or more over a mean period of 4.1 years. The amount of denervated left 
ventricle, i.e. the defect size in the group (n=33) that reached the outcome, was significantly 
higher (33 SD 10% vs 26 SD 11%; p=0.001). In comparison, the overall mean defect size in 
our sample was 15 SD 10%. Thus, our sample comprised a cohort with a smaller sample size 
and defect size was similar in those with and without NSVT (p=1.00). 
The PAREPET study has a more SCD-specific outcome, although it is measured very 
conservatively, in contrast to other studies of innervation that use composite endpoints. In 
another study (n=116) also eligible for ICDs, those with a high 123I-mIBG myocardial 
imaging-derived defect score significantly more frequently met the composite endpoint death 
and appropriate ICD therapy.595 
In a study by Pietilä et al, 46 patients with ischemic or nonischemic cardiomyopathy, NYHA 
II/III (mean EF 35 SD 8%) were followed for a mean of 55 SD 19 months.312 Using the 
median retention of 0.184 SD 0.061, significantly more patients reached the endpoint (death 
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due to SCD or heart failure) in the group below the cut-off (3 vs 8; p<0.02). Notably, 9 of 11 
deaths were considered as sudden. 
Autonomic nervous system dysfunction has been elucidated in ischemic cardiomyopathy and 
dilated cardiomyopathy. The absolute retention was approximately reduced by 40% 
compared to healthy controls.316,317,538 
In ADMIRE-HF, 961 patients in NYHA II/III with EF≤35% either due to ischemic 
cardiomyopathy or nonischemic cardiomyopathy with a mean follow-up of 17 months were 
studied using 123I-mIBG myocardial imaging. Measurements of denervation were strongly 
associated with the composite outcome of cardiac death, NYHA class progression, and 
sustained VT/appropriate ICD therapy.596  
Other smaller studies have shown an association between 123I-mIBG myocardial imaging 
parameters and VT/VF.592,596–598 Moreover, the defect size may indicate the risk of VT/VF.623 
We explored this in our sample, but defect size, heterogeneity index, and transmural gradients 
were non-significantly associated with NSVT as outcome.  
Furthermore, clearance rate in the model can be used as a surrogate of denervation. Here, an 
interesting finding, with borderline significance for the NSVT group was noticed. Based on 
the idea of the relevance of transmural gradients in HCM, the clearance rate of the 
endocardium/epicardium was analyzed. Again, it was borderline significant. The transmural 
gradient, with a higher degree denervation of the endocardium compared to the epicardium, 
turned out to be a sensitive marker of NSVT with a borderline significance. Using the 
concept of mismatch, defect size difference derived from RI and MBF at rest/stress was 
calculated but did not show a significant association with NSVT.599 
10.5.6 Limitation 
This first triple-tracer PET study of HCM patients with ICDs with a uniform assessment of 
the outcome of NSVT was a novel approach to characterization and risk marker evaluation. 
However, there are several limitations. First, although NSVT is an established risk factor in 
HCM, it is a surrogate of SCD. Secondly, an episode of arrhythmia is the endpoint of a 
complex interplay of cardiac substrate and potential triggers that are unknown in the 
individual case. Thirdly, PET studies often have small sample size and analyses are prone to 
both type I and type II errors in statistical hypothesis testing. It should be highlighted that this 
study has an explorative design and confirmatory studies are needed before risk stratification 
can be improved. Nevertheless, novel approaches are needed to refine risk stratification in 
HCM, which remains a challenge. 
10.5.7 Summary 
In this study, HCM patients with ICD underwent PET with three tracers (15O-water, 11C-
acetate, and 11C-HED) for evaluation of MBF, oxidative metabolism, and sympathetic 
innervation. MBF at rest was 0.91 ml/g/min at rest (slightly decreased) and decreased at 
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adenosine stress 1.59 ml/g/min which is reduced compared to normal hearts. The mean TPG 
(endocardium/epicardium ratio) was 1.14 SD 0.09 at rest and inversed at stress, 0.92 SD 0.16. 
The main finding was that patients with NSVT had significantly lower gradients at stress 
(p=0.022) and borderline at rest (p=0.059). Global MBF at rest and stress were not 
significantly different with regard to NSVT. Mean MVO2 was 0.088 ml/g/min and the MEE 
was hampered, 18.5%. Sympathetic denervation was present, RI 0.11 /min; a higher volume 
of distribution (p=0.089), transmural gradient of clearance rate (p=0.061) and lower clearance 
rate (p=0.052) showed tendency of association with the outcome NSVT. Based on 
pathophysiologically plausible mechanisms of the TPG at stress and arrhythmia in this 
explorative study, a potentially novel risk marker of SCD in HCM has been elucidated. 
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11 FUTURE PERSPECTIVES 
HCM continues to fascinate clinicians and researchers. The heterogeneity and unpredictable 
nature of the disease expression requires careful evaluation over the life course. Despite 
efforts in risk stratification, there will always be limited sensitivity and specificity with regard 
to SCD prediction. In addition to current guidelines on risk assessment, further incorporation 
of additional risk markers will hopefully improve outcomes. Such novel risk markers should 
ideally be simple, easily available, and have incremental value if applied in routine care. 
Nevertheless, more sophisticated imaging tools may be useful in HCM research and should 
be welcomed, even if they are not part of clinical routine in the near future. While PET is 
currently costly, requires considerable resources, and is not yet widely available, it provides a 
valuable insights into pathophysiological mechanisms and explores the potential predictors of 
clinically relevant outcome measurements.23,24 PET accurately quantifies pathophysiological 
parameters and the high sensitivity is beneficial, because most HCM patients have slow 
disease progression, which would be valuable in evaluation of therapies. However, the lack of 
standardization of methodology in PET, including reference values, needs to be addressed 
and global collaborations are warranted.  
Larger studies based on our initial findings of risk markers would provide necessary 
information. MBF at stress, especially TPF using 15O-water but also findings from 11C-HED, 
are promising candidates for further studies. Ideally, such studies should be prospective, have 
long-term follow-up, be powered for detection of different outcomes, such as SCD (or a 
surrogate) and disease progression, including systolic heart failure. Moreover, PET could 
provide accurate and sensitive outcome assessment in intervention studies, such as septum 
reductive procedures (ASA or myectomy) or pharmacological trials. Patients without ICDs 
would likewise be interesting and relevant to study. It can be suggested that patients with 
estimated intermediate risk of SCD should be a prioritized targeted subgroup.  
Studies should be designed so that confounding can be addressed by a randomized controlled 
trial or, more realistically, observational trials with robust assessment of predictors and 
outcomes and the possibility to adjust for multiple interactions among variables. The 
unpredictable nature of arrhythmia and definite assessment of outcome need to be addressed. 
It is important to distinguish outcome measurements, as they may have different predictors. 
SCD and heart failure are often combined rather than separated, even though there are clear 
differences in their respective clinical management. In order to overcome the unknown 
burden of arrhythmia without an ICD, the insertable cardiac monitor could be an alternative. 
Indeed, it is crucial to improve sensitivity and specificity in SCD risk assessment, albeit 
difficult. Imaging tools, including PET have the potential to refine the risk stratification in 
HCM. Further standardized prospective multicenter studies are warranted to explore and 
confirm additional tools for risk assessment with clearly defined outcome measurements. 
As overall management of HCM continue to improve, it is important to revise guidelines and 
risk stratification algorithms. Because many patients have a low annual event rate of life-
threatening arrhythmias, large studies are needed to accurately predict outcomes and validate 
  143 
stratification systems, especially in specific subgroups and diverse settings. Therefore, joint 
collaborations across borders are welcome. In this connection, it is important to include 
unselected patients throughout the cardiology community outside centers of excellence. A 
close cooperation between clinicians with diverse expertise will hopefully be spurred by 
digitalization of health care. Furthermore, educational efforts among health care 
professionals, patients, and relatives will be crucial to improve the quality of care and 
implement guidelines. Future perspectives may include machine learning to identify risk 
factors and assist physicians in decision-making, which already has shown promising 
yield.600 The diagnostic challenges in HCM remain problematic and need to be addressed in 
future endeavors involving health care digitalization and networking among experts and 
general health care providers. 
ICD technology has improved and the use of S-ICD systems in HCM can be expected to 
increase. Because HCM patients are often younger, have long life expectancy, and are prone 
to lead-related complications, S-ICD technology should be embraced. The possibility to 
combine S-ICD with leadless pacing may further enhance its role and make it a more desired 
device choice for HCM patients. 
Noninvasive ECG technologies, including smart devices such as watches, may offer a new 
avenue for evaluation of HCM patients. These smart devices may help screen for atrial 
fibrillation and other arrhythmias and monitor activity levels. 
The genetic basis for understanding the molecular mechanisms in disease has opened a new 
era. Notwithstanding, this knowledge needs to be further elucidated and translated into 
clinically relevant tools. Genetically based interventions have the potential to prevent disease 
progression or even obliterate the disease entirely. Recently, CRISPR-Cas9 based gene 
editing was applied in a human embryo to correct a gene mutation.601 
Indeed, technological advances are needed to revolutionize treatments. At the same time, a 
holistic approach incorporated into the clinical management is warranted to understand the 
patients’ perspectives and allocate resources for optimal care. A bright future for HCM 
patients depends on the implementation of current knowledge, appropriate resources, and 
innovation based on fruitful research collaborations.  
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12 CONCLUSIONS 
The following conclusions of this thesis are based on Paper Ⅰ-Ⅴ. 
● Patients to receive ICDs due to hypertrophic cardiomyopathy were based on known risk 
factors for sudden cardiac death at the time. 
● ICDs effectively terminate potentially life-threatening ventricular arrhythmias in 
hypertrophic cardiomyopathy. 
● The cumulative incidence of first appropriate ICD therapy in hypertrophic cardiomyopathy 
at 1 year, 3 years, and 5 years were 8%, 15%, and 21%, respectively. 
● Left ventricular ejection fraction less than 50% and atrial fibrillation are strong predictors 
of appropriate ICD therapy. 
● In hypertrophic cardiomyopathy patients with ICDs, the main cause of death is 
deterioration of systolic function leading to end-stage heart failure. 
● The standardized mortality ratio is 3.4 in hypertrophic cardiomyopathy patients with ICD 
compared to the Swedish general population. 
● Generic health-related quality of life, both mental and physical components, is lower in 
hypertrophic cardiomyopathy patients with ICDs than in Swedish population norms. 
● Systolic heart failure and atrial fibrillation are determinants of low health-related quality of 
life, especially physical functioning. 
● From a qualitative point of view, hypertrophic cardiomyopathy patients with ICDs perceive 
poor health due to limiting dyspnea.  
● ICD patients with hypertrophic cardiomyopathy feel grateful for the device, even after 
experiencing inappropriate shocks, because it gives them hope during their life course despite 
necessary restrictions and adaptation.  
● The knowledge about the disease hypertrophic cardiomyopathy and device therapy varies 
substantially among patients and the support from the health care providers is generally 
constrained to technical issues rather than an attempt at a holistic approach. 
● Patients with hypertrophic cardiomyopathy and ICDs show decreased myocardial blood 
flow at stress, altered oxidative metabolism, and sympathetic denervation using the tracers 
15O-water, 11C-acetate, and 11C-HED during exams with positron emission tomography. 
● The endocardium/epicardium myocardial blood flow gradient at stress is lower in 
hypertrophic cardiomyopathy patients with nonsustained ventricular tachycardia. 
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13 ABSTRACT IN SWEDISH (SAMMANFATTNING) 
Bakgrund. Hypertrofisk kardiomyopati (HCM) är ett heterogent tillstånd med olika 
sjukdomsuttryck inklusive plötslig hjärtdöd, vilket dock kan förebyggas med en implanterbar 
kardiell defibrillator (ICD). Syfte. Det övergripande syftet med avhandlingen var att belysa 
olika aspekter av ICD-behandling hos patienter med HCM. Detta innefattar ICD-användning 
vid HCM med tonvikt på riskvärdering avseende ventrikulära arytmier, mortalitet och 
dödsorsaker, mätning av hälsorelaterad livskvalitet, kvalitativa aspekter av hur det är att leva 
med en ICD, karakterisering med positronemissionstomografi (PET) och undersökning av 
riskmarkörer för plötslig död. Metod. Det svenska pacemaker och ICD registret användes för 
att identifiera tänkbara patienter. Socialstyrelsens patientregister, dödsorsaksregistret, 
Statistiska centralbyrån och journaler användes. SF-36 användes för att kvantifiera 
hälsorelaterad livskvalitet. Intervjuer analyserades kvalitativt med hermeneutik och 
innehållsanalys. PET och ekokardiografi genomfördes. Resultat och Slutsatser. I delarbete 
I, baserat på den nationella kohorten av oselekterade patienter med hypertrofisk 
kardiomyopati, konstaterades att riskvärdering avseende ICD skedde utifrån, vid tidpunkten, 
etablerade riskfaktorer avseende plötslig död. ICD bryter effektivt potentiellt livshotande 
ventrikeltakykardi hos patienter med HCM. Den kumulativa incidensen av första adekvata 
ICD-behandlingen vid 1, 3 och 5 år var 8 %, 15 % respektive 21 %. Ejektionsfraktion under 
50 % och förmaksflimmer utgör starka prediktorer för adekvat ICD-behandling. I delarbete II 
visades att för HCM patienter med ICD var huvudsakliga dödsorsaken försämring av 
systolisk funktion som leder till terminal hjärtsvikt. Däremot upphör närmast plötslig hjärtdöd 
till följd av arytmi. Alltjämt föreligger en förhöjd dödsrisk (standardiserad mortalitetskvot 
3.4) jämfört med svenska befolkningsdata matchad avseende kön, ålder och kalendertid. I 
delarbete III, var generisk hälso-relaterad livskvalitet, både mental och fysisk, lägre hos 
patienter med HCM och ICD än svensk ålders och könsmatchad normpopulation. Systolisk 
hjärtsvikt och förmaksflimmer var utslagsgivande för låg hälsorelaterad livskvalitet, särskilt 
fysisk funktionsförmåga. I delarbete IV baserat på kvalitativ innehållsanalys av intervjuer 
med HCM patienter med ICD konstaterades försämrad hälsa till följd av begränsande 
andfåddhet men de anpassade sig och accepterade dessa livsstilsförändringar. De var 
tacksamma för ICD:n som gav dem känsla av hoppfullhet under livets trots nödvändiga 
restriktioner och anpassning, till och med efter inadekvata chockbehandlingar. Kunskapen om 
sjukdomen och ICD varierar påtagligt och stöd från sjukvården är vanligen begränsat till 
tekniska delar snarare än försök till holistisk ansats. I delarbete V, visade sig HCM-patienter 
med ICD representera allvarlig sjukdom uttryckt som minskat myokardiellt blodflöde vid 
adenosinstress, förändrad oxidativ metabolism och sympatikoton denervering vid användande 
av de radioaktiva spårämnena 15O-vatten, 11C-acetat och 11C-HED vid PET undersökning. 
Kvoten myokardiellt blodflöde endokardium/epikardium vid adenosinstress är lägre hos 
patienter som har icke-ihållande ventrikeltakykardi vilket utgör en potentiell markör för att 
förbättra riskvärdering avseende plötslig hjärtdöd. 
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14 POPULAR SCIENCE SUMMARY 
Hypertrophic cardiomyopathy (HCM) is a varied disease, often with symptoms such as 
shortness of breath and risk of sudden death due to cardiac arrhythmias mainly from the 
ventricles of the heart. An implantable cardioverter defibrillator (ICD) has the capacity to 
terminate such arrhythmias by either overdrive pacing or an electrical shock. The aim of this 
doctoral thesis was to elucidate different aspects of ICD treatment in patients with HCM. It 
focuses on risk stratification for life-threatening arrhythmias, mortality and cause of death, 
assessment of quality of life, qualitative aspects of living with an ICD, and characterization 
using imaging tools such as positron emission tomography (PET) to explore risk markers for 
sudden death. The Swedish Pacemaker and ICD Registry was retrieved to identify eligible 
patients. Data from the National Patient Registers, the Cause of Death Register, Statistics 
Sweden, and medical records were used. Quality of life was assessed using the questionnaire 
SF-36. Interviews were analyzed by hermeneutics and latent content analysis. PET and 
echocardiography exams were performed.  
In Paper Ⅰ, the nationwide sample of all HCM patients with ICDs was based on established 
risk factors for SCD at the time. ICDs effectively terminate life-threatening ventricular 
arrhythmias in hypertrophic cardiomyopathy. After 1, 3 and 5 years, 8%, 15%, and 21% of 
the patients, respectively, had experienced appropriate ICD therapy. The study used the 
ejection fraction, which is the proportion of blood in the heart’s large lower left chamber that 
is ejected out into the body with each cardiac contraction. The ejection fraction is typically 
measured with echocardiography. An ejection fraction below 50% and/or atrial fibrillation 
are strong predictors that an ICD patient will receive appropriate therapy from the device at 
some point. In Paper Ⅱ, it was shown that for hypertrophic cardiomyopathy patients with 
ICDs, the main cause of death is deterioration of the ejection fraction, leading to end-stage 
heart failure. The ICD is very effective at terminating arrhythmias, so the risk of sudden death 
is almost gone. Still, there is an increased risk of death, more than threefold compared to the 
Swedish general population with the same age, sex at the same time period. In Paper Ⅲ, 
quality of life, both mental and physical components, was shown to be lower in HCM 
patients with ICDs than in Swedish population norms of the same age and sex. Low ejection 
fraction and atrial fibrillation are also determinants of low quality of life. This is more 
pronounced in physical functioning. In Paper Ⅳ, HCM patients with ICDs appear to perceive 
that they are in poor health due to limiting shortness of breath, but they nevertheless accept 
the change in life style. They feel grateful for their ICD device, which gives them hope even 
after experiencing inappropriate shocks and despite necessary restrictions and adaptation. The 
knowledge about the disease and device therapy varies substantially and the support from 
health care providers is generally constrained to technical issues rather than an attempt to 
achieve a holistic approach. In Paper Ⅴ, HCM patients with ICDs represent advanced disease 
expression determined as decreased myocardial blood flow at stress, altered metabolism, and 
impairment of the sympathetic nervous system that controls the heart. This was measured 
using radiolabeled tracers in PET exams. The endocardium/epicardium myocardial blood 
flow gradient (i.e. the inner half of the heart muscle divided by the outer half) at stress is 
lower in hypertrophic cardiomyopathy patients with a certain type of arrhythmia (ventricular 
tachycardia that lasts less than 30 s). This knowledge can be used to improve risk 
stratification in HCM and select the right candidates for ICDs. 
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15 POPULAR SCIENCE SUMMARY IN SWEDISH 
(POPULÄRVETENSKAPLIG SAMMANFATTNING) 
Hypertrofisk kardiomyopati (HCM) är ett heterogent tillstånd med olika sjukdomsuttryck 
inklusive plötslig hjärtdöd vilket dock kan förebyggas med en implanterbar kardiell 
defibrillator (ICD) som har förmåga att bryta rytmrubbningar. Det övergripande syftet med 
avhandlingen var att belysa olika aspekter av ICD-behandling hos patienter med HCM. Detta 
innefattar ICD-användning vid HCM med tonvikt på riskvärdering avseende livshotande 
rytmrubbning, dödlighet och dödsorsaker, mätning av livskvalitet och aspekter av hur det är 
att leva med en ICD, karakterisering med bildavgivningssättet positronemissionstomografi 
(PET) och undersökning av riskmarkörer för plötslig död. Det svenska pacemaker och ICD 
registret användes för att identifiera tänkbara patienter. Socialstyrelsens patientregister, 
dödsorsaksregistret, Statistiska centralbyrån och journaler användes. SF-36 användes för att 
beräkna livskvalitet. Intervjuer analyserades kvalitativt med hermeneutik och innehållsanalys. 
PET och hjärtultraljud genomfördes. 
I delarbete I, baserat på den nationella kohorten av oselekterade patienter med hypertrofisk 
kardiomyopati, konstaterades att riskvärdering avseende ICD skedde utifrån, vid tidpunkten, 
etablerade riskfaktorer avseende plötslig död. ICD bryter effektivt potentiellt livshotande 
rytmrubbning hos patienter med HCM. Efter 1, 3 och 5 år hade 8 %, 15 % respektive 21 % 
haft adekvat ICD-behandling till följd av rytmrubbning. Ejektionsfraktion (ett mått på 
andelen blodvolym som pumpas ut i varje hjärtslag) under 50 % och förmaksflimmer har ett 
starkt samband med adekvat ICD-behandling. I delarbete II visades att för HCM patienter 
med ICD var den huvudsakliga dödsorsaken försämring av pumpkraft mätt som 
ejektionsfraktion vilket leder till dödlig hjärtsvikt. Däremot försvinner närmast plötslig 
hjärtdöd som dödsorsak. Alltjämt föreligger en förhöjd dödsrisk, drygt trefaldig jämfört med 
övrig befolkning med samma kön och ålder. I delarbete III, sågs att mental och fysisk 
hälsorelaterad livskvalitet var lägre hos patienter med HCM och ICD än övrig jämförbar 
befolkning. Nedsatt ejektionsfraktion och förmaksflimmer var förknippat med låg 
livskvalitet, särskilt fysisk funktionsförmåga. I delarbete IV baserat på intervjuer av HCM 
patienter med ICD framkom försämrad hälsa till följd av begränsande andfåddhet men de 
anpassade sig och accepterade dessa livsstilsförändringar. De var tacksamma för ICD:n som 
gav dem känsla av hoppfullhet under livets nödvändiga restriktioner och anpassning, till och 
med efter inadekvata chockbehandlingar. Kunskapen om sjukdomen och ICD varierar 
påtagligt och stöd från sjukvården var vanligen begränsat till tekniska delar snarare än försök 
till holistisk ansats. I delarbete V, visade sig HCM-patienter med ICD representera allvarlig 
sjukdom uttryckt som försämrat blodflöde i hjärtmuskeln vid stresspåslag, förändrad 
ämnesomsättning och försämring av nervsystemet som styr hjärtat när det undersöktes med 
radioaktiva spårämnen i PET-kameran. Kvoten blodflöde endokardium/epikardium (det vill 
säga innerhalvan dividerad med ytterhalvan) vid stresspåslag var lägre hos patienter som har 
kammarytmrubbning som varar mindre än 30 sekunder. Denna kunskap kan användas för att 
förbättra riskvärdering vid HCM och välja ut de som behöver en ICD.
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